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Chapter 1.1
DEFINITION
Chronic mesenteric ischemia (CMI) is defined as insufficient blood supply to the gastro-
intestinal (GI) tract causing ischemic symptoms with a duration of at least 3 months 
according the latest guidelines (1). CMI requires timely diagnosis and treatment to 
prevent the development of acute mesenteric ischemia, which is associated with high 
morbidity and mortality. CMI is a diagnosis that is difficult to establish as symptoms 
are highly variable and diagnostic tests may be inconclusive.
EPIDEMIOLOGY
The exact incidence of CMI in the general population is unknown, since population 
based incidence studies are lacking. However, the number of revascularization 
procedures for CMI is increasing. Data from the National (Nationwide) Inpatient Sample 
(NIS) database showed a total of 14,897 revascularization procedures performed for 
CMI between 2000 and 2012 in the United States of America (USA)(2). The number of 
patients undergoing revascularization for CMI was significantly increased from 1.8 per 
million in 2000 to 5.6 per million in 2012 (p<0.01)(2). The increase in revascularization 
procedures for CMI does not necessarily reflect an increase in the prevalence of CMI 
but may be a sign of increased recognition of this disease entity and/or the increase of 
minimally invasive treatment options.
ANATOMY
Three mesenteric arteries provide blood supply to the intestines: the celiac artery (CA), 
superior mesenteric artery (SMA) and inferior mesenteric artery (IMA) (Image 1 and 
Image 2). The CA supplies blood to the stomach, liver, part of the pancreas and the 
proximal duodenum, whereas the SMA supplies blood to the distal duodenum, small 
bowel and the proximal colon and the IMA provides the blood supply to the distal colon. 
The anatomy of the mesenteric arteries shows some inter-individual variability(3) but 
there is always an abundant collateral network between these arteries. The CA and SMA 
are anastomosed by the pancreaticoduodenal arteries named after their describers Rio 
Branco and Bühler(4). The SMA and IMA are proximally connected by the arcade of 
Riolan and the arcade of Villemin and more distal by the arcade of Drummond. The most 
distal end of the mesenteric arteries are the superior rectal arteries which originate 
from the internal iliac arteries via the middle rectal arteries.
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Image 1. CTA image in sagittal plane visualizing normal anatomy of the CA, SMA and IMA (top-
down, respectively).
Image 2. 3D CTA image visualizing normal anatomy of the CA, SMA and IMA (top-down, respec-
tively).
1.1
14
Chapter 1.1
ETIOLOGY
Atherosclerotic stenosis of one or more mesenteric arteries is causing CMI in >90% of 
the cases(5). Less frequently, CMI is caused by vasculitis. Asymptomatic mesenteric 
stenoses are common in the general population and prevalence increases with age. 
The  reported prevalence of asymptomatic CA and/or SMA stenosis is 3% in patients 
under 65 years and 18% in patients older than 65 years(6). Multi-vessel mesenteric 
stenoses causing CMI is a well-accepted conception, whereas insufficient blood supply 
caused by isolated mesenteric stenosis is thought to be limited because of abundant 
collaterals. If the collateral circulation is insufficient, however, revascularization of a 
single-vessel stenosis will result in symptom relief(7-10). The most common cause of 
isolated CA stenosis is median arcuate ligament syndrome (MALS): anatomical eccentric 
compression of the CA and/or celiac ganglion by the median arcuate ligament (MAL) 
and diaphragmatic crura(11). The degree of stenosis caused by the MAL depends on the 
respiratory cycle. The MAL moves caudally during inspiration, releasing the compression 
on the CA and increasing compression during expiration (Image 3). Also, compression 
that only occurs during inspiration may be observed as well. Characteristics of patients 
with CMI differ depending on the underlying cause being MALS or atherosclerosis(Table 
1)(12-18).
Image 3. A 48-year-old woman presented with postprandial abdominal pain and 10 kg weight 
loss. CTA showed compression of the CA, with increased compression in expiration (panel A) and 
less compression in inspiration (panel B). Patient was planned for surgical release of CA. After 
successful release, patient had gained weight 5 kg and was symptom free. CTA 11 months after 
surgery showed an open CA (panel C expiration and D inpiration).
15
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Table 1. Reported prevalence of characteristics of patients with atherosclerotic CMI versus 
patients with CMI based on MALS.
Atherosclerotic CMI(12) MALS(13-18)
Mean age (years) 69 37-54
Female 62% 69-78%
Smoking 66% 33-63%
Hypertension 64% 33%
Hyperlipidemia 41% 13%
CVD 54% 6%
CMI =chronic mesenteric ischemia; CVD = cardiovascular disease; MALS = median arcuate ligament 
syndrome.
Chronic non-occlusive ischemia (NOMI) or ‘‘migraine abdominale’’(19) is characterized 
by symptoms of CMI in the absence of a vascular stenosis and is diagnosed in up to 
13–16% of all CMI patients(10). Several pathophysiological mechanisms causing chronic 
NOMI have been suggested: underlying conditions such as cardiac and pulmonary 
insufficiency, shunts, occlusion of smaller mesenteric arteries due to spasms or micro-
emboli, and autonomic dysfunction. Therapy is directed towards amelioration of 
adverse effects caused by the underlying pathophysiological mechanism. Vasodilating 
drugs are applied in case of autonomic dysfunction and optimization of oxygen supply 
to the GI tract is applied in case of underlying cardiac or pulmonary disease. Successful 
treatment of these patients, however, is challenging because the etiology of chronic 
NOMI is not fully unraveled yet.
CLINICAL PRESENTATION
Typical CMI symptoms are postprandial abdominal pain with food aversion and weight 
loss. The abdominal pain is classically located in the mid-abdomen or epigastrium and 
usually starts 20–30 minutes after a meal and lasts 1–2 hours. Atypical symptoms 
are constant abdominal discomfort, nausea, vomiting, diarrhea or constipation(1). 
Abdominal bruit may be present during physical examination; however, the ‘‘classic 
CMI triad’’ of postprandial abdominal pain, weight loss and abdominal bruit is only 
present in 16–22% of CMI patients(8, 20).
1.1
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DIAGNOSIS
In the absence of a golden standard test, the diagnosis of CMI is established by consensus 
in a multidisciplinary meeting attended by vascular surgeons, gastroenterologists 
and (interventional) radiologists(1, 21). The consensus diagnosis is based on clinical 
symptoms, radiological evaluation of the mesenteric vasculature and if available, 
functional assessment of mucosal ischemia(22-24). The value of symptoms alone is 
limited for the prediction of the diagnosis of CMI(20, 25, 26).
Computed tomography angiography (CTA) is the primary imaging modality in patients 
with a moderate or high suspicion of CMI to assess the mesenteric arteries and to detect 
other intra-abdominal pathology according the European Society of Vascular Surgery 
(ESVS) guidelines(1). CTA depicts various atherosclerotic plaque components such as 
soft plaque and calcifications with a sensitivity for mesenteric artery stenosis of 100% 
and a specificity of 95%(27). Current magnetic resonance angiography (MRA) techniques 
do not seem as accurate as CTA, especially for the IMA and smaller branch vessels(28). 
When CTA is not feasible, i.e. in the presence of contrast allergy or renal insufficiency, 
MRA can be used as an alternative imaging modality according the American College of 
Radiology (ACR) guidelines(29). Duplex ultrasound (DUS) can be used as first screening 
imaging modality to identify a mesenteric artery stenosis. DUS identifies a ≥70% CA 
stenosis with a sensitivity of 72-100% and a specificity of 77-90% and a ≥70% SMA 
stenosis with a sensitivity of 72-100% and a specificity of 84-98%(30, 31). However, DUS 
is operator dependent, technically challenging and the flow velocities of the evaluated 
artery could be influenced by respiration, the presence of concomitant stenosis in 
other mesenteric vessels, and existing stents. Digital subtraction angiography (DSA) is 
reserved for treatment of occlusive mesenteric artery disease and is replaced by CTA 
as diagnostic modality. Plain abdominal X-ray has no role in the diagnosis of CMI.
Dynamic imaging is important to detect a CA stenosis caused by MALS since the grade 
of stenosis varies with respiration in contrast to atherosclerotic stenosis. CTA, MRA, 
DUS or DSA during both inspiration as expiration phases are sufficient.
A functional test to prove actual GI ischemia is needed since the prevalence in the 
asymptomatic general population is high and symptoms of CMI are largely overlapping 
with many other disorders. Visible light spectroscopy (VLS) performed during upper 
endoscopy allows measurement of the oxygen saturation of the upper GI mucosa 
17
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using a fiber-optic catheter passed through the accessory channel of the endoscope 
connected to the VLS oximeter (T-Stat 303 Microvascular Oximeter; Spectros, Portola 
Valley, California, see Image 4)(32). The sensitivity of VLS-measurements for the 
diagnosis of CMI is 90% and the specificity is 60% if mucosal oxygen saturation cut-off 
values of <63% in the antrum of the stomach, <62% in the duodenal bulb and <58% in 
the descending duodenum are used(33). Since VLS is relatively new, validation studies 
have to be performed.
Image 4. Visible light spectroscopy (VLS) performed during upper endoscopy measures the 
mucosal oxygen saturation.
Tonometry is another functional test that measures luminal pressure of carbon dioxide 
(PCO
2
) by a nasogastric and nasojejunal catheter attached to a capnography (Tonocap©). 
Luminal PCO
2
 increases during mesenteric ischemia. Exercise tonometry is performed 
during a bicycle test (sensitivity 78%, specificity 92%(10)) and 24-hours tonometry is 
performed using test meals as provocation of ischemia (sensitivity 76%, specificity 
94%(24)).
A functional test is not needed in the work-up of the most common CMI suspected 
patients with typical symptoms and multi-vessel disease (Figure 1). However, especially 
in the work-up of single vessel disease a functional test is a prerequisite. It is therefore 
recommended to refer these patients to a specialized center to undergo functional 
testing. Research is in progress to develop simple and reliable functional tests that can 
be widely applied.
1.1
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Figure 1. Algorithm for clinical management of CMI.
* refer for functional test. Suitable functional tests are upper GI endoscopy with visible light 
spectroscopy (VLS) or gastric-jejunal tonometry (24-hours tonometry or exercise tonometry). CA = celiac 
artery; CMI = chronic mesenteric ischemia; CT = computed tomography; CTA = computed tomography 
angiography; DUS = duplex ultrasound; MR = magnetic resonance; MRA = magnetic resonance 
angiography; NOMI = non-occlusive mesenteric ischemia; PMAS = percutaneous mesenteric artery 
stenting; SMA = superior mesenteric artery.
Laboratory tests such as leucocytes, D-dimer, lactate and C-reactive protein are not 
useful for detection of CMI(1, 34, 35). Since CMI is a state of transient ischemia episodes 
induced by eating, fasted marker levels are presumably not sufficient to indicate CMI. 
In a study in which several serum markers before and after a meal were determined 
in patients suspected of CMI, a significant increase of D-dimer was reported in 32 
CMI patients after a meal in contrast with 8 patients without CMI(34). Another study 
in 49 CMI suspected patients reported a significant increase in intestinal fatty-acid 
19
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binding protein (I-FABP) levels in patients with positive tonometry results after a meal 
in contrast with patients with  normal response after a meal(35). Further research and 
larger studies are needed to potentially identify a sensitive and specific biomarker for 
detecting CMI.
In contrast to a diagnosis of acute ischemic colitis, endoscopic assessment of the 
mucosa by visual appraisal or taking biopsies plays no crucial role in detecting CMI. 
In CMI patients atrophy of the duodenal mucosa and non-Helicobacter pylori/non-
nonsteroidal anti-inflammatory drug gastric or duodenal ulcers are observed in a 
minority of cases(25). Pathology seen in CMI patients during upper GI endoscopy is 
shown in Image 5. Histological examination of biopsy samples are not discriminative 
for the diagnosis of CMI(36). Nevertheless, upper endoscopy remains indicated in CMI 
suspected patients to exclude alternative diagnoses, such as peptic ulcer.
Image 5. Pathology seen in CMI patients during upper GI endoscopy. A. Ischemic ulceration in 
the stomach, B. patchy whitening of the gastric mucosa, C. duodenual whiteness typical on the 
top of the duodenal folds and D. upper GI endoscopy in the same patient as C but after successful 
revascularization shows normal duodenal mucosa.
Multi-vessel stenoses and classic symptoms will lead to a straightforward diagnosis 
of CMI. In case of single-vessel disease, careful investigation for alternative causes is 
warranted(1). Exclusion of other etiologies by imaging of the upper abdomen (DUS/
1.1
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CT/MR) for gallstones and pancreatitis and upper endoscopy in patients suspected of 
CMI is important to prevent overtreatment (Figure 1). When a consensus diagnosis 
of occlusive CMI is established in the multidisciplinary meeting, patients are planned 
for revascularization therapy. A definitive diagnosis of CMI is proven when technically 
successful treatment results in durable symptom relief.
THERAPY
Revascularization is indicated in patients with occlusive CMI to relief symptoms, improve 
quality of life, restore normal weight and to improve survival by preventing bowel 
infarction (acute-on-chronic mesenteric ischemia)(1). The challenge is to select the 
patient with mesenteric stenosis who will benefit from treatment. Revascularization 
is accepted in case of symptomatic multi-vessel stenosis (Image 6). Since the presence 
of the mesenteric collateral circulation is assumed to prevent single-vessel CMI, 
revascularization is up for discussion in case of single-vessel stenosis (Image 3 and 
Image 7).
Image 6. A 69-year-old woman presented with postprandial abdominal pain and 10 kg weight 
loss since three months. A significant stenosis of the CA and SMA was shown on CTA (panel 
A). A consensus diagnosis of multi-vessel CMI was established and patient was plannend for 
endovascular revascularization. The CA and SMA were successfully stented. CTA 6 months after 
revascularization showed open stents (panel B) and the patient was free of symptoms and her 
weight was increased by 12 kg.
21
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Image 7. A 50-years-old man presented with postprandial abdominal pain and 13 kg weight 
loss. CTA showed a significant stenosis of the SMA and <50% CA stenosis (panel A). His mucosal 
saturation levels were decreased as detected by visible light spectroscopy. A consensus diagnosis 
of single-vessel CMI was established and patient was planned for stent placement of the SMA. 
CTA 6 months after revascularization showed an open SMA stent (panel B). The patient was free 
of symptoms and his weight was increased by 7 kg.
Open surgical revascularization has been the standard therapy modality for years. 
However, endovascular revascularization is less invasive and has become the therapy 
of choice in most centers over the past two decades(1-3). The number of endovascular 
procedures performed for CMI in the USA has increased significantly from 0.6 in 2000 
to 4.5 per million persons in 2012 (p<0.01)(35).
Prospective studies comparing percutaneous transluminal angioplasty (PTA) alone 
with primary stenting are lacking. However, in parallel to renal artery stenosis and the 
advantage of stent placement over PTA in this patient group, endovascular therapy 
for mesenteric stenosis consists of stent placement according the ESVS and Society 
of Interventional Radiology (SIR) guidelines(1, 3). Mesenteric stenoses are usually 
located at the ostium and are therefore prone to recoil after PTA(3, 36, 37). The 
endovascular approach for percutaneous mesenteric artery stenting (PMAS) is trans-
brachial access (TBA) or trans-femoral access (TFA), however trans-radial approach 
(TRA) showed a decrease in major access-site complications with similar procedural 
and clinical outcomes in interventional cardiology. Current guidelines do not issue 
recommendations on TRA for PMAS since literature on TRA specific for mesenteric 
artery procedures is lacking(31). Bare-metal stents are standard care but retrospective 
1.1
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data have reported better primary patency rates when using covered stents(39). 
Outcome of a randomized multicenter clinical trial (the study protocol is described in 
Chapter 8) is currently awaited to confirm the superiority of covered stents for PMAS.
Open surgical revascularization can be considered if endovascular approach has failed, if 
endovascular revascularization is technically not possible due to extensive occlusion and 
calcification, contra-indications to radiation or contrast media, or if revascularization is 
needed in young patients with complex non-atherosclerotic lesions caused by vasculitis 
or mid-aortic syndrome(1). Open surgical revascularization can be performed antegrade 
(from the supraceliac aorta), or retrograde (from the iliac artery), or hybrid with open 
access to the SMA and retrograde stenting. Autogenously revascularization techniques 
are first choice but a prosthetic conduit can be used as bypass for one or more vessels 
as well. This thesis focuses on endovascular revascularization and not on open surgical 
revascularization.
Overall technical success rates of endovascular mesenteric revascularization varied 
from 85-100% versus technical success rates of surgical revascularization of 97-100%(3, 
6, 40). Relative contraindications for endovascular revascularization associated with 
lower technical success rate and/or increased procedural complications are highly 
tortuous aorta-iliac arteries, long-segment occlusion, small-diameter distal vessels and 
heavily calcified stenosis(3). It should be emphasized that ostial occlusion does not 
exclude PMAS. In a study of 185 CA and SMA vessels treated with PMAS, 21% of the 
revascularized vessels (9 CA and 30 SMA) were occluded prior to PMAS(41).
Reported complication rates of surgical revascularization in CMI patients are 13-40%(24, 
42) and reported endovascular complication rates are between 0-31% (Table 2)(2, 3). 
In 4-38% of the cases the complication of the endovascular intervention is access-site 
related, whereby access-site hematomas are most reported(3, 12).
The therapy for MALS consists of surgical release of the MAL, adjacent crus of the 
diaphragm and removal of the celiac plexus (Image 3). If stenosis of the CA persists 
after adequate surgical release, additional bypass surgery or endovascular therapy 
is performed(43). An endoscopic retroperitoneal release is favorable since this has 
been proved feasible and less invasive with comparable short-term results as the open 
procedure(17). PMAS is contraindicated as primary therapy for MALS, since the high 
risk of stent fracture resulting in re-stenosis(3).
23
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Table 2. Reported type of complications of mesenteric endovascular revascularization versus 
mesenteric surgical revascularization.
Complications endovascular 
revascularization(29, 31)
Complications surgical 
revascularization(25, 37)
Hematoma Bowel resection
Dissection access-site Acute renal failure
Mesenteric dissection Acute myocardial infarction
Thrombosis Stroke
Branch perforation Peripheral vascular disease
Stent dislodgement Hemorrhage
Distal thromboembolization Respiratory failure
CLINICAL OUTCOME AFTER TREATMENT
Repeated follow-up after therapy for CMI might be considered to detect symptomatic 
restenosis according the ESVS guidelines(1). Routine repeated imaging after therapy 
may show re-stenosis, but the benefit of treating asymptomatic re-stenosis is unknown. 
Antiplatelet therapy is recommended after revascularization and dual antiplatelet 
therapy may be considered for 3-12 months(1, 29, 31).
In-stent stenosis can be seen in 28-36% of endovascular treated patients within 2 years 
after PMAS(31). This number is lower after surgical revascularization with 0-25%(5, 
38). Independent predictors of re-stenosis after mesenteric revascularization are 
endovascular revascularization, prior mesenteric intervention, female gender, and small 
(<6 mm) SMA diameter(39). Severe mesenteric calcification, occlusions, longer lesions, 
and small vessel diameter are associated with an increased risk of distal embolization, 
re-stenosis and re-interventions after endovascular revascularization(38).
Surgical revascularization is associated with a superior long-term patency rate compared 
to endovascular revascularization (cumulative odds ratio 3.57, 95% CI 1.82-6.87, 
p=0.0002)(40). Table 3 shows the 1-year and 5-years primary patency rates and primary 
assisted patency rates of surgical versus endovascular revascularization(31, 40-42).
1.1
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Table 3. The 1-year and 5-years primary patency rates and primary assisted patency rates of 
surgical versus endovascular revascularization for CMI.
Surgical revascularization
(31, 40, 41)
Endovascular revascularization
(31, 42)
1-year primary patency 
rate
91% 58-88%
1-year primary assisted 
patency rate
96% 90%
5-years primary patency 
rate
74-90% 45-52%
5-years primary assisted 
patency rate
96-98% 69-79%
primary patency rate = uninterrupted vessel patency after initial intervention without repeat 
intervention(31); primary assisted patency rate = successful restoration of vessel patency by 
revascularization therapy of restenosis or a newly occurring arterial stenosis of the previously treated 
lesion. Primary assisted patency ends with vessel occlusion(31).
A recently published meta-analysis included 100 observational studies to compare 
endovascular revascularization (10,679 patients) and open surgical revascularization 
(8047 patients)(12). Risk of in-hospital complications was significantly increased in the 
open surgical revascularization group (relative risk (RR) 2.19, 95% CI 1.84-2.60). The 
risk of 3-years recurrence was lower in the patients treated with open surgery than 
in the patients treated with endovascular approach (RR 0.47, 95% CI 0.34-0.66). The 
3-years survival rate was not significantly different (RR 0.96, 95% CI 0.86-1.07). The ESVS 
guidelines recommend to offset the superior long-term results of open revascularization 
against the possible early benefits of endovascular revascularization in the absence of 
randomized controlled trials(1).
Immediate symptom relief is reported in 90-98% of surgically treated patients and 
remains excellent after 5 years with 89-92%(5). After endovascular revascularization, 
immediate symptom relief was reported in 87-95%, symptom relief after 3 years in 61-
88%, and in 51% after 5 years(5).
A retrospective analysis of prospectively collected data (10,920 endovascular 
revascularized patients versus 4555 surgical revascularized patients) showed that 
endovascular revascularization is associated with a significantly lower in-hospital 
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mortality rate of 2.4%, shorter length of hospitalization by 10 days, and reduced costs 
of $25,000 for hospitalization compared to surgical revascularization(43).
CONCLUSION
Although the exact incidence of CMI is unknown, it is expected that the incidence 
will increase in the upcoming years due to the aging population and the increasing 
prevalence of cardiovascular disease (CVD) in Europe. CVD patients have an increased 
life expectancy due the improved diagnostics and better therapeutic opportunities but 
these patients are also prone to develop mesenteric atherosclerosis. Patients with CMI 
present usually with GI symptoms. The diagnostic work-up of the patient suspected of 
CMI and therapeutic management is multidisciplinary. The current clinical management 
of CMI is summarized in an algorithm (Figure 1). Early diagnosis is important to timely 
treat, improve quality of life and to prevent acute-on-chronic mesenteric ischemia.
1.1
CHAPTER
1.2
Aims and outline of the thesis
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AIMS
The exact prevalence of CMI is not known and CMI is often described as a rare disease 
in literature. However, the incidence of revascularization procedures for CMI is 
increasing(2) and given the aging population and increasing prevalence of CVD with 
increased life expectancy due to the improved diagnostic and therapeutic opportunities, 
the incidence of CMI is expected to increase in the upcoming years. Therefore, it is 
important to put CMI in the picture. This thesis aims to provide insights in different 
aspects of the diagnosis and therapy of CMI to optimize the diagnostic work-up and 
treatment for this specific patient group. The outline of this thesis is discussed below.
OUTLINE OF THIS THESIS
This thesis is divided into four parts. Part I contains the introduction of this thesis. 
Chapter 1.1 describes the general introduction on CMI including the definition, 
epidemiology, etiology, clinical presentation, diagnostic work-up, therapy and clinical 
outcome of CMI and the anatomy of the mesenteric vasculature followed by Chapter 
1.2 describing the aims and outline of this thesis.
Part II focusses on different aspects of the current diagnostic procedures for CMI and 
strategies and insights to optimize the diagnostic work-up. This part starts with an 
overview of the current imaging techniques for the mesenteric vasculature in Chapter 2.
The current diagnostic work-up for CMI is cumbersome and time-consuming with 
invasive diagnostic interventions in the absence of a gold standard test. All patients 
suspected of CMI are currently exposed to this extensive diagnostic work-up. This 
results in unnecessary diagnostic procedures for patients without CMI and delay in 
treatment for patients with CMI. An easy-to-use tool is needed to assess the risk of 
CMI in patients suspected of CMI and to guide clinical decision making. Chapter 3 
describes the multicenter external validation of a prediction model for CMI as previously 
published by our study group. Furthermore, an updated version of the score chart is 
presented in this chapter based on the performance of the prediction model in the 
combined original and validation cohort and by including the cause of CA stenosis 
(MALS or vascular disease).
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VLS is a functional test to detect mucosal ischemia during upper GI endoscopy. VLS 
is currently used in clinical practice in the diagnostic work-up for CMI. Since VLS is a 
relatively new diagnostic test, further validation of VLS is needed. Chapter 4 describes 
the interobserver and intraobserver validation of VLS measurements during upper GI 
endoscopy.
Upper GI endoscopy is performed in fasting state and subsequently the VLS 
measurements are performed in fasting state. Symptoms of CMI are usually provoked 
by a meal; therefore VLS performed in fasting state could potentially underdiagnose 
CMI. Chapter 5 describes a study in patients suspected of CMI and healthy controls 
who underwent VLS measurements in both fasting state and after luminal feeding to 
assess the additional value of postprandial VLS measurements for the diagnosis of CMI.
Further validation of VLS is performed in a porcine model study by comparing VLS 
measurements and a calibrated microvascular oxygen tension (μPO
2) 
measurement 
technique as described in Chapter 6.
The last chapter of Part II, Chapter 7, introduces a novel promising technique to measure 
oxygen-dependent signal in the cells of the GI tract during upper GI endoscopy. This 
chapter describes a pilot study in healthy controls to assess the feasibility and safety 
of this technique during upper GI endoscopy.
Part III describes various therapeutic elements of CMI. Endovascular revascularization is 
the therapy of choice and bare-metal stents are currently standard care for endovascular 
revascularization of atherosclerotic CMI. A retrospective cohort study showed better 
patency for covered stents in atherosclerotic CMI patients(44). The study protocol for 
a multicenter, randomized controlled trial of bare-metal stents versus covered stents 
in patients with atherosclerotic CMI is described in Chapter 8.
Revascularization therapy for multi-vessel mesenteric arterial disease is generally 
accepted. A single mesenteric arterial stenosis is seldomly symptomatic due to the 
existence of the abundant mesenteric collateral network. However symptomatic 
single vessel disease may develop when the extent of stenosis is too severe and/or 
the collateral network is insufficient. The challenge is to identify those patients with 
isolated mesenteric arterial disease and abdominal complaints who will benefit from 
revascularization. Chapter 9 describes the long-term clinical success rates for single 
1.2
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mesenteric artery revascularization of either CA or SMA in patients with chronic GI 
symptoms and confirmed mucosal ischemia with VLS or tonometry.
The vascular approach for endovascular mesenteric arterial interventions is TBA or 
TFA according the current guidelines(31). Literature on coronary artery intervention 
shows less major access-site complications for TRA than for TBA and for TFA with 
similar procedural and clinical outcomes(45-49). Current guidelines do not issue any 
recommendations on the use of TRA for mesenteric arterial interventions since studies 
on TRA for this specific indication are lacking. Chapter 10.1 describes a single-center 
cohort study of patients with an endovascular mesenteric intervention with TRA, TBA 
or TFA. The feasibility and safety of TRA is compared with the feasibility and safety of 
TFA and TBA. Chapter 10.2 describes a severe complication of a TRA procedure for 
brachiocephalic stent placement.
Since the prevalence of mesenteric arterial stenosis in the general population is high, 
it is challenging to define the clinical significance of a mesenteric arterial stenosis, 
especially in case of single vessel mesenteric disease. Pressure measurements are 
used in interventional cardiology to define the clinical significance of a coronary 
artery stenosis and to guide treatment decision. Consensus on the use of pressure 
measurements for mesenteric arterial stenosis is lacking. A cohort study on pressure 
measurements in patients with mesenteric stenosis is described in Chapter 11 to 
define a clinically significant CA or SMA stenosis by correlating mesenteric pressure 
measurements with clinical success.
Part IV starts with a summary of the main findings of this thesis in Chapter 12.1 followed 
by the general discussion in Chapter 12.2 and further directions for future research in 
Chapter 12.3. Finally, Chapter 12.4 provides a brief conclusion of this thesis.
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ABSTRACT
Imaging of the mesenteric vasculature is crucial in diagnosing vascular disease of the 
gastro-intestinal tract such as acute or chronic mesenteric ischemia caused by arterial 
stenosis, embolism or thrombosis, mesenteric vein thrombosis and mesenteric aneurysm 
or dissection. The reference standard for imaging of the mesenteric vasculature is digital 
subtraction angiography. However, modalities as duplex ultrasonography, computed 
tomography angiography and magnetic resonance angiography are developing rapidly 
and may provide accurate imaging non-invasively. This review provides an up-to-date 
overview of the anatomic resolution, clinical application, emerging techniques and 
future perspectives of these four radiological modalities for imaging of the mesenteric 
vasculature.
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INTRODUCTION
Imaging of the mesenteric vasculature plays a crucial role in diagnosing vascular disease 
of the gastro-intestinal tract such as acute or chronic mesenteric ischemia caused by 
arterial stenosis, embolism or thrombosis, mesenteric vein thrombosis and mesenteric 
aneurysm or dissection.
Three main branches of the abdominal aorta vascularize the gastro-intestinal tract: the 
celiac artery (CA), the superior mesenteric artery (SMA) and the inferior mesenteric 
artery (IMA); see Image 1 and Image 2. The CA provides blood supply to the stomach, 
liver, part of pancreas and the proximal part of the duodenum. The SMA provides 
blood supply to the distal duodenum, small bowel and the proximal colon. Blood supply 
to the distal colon is provided by the IMA, which is relatively small compared to the 
CA and SMA. Collaterals connect the three main branches and these can exist within 
one mesenteric artery, between two mesenteric arteries, or between mesenteric and 
parietal or body wall vessels.
Image 1. (2D) CTA image in sagittal plane visualizing normal anatomy of the CA, SMA and IMA 
(top-down, respectively).
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Image 2. 3D CTA image visualizing normal anatomy of the CA, SMA and IMA (top-down, respec-
tively).
The mesenteric venous system is localized parallel to the arterial mesenteric system. 
The superior mesenteric vein (SMV) receives venous blood from the duodenal, 
pancreatic, right gastroepiploic, jejunal, ileal, right colic and middle colic veins. The 
inferior mesenteric vein (IMV) receives venous blood from the left colic, sigmoid and 
superior haemorrhoidal veins and generally drains into the splenic vein, less frequently 
into the SMV. In addition, the splenic vein receives venous blood from the pancreatic, 
left gastroepiploic and short gastric veins. The splenic vein and SMV drain into the 
portal vein (PV).
The reference standard for imaging of the mesenteric vasculature is digital subtraction 
angiography (DSA). DSA is an invasive, i.e. endovascular, procedure using X-ray and 
iodine contrast media, the latter being a potentially nephrotoxic contrast agent. DSA 
allows diagnosis and treatment of vascular mesenteric disease in one single procedure. 
Novel radiological techniques are being developed rapidly. Three most important 
non-invasive modalities for imaging of the mesenteric vasculature are US, computed 
tomography angiography (CTA) and magnetic resonance angiography (MRA). This review 
starts with a description of the most frequent mesenteric vascular diseases followed 
by an up-to-date overview of the anatomic resolution, clinical application, emerging 
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techniques and future perspectives of each of these four modalities for imaging of the 
mesenteric vasculature.
MESENTERIC VASCULAR PATHOLOGY
Acute mesenteric ischemia (AMI) is caused by an acute event resulting in decreased 
blood supply to the gastro-intestinal tract. AMI is a life-threatening condition with a high 
mortality and prompt diagnosis followed by treatment is of utmost importance. In most 
cases (approximately 40-50%), AMI is caused by acute occlusion due to an embolism 
in the SMA. AMI has several etiologies: 1. in 20-30% thrombosis of a mesenteric artery 
associated with atherosclerotic disease, 2. in 25% non-occlusive mesenteric ischemia 
(NOMI) and 3. in 5-15% portomesenteric venous thrombosis(1). Nowadays, a shift in 
the etiology of AMI from embolism towards atherosclerotic disease is appreciated in 
Western countries because of aging of the population, which results in higher prevalence 
of atherosclerosis. Furthermore, the use of anticoagulation therapy is increasing, 
thereby potentially reducing the incidence of embolic events. This hypothesis is not 
yet confirmed in a population-based study(2, 3).
Chronic mesenteric ischemia (CMI) is most frequently caused by atherosclerosis. CMI 
often presents with postprandial pain and weight loss. Revascularization is needed for 
symptom relief and may be considered to prevent acute ischemia (acute on chronic 
mesenteric ischemia). Other causes of CMI are median arcuate ligament syndrome 
((MALS) or celiac artery compression syndrome (CACS)) or, less common, fibromuscular 
dysplasia (FMD) or vasculitis. Historically, surgical revascularization was therapy of 
first choice for atherosclerotic CMI, but minimally invasive endovascular approaches 
encompassing percutaneous transluminal angioplasty (PTA) and stent placement have 
emerged leaving surgical interventions for complex disease only.
Mesenteric artery stenosis is highly prevalent in the (asymptomatic) population. Cohort 
and population based duplex ultrasonography (DUS) studies in asymptomatic individuals 
show an overall prevalence of mesenteric artery disease of 18%, isolated CA stenosis 
up to 15%, isolated SMA stenosis approximately 1% and two vessel disease in up to 
7% of the population(4-7). Autopsy series showed a higher prevalence of mesenteric 
artery disease of 29% overall and two or three vessel disease in 15%. The prevalence 
of mesenteric artery disease in these autopsy series is age related, 67% for the subjects 
aged 80 years or more compared with a prevalence of 6% among the subjects of less 
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than 40 years old(8). Concluding, mesenteric artery stenosis is a common finding in 
imaging of the mesenteric vasculature but not necessarily related to symptoms. The 
combination of stenosis detected with radiological imaging, clinical symptoms and 
a positive gastro-duodenal mucosal functional test as tonometry and visible light 
spectroscopy is essential for the diagnosis of mesenteric ischemia, especially in CMI(9-
12).
Mesenteric vein thrombosis involves the SMV and rarely the IMV. Five to 15% of all 
mesenteric ischemia cases are caused by mesenteric vein thrombosis. Underlying causes 
of mesenteric vein thrombosis can be primary (idiopathic) or secondary. Secondary 
causes are underlying coagulopathy due to hereditary factors (e.g. deficiencies in 
Factor III, protein C, protein S or antithrombin, polycythemia vera) or acquired factors 
(e.g. paraneoplastic, intra-abdominal inflammatory disease, abdominal surgery, oral 
contraceptive use, cirrhosis and portal hypertension)(1, 13).
Aneurysms of the CA, SMA and IMA are rare, contributing an incidence of 4%, 5.5% 
and 1% of all visceral vessel aneurysms, respectively(14). CA aneurysms are caused 
by atherosclerosis, tunica media degeneration, trauma, vascular disorder or mycotic 
infection. Most CA aneurysms are asymptomatic and are incidentally detected with 
radiological imaging. Presenting symptoms of a CA aneurysm are epigastric pain, 
abdominal bruit, gastrointestinal haemorrhage, jaundice, haemoptysis or palpable 
mass. The risk of spontaneous rupture of a CA aneurysm seems to be low, however 
rupture is associated with high morbidity of up to 100%(15, 16). Surgical intervention 
or endovascular embolization are the options for therapy of a CA aneurysm to prevent 
rupture. Criteria for appropriate patient selection for therapy of CA aneurysms do not 
exist at the moment. Possible selection criteria are size of the aneurysm, symptomatic 
aneurysms and rapid enlargement of the aneurysm(15, 16).
SMA aneurysms are most commonly detected in the proximal 5 cm of the SMA. The 
prevalence of SMA aneurysm is higher compared to TC aneurysms. Atherosclerosis, 
infectious disease, dissection, trauma and inflammatory processes as pancreatitis 
or biliary tract disease are causes of SMA aneurysms. Most SMA aneurysms present 
symptomatic with comparable symptoms as CA aneurysms and treatment is required 
because of frequent spontaneous rupture, even in case of an asymptomatic SMA 
aneurysm. Treatment options are identical as CA aneurysms.
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Dissection of mesenteric vessels is reported as involvement in aorta dissection cases 
and in spontaneously cases of CA or SMA dissection. Asymptomatic patients and even 
symptomatic patients without evidence of ischemia can be observed and followed with 
intermittent imaging(17). However, blood flow in these vessels can decrease or, rarely, 
completely obstruct if the dissection flap extends into the vessels resulting in intestinal 
ischemia. Therapy consists of surgical or endovascular intervention.
DUPLEX ULTRASONOGRAPHY
In 1984, Jäger et al. described a patient with symptoms of chronic gastro-intestinal 
ischemia as post-prandial abdominal pain, weight loss and diarrhoea with elevated 
blood flow velocity of the CA and SMA defined by DUS Doppler imaging. Elevated 
blood flow velocities indicated severe stenosis of the CA and SMA and subsequent 
DSA confirmed stenosis in both arteries(18). Two years later, Nicholls et al. published 
their results of the use of hemodynamic parameters obtained by DUS in identifying 
mesenteric insufficiency in a small cohort of normal subjects and patients referred for 
analysis of CGI(19). At the moment, DUS imaging is still used for imaging of mesenteric 
vasculature.
The primary clinical application of mesenteric DUS is to identify proximal stenosis of 
the SMA and CA appreciated from both anatomic and hemodynamic changes. The CA 
and SMA are relatively easy to examine. Moreover, it is feasible to examine the IMA 
with US, but the IMA is generally difficult to visualize with DUS due to its more distal 
localization and smaller size. DUS of mesenteric artery stenosis beyond the artery’s 
origin is limited due patient’s body habitus or overlying bowel gas.
DUS is observer dependent and should therefore be performed by an experienced 
sonographer. Interpretability of duplex ultrasound imaging of the CA and the SMA 
varies between 68% good and 11% moderate interpretability(20). The patient should 
be fasting before the examination in order to prevent postprandial flow changes 
and with an optimal moment of duplex scanning in the morning when bowel gas is 
minimal. Respiration influences duplex parameters in the CA and SMA with generally 
higher values during expiration(20). The head of the bed is tilted 30° and the patient 
is positioned in supine position. The mesenteric vessels of interest are identified with 
2-dimensional grayscale imaging (B-mode) and the presence of a disease process within 
the lumen of the mesenteric vessels can be assessed (see Image 3). First, the presence 
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of blood flow will be assessed using Doppler ultrasound. Absence of any blood flow 
indicates complete occlusion of the selected vessel and should also be suspected when 
interpretability is poor(20). A potential pitfall is the presence of flow beyond an occlusion 
because of collateral flow from other mesenteric arteries of the abdominal wall. When 
blood flow is present, the waveform is analyzed and the peak systolic velocity (PSV) and 
end diastolic velocity (EDV) will be determined. Flow measurements should be obtained 
with an insonation angle between the probe and the blood vessel between 45° and 60°. 
An angle exceeding 60° will result in elevated and unreliable velocities.
Image 3. Visualization of the CA and SMA with US.
In literature, several reports are published with different thresholds for detecting 
significant stenosis of the mesenteric arteries with US. At the moment, no consensus 
has been reached on which threshold should be used. Table 1 shows an overview 
of reported threshold velocities and their sensitivity and specificity in detecting 
significant (≥50% and ≥70%) stenosis of the SMA or CA. Respiration and the presence 
of concomitant stenosis influence threshold values(20, 21).
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The waveform of the CA is different compared to the waveform of the SMA in fasting 
state. The PSV of the SMA is higher compared to the PSV of the CA. Furthermore, the 
EDV of the SMA is lower compared to the EDV of the CA. The SMA often shows a short 
flow reversal at the end of the systole. This reverse flow component is generally not 
appreciated in the CA. Image 4 and Image 5 show the waveform of the CA and SMA, 
respectively.
Image 4. Waveform of the CA analyzed with US-Doppler.
Image 5. Waveform of the SMA analyzed with US-Doppler.
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The accuracy of DUS assessment of the mesenteric vessels is strongly dependent on the 
performer and adequate assessment can be limited in obese patients, in patients with 
overlying bowel gas and in patients with severe vessel calcification. In the acute setting, 
DUS assessment can be impossible due to the abdominal pressure by the performer in 
a patient with acute abdominal pain. However, Sartini et al. performed a pilot study in 
patients presenting at the emergency department with abdominal pain with no specific 
diagnosis after initial work-up. Diagnostic mesenteric DUS images were obtained in 96% 
of the 47 patients and sensitivity, specificity and negative predictive value of DUS for 
occlusive AMI were 100%, 64% and 100%, respectively. These results suggest a role 
of DUS in the emergency department in identifying patients who require CTA or DSA 
immediately, but this have to be substantiated in a larger population(22).
DUS can detect proximal stenosis of the CA and SMA, but the role of DUS after 
endovascular treatment in detecting in-stent stenosis is still matter of debate. Possibly, 
a stent decreases the compliance of the artery causing elevated PSV values resulting 
in overestimation of in-stent stenosis, a phenomenon also described in renal and 
carotid stenting(23-27). Retrospective cohort studies confirmed the overestimation 
of mesenteric in-stent stenosis if native duplex criteria were used(28, 29). Prospective 
validation studies of specific mesenteric in-stent stenosis duplex criteria are needed.
DUS surveillance is recommended in patients treated with mesenteric bypass grafts(30). 
The type of bypass used can differ: retrograde or antegrade and origin from the aorta, 
iliac vessels or other visceral arteries. Liem et al. reported no significant differences in 
mesenteric bypass DUS outcomes for different sorts of inflow arteries, however, graft 
diameter affects mesenteric bypass DUS outcome possibly(31).
DUS can also detect mesenteric aneurysms. Typical signs of an aneurysm at DUS 
are significant vessel wall thickening, presence of plaques and increased flow with 
the ‘aliasing’ phenomenon. DUS can provide information of a thrombus inside the 
aneurysm(32).
Concluding, DUS of the mesenteric vasculature is a non-invasive, low-cost radiological 
modality without radiation exposure with acceptable specificity and sensitivity in 
detecting mesenteric artery stenosis. DUS is therefore useful in the work-up of CMI 
and in the follow-up after surgical or endovascular treatment. However, the outcome of 
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DUS is operator dependent and DUS of the mesenteric vasculature is limited in analyzing 
the IMA and distal stenosis.
CTA
Multi-detector computed tomography (MDCT) technique with contrast enhancement 
allows fast scanning of the mesenteric vasculature with high spatial resolution enabling 
multi-planar image reconstruction. CTA technique produces volume data sets, which 
can be converted into any projection, including surface rendered 3D images (see Image 
2). Both hardware and software developments in CT techniques permit fast scanning 
with imaging times less than 1 second for the abdomen with low radiation exposure. In 
additional, dual source (= the use of two x-ray sources and two x-ray detectors mounted 
on a single CT gantry) dual energy (= CT datasets representing 2 different X-ray energies) 
CT techniques may considerably reduce the amount of iodine contrast agent needed 
to visualize the mesenteric arteries. CTA is nowadays the first-line imaging modality for 
the diagnosis of AMI and CMI with high accuracy. Therefore, CTA is replacing DSA as a 
diagnostic tool because of its non-invasive nature(33, 34).
CTA is performed with intravenous iodine contrast agent for enhancing both vessels 
and parenchymatous organs. Image acquisition is performed with the contrast bolus 
arriving in the arterial and portal venous phase to detect mesenteric vascular pathology 
and associated intestinal and parenchymal changes. High-density oral positive contrast 
agents should not be used, because the distinction between mesenteric vessels and 
bowel lumen will be obscured. The use of water as a negative contrast agent has been 
advocated previously(34). Axial images are reconstructed to thin axial slices of 1-3 mm 
for further multiplanar reformatting. It is of note that slice thickness should preferably 
be smaller than the size of the smallest mesenteric artery, conforming the need for 
even thinner slices below 1 mm. Current CT systems cover the entire abdomen during 
a breath hold of several seconds and automated bolus timing techniques provides 
accurate scan timing with regard to the arrival of contrast in the mesenteric arteries. 
The origin of the CA, SMA and IMA are best visualized in sagittal or sagittal oblique 
plane and branches of the mesenteric arteries are best visualized in coronal, coronal 
oblique or axial oblique plane. CTA can analyze the extend and characteristics of the 
stenosis or occlusion and the relation with the branch vessels. If collateral pathways or 
more prominent vessels are present in the surrounding area of a stenosis, the suspicion 
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of a hemodynamically significant stenosis raises. Moreover, CTA can detect other 
gastrointestinal findings related to (acute) mesenteric vascular pathology: thickening 
of the bowel wall, bowel dilatation, bowel wall attenuation, free intra-abdominal air, 
mesenteric fat stranding, intestinal pneumatosis intestinalis and portal venous gas. CTA 
can perform anatomic mapping of the surrounding gastrointestinal structures, which 
is useful in preoperative planning to visualize the local anatomy. Finally, CTA visualizes 
the entire gastrointestinal and genitourinary tract to rule out other causes of chronic 
and acute abdominal pain.
The CTA images are transferred to a 3D workstation, which converts the 2D slices into 
3D images. Three-dimensional CTA produces images with high spatial resolution in 
any possible image plane for an optimal visualization of the mesenteric vasculature, 
especially for the evaluation of small and distal arteries and complex anatomy. Chen 
et al. reviewed the records of cohort patients with significant unsuspected mesenteric 
arterial pathology who underwent axial CTA with 3D multiplanar reconstructions. In 
66% of the patients no mesenteric arterial lesion of the CA or SMA was seen on axial 
CTA but definitely found on 3D CTA(35).
Arterial embolism presents on CTA as a filling defect in the lumen of the mesenteric 
vessel. In case of occlusion of the artery by an embolism, the ‘cut-off’ sign can be 
seen: abrupt termination of the affected artery. Arterial thrombus is seen as focal 
stenosis of the vessel often with calcified atherosclerosis. The obstruction is occlusive 
if the thrombus spans the complete width of the lumen and no blood flow is identified. 
Arterial thrombosis is often located proximal to the origin of the affected generally 
atherosclerotic vessel, in contrast to arterial embolism, which is located more distally. 
See Images 6-10 for CTA images of mesenteric arterial thrombosis. Mesenteric venous 
thrombosis (Image 11) is seen as a persistent, well-defined filling defect in the venous 
lumen with central low attenuation. The walls of the vein can be thickened due to 
thrombophlebitis and the vein can expand due to the clot. Furthermore, collateral 
circulation, engorgement of mesenteric veins upstream and mesenteric oedema can 
be detected with CTA. The sensitivity of CTA for venous mesenteric thrombosis is lower 
compared to arterial stenosis. The sensitivity can be improved with use of two-phase 
imaging to enhance venous drainage.
2
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Image 6. CTA image of CA thrombosis.         Image 7. CTA image of CA thrombosis.
Image 8. CTA image of SMA thrombosis.       Image 9. CTA image of SMA thrombosis.
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Image 10. Sagittal CTA image of aorta-mesenteric artery thrombosis (thrombosis into the CA 
is indicated with a black arrow and thrombosis into the SMA is indicated with a white arrow).
Image 11. Coronal CTA image of SMV thrombosis, the extensiveness of the SMV thrombosis is 
shown between the black arrows.
2
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Vasculitis is difficult to differentiate from atherosclerosis and can present as vascular wall 
thickening, occlusion of the affected vessel, aneurysm formation and wall enhancement. 
If mesenteric ischemia is caused by a low-flow state, non-occlusive mesenteric ischemia 
(NOMI) due to heart failure, shock, hypovolemia, dehydration, chronic renal failure, 
CTA may show diffuse thickened bowel wall within small and pruned blood vessels(36). 
These signs are non-specific and can be seen in mesenteric ischemia.
CTA is superior to DUS in detecting mesenteric aneurysms (Image 12-13) because of 
complete visualization of the mesenteric arteries and the surrounding tissue. CTA 
provides information of the size and volume of the aneurysm and degree of thrombosis, 
but can also define collateral flow information which is important knowledge for surgical 
or endovascular treatment.
Image 12. CTA image of CA aneurysm with dissection (indicated between the black arrows).
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Image 13. CTA image of SMA aneurysm in a patient with Q-fever.
Dissection of a mesenteric vessel is well detected by CTA (Image 14). The exact location 
and extend of the dissection flap can be analyzed easily and this information can be 
used for pre-interventional planning.
Image 14. CTA image of CA dissection, the intimal flap is indicated with a white arrow.
2
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CTA can be used to detect in-stent stenosis after endovascular treatment (Image 15). 
Intimal hyperplasia presents as a hypodense rim on the inner stent surface on CTA. Stent 
fraction (Image 16) and migration can also be detected by CTA. Finally, CTA can visualize 
grafts, graft anastomoses, intimal hyperplasia of bypasses and vessel patency after PTA.
Image 15. CTA image of subtle in-stent stenosis of the SMA due to intimal hyperplasia, shown 
between the black arrows.
Image 16. CTA image of CA stent fracture (indicated with the white arrow) and a long uncom-
plicated stent in the SMA.
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Table 2 shows an overview of the known sensitivity and specificity rates of CTA for 
diagnosing AMI and CMI. The sensitivity and specificity reported in the last decade is 
93-100% and 90-100%, respectively. The sensitivity and specificity rates are increasing 
over time, due to the developments and advancements in CTA techniques. Though, 
this sensitivity and specificity rates are mostly derived from studies with patients 
clinically suspected of AMI. In clinical practice, AMI is often diagnosed unexpectedly 
after imaging for acute abdominal pain. The protocol of these acute CT-scans performed 
in an emergency setting is often suboptimal for the diagnosis of AMI. As a result, AMI is 
underdiagnosed in CT-scans performed in patients with abdominal pain without clinical 
suspicion of AMI(2).
Table 2. Overview of sensitivity and specificity rates of CTA in diagnosing AMI and CMI.
First author
(publication year)
CTA sensitivity CTA specificity
Taourel (66)
(1996)
64% 92%
Kirkpatrick (59)
(2003)
96% 94%
Wiesner (67)
(2004)
80% 100%
Zandrino (68)
(2006)
92% 100%
Aschoff (69)
(2008)
93% 100%
Ofer (70)
(2008)
89% 97%
Akyildiz (71)
(2009)
93% 90%
Menke (72)
(2010)
Meta analysis (59, 67-71)
93% 96%
Yikilmaz (73)
(2011)
100% 100%
Schaefer (48)
(2013)
CA 100%
SMA n.a.
CA 95%
SMA 98%
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CTA is a non-invasive, widely available and fast imaging modality with high sensitivity 
and specificity for evaluation of the mesenteric vasculature. CTA techniques are 
developing rapidly resulting in even faster imaging techniques, lower radiation and 
lower iodine contrast agent exposure. Furthermore, resolution of the CT images is still 
increasing. Development of 3D CTA techniques ensures higher accuracy in detecting 
mesenteric vascular pathology, even in the smaller vessels. Despite the radiation and 
intravenous nephrotoxic contrast exposure, CTA is the first-line approach for AMI and 
CMI.
MRA
Gadolinium contrast-enhanced MRA of the mesenteric vasculature can visualize 
mesenteric stenosis and occlusions. MR technique uses a strong magnetic field. The 
technique is based on the relaxation of protons after excitation by a radio frequency (RF) 
pulse. Gadolinium changes the speed of this relaxation after the RF pulse. This results 
in optimal contrast between the bright blood and darker stationary tissue due to the 
T1-shortening effect of gadolinium and tissue that has not yet been perfused by the 
contrast agent. Today, modern MR systems acquire high-resolution MRA images within 
a single breath hold. This reduces motion artefacts and artefacts from bowel peristalsis. 
A major shortcoming of MRI is its inability to demonstrate calcifications, which makes 
the differentiation between atherosclerotic disease and MALS difficult. Still, MRA is a 
time consuming and expensive test, which is not often promptly available. This results 
in a limited role for MRA, especially in the acute setting.
MRA is usually performed on an 1.5T or 3T MR field strength in the arterial and venous 
phase comparable to CTA contrast timing. The contrast agent used is gadolinium, which 
only has a few side effects such as a low incidence of allergic reactions, a minimal 
nephrotoxic effect compared to the contrast agent used with CTA for a similar volume 
and the recently described potential development of nephrogenic systemic fibrosis 
in patient with kidney failure(33, 37). Main limitations of MRA are the length of MRA 
examination up to 1 hour, claustrophobia, and contra-indications such as implanted 
cardiac devices and metal foreign bodies
MRA has high sensitivity and specificity for stenosis of the origin of the SMA and CA 
(Image 17-18), but has lower sensitivity and specificity for the smaller downstream 
vessels and IMA(33). Shirkhoda et al. evaluated the mesenteric circulation with MRA 
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and reported good visualization of the SMA in 85%, CA in 75%, IMA in 25%, first-order 
branching in 75%, second-order branching in 60%, third-order branching in 50%, SMV 
in 85% and portal vein in 85% of all performed MR angiograms(38). The inter-observer 
variability of MRA is reported as near perfect for proximal stenosis of the CA and SMA 
and moderate for the IMA(39). MRA tends to overestimate stenosis, which decreases 
the specificity(39). MRA is less sensitive for detection of calcification compared to CTA 
and secondary signs of AMI as bowel wall thickening and mesenteric fat stranding are 
more difficult to assess. Furthermore, the resolution of MRA is not sufficient to visualize 
NOMI(40). Ernst et al. reported the comparison of MRA with DSA for visualization of 
the mesenteric vessels specific. They concluded a good agreement for the SMA and 
excellent agreement for the SMV and poor agreement for the branches of the SMA(41). 
MRA has similar performances to CTA in detecting mesenteric aneurysms(32). Table 3 
shows the sensitivity and specificity of MRA for several mesenteric vascular pathologies.
Image 17. MRA image of CA stenosis; the CA, SMA and IMA are top-down shown with the black 
arrows, respectively.
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Image 18. MRA image of CA stenosis (black arrow) and SMA stenosis (white arrow).
Table 3. Overview of sensitivity and specificity rates of MRA
First author
(publication year)
Pathology MRA sensitivity MRA specificity
Holland (74)
(1996)
Mesenteric stenosis ≥ 50% 100% 100%
Meaney (60)
(1997)
CMI > 75% stenosis 100% 95%
Kreft (75)
(2000)
Portal venous thrombosis 100% 98%
Schaefer (48)
(2013)
Mesenteric stenosis ≥ 50% CA 92%
SMA n.a.
CA 84%
SMA 96%
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MRA is not suitable to assess stent patency due to (metal) stent-induced artefacts. 
However, MRA is suitable for visualizing grafts, graft anastomoses, intimal hyperplasia 
of bypasses and follow up of vessel patency after PTA(42).
An advantage of MRI is the possibility to perform blood flow measurements, i.e. 
measurements of flow profiles, stroke volumes and peak velocities using cine phase 
contrast MR imaging. Cine phase contrast MR techniques enable non-invasive qualitative 
assessment of presence, magnitude and direction of blood flow in 2 and currently also 
3 directions (4D MR flow). The retrieved dataset can be processed for estimation of 
blood flow velocity, volume flow rate and displaced volumes. In healthy subjects the 
mesenteric blood flow will increase after a meal. This increase can be measured 15 
minutes postprandially with a peak velocity after 30 minutes. This postprandial blood 
flow increase assessed with cine phase contrast MR technique is reported in the SMA, 
SMV and PV(43-45). In patients with chronic mesenteric ischemia the mesenteric blood 
flow is suspected to increase less postprandially compared to healthy subjects, due to 
hemodynamically significant stenosis of one or more mesenteric vessels. Significantly 
less increase in postprandial blood flow of the SMV in patients with CMI compared to 
healthy subjects is shown with use of the MR flow technique. Although, the postprandial 
blood flow increase of the PV did not significantly differ in patients with CMI versus 
healthy subjects(45). Furthermore, the existence of a negative correlation between 
the degree of the SMA stenosis and the degree of postprandial blood flow increase 
in the SMA measured by MR has been reported(46). The cine phase contrast MR 
technique is a promising technique for non-invasive functional assessment of the 
mesenteric vasculature. More research is needed to assess the use of the technique in 
the diagnostic work-up for CMI and other mesenteric diseases.
Concluding, MRA is a non-radiation imaging technique that can visualize the proximal 
CA and SMA accurately. Due to lower resolution of MRA compared to CTA, the IMA and 
distal branches of CA and SMA are visualized less accurately. Cine phase contrast MR 
technique can assess the mesenteric blood flow pre- and postprandial non-invasively 
and might become a discriminatory functional test for in the diagnosis of CMI.
2
62
Chapter 2
DSA
Catheter-based arteriography is the gold standard in diagnosing mesenteric arterial 
disease and still is the reference standard. Due to its invasive nature, and the technical 
improvements in CTA techniques, its use for diagnosis has been replaced by non-
invasive CTA largely. Other less invasive modalities as DUS and MRA have been used 
increasingly for diagnosis as quality increased(47). Only one study compared the non-
invasive modalities CTA, MRA and DUS with DSA. CTA provided the best image quality 
with the best diagnostic accuracy(48).
Angiography of the mesenteric vessels can be performed by a femoral, brachial or 
radial approach. Femoral or radial access is first choice as brachial access has a higher 
complication rate(49). In case of a steep angle of the mesenteric arteries with regard to 
the aorta, a radial approach may be more appropriate than a femoral approach. Sheath 
diameter should be chosen according to expected intervention and material used, but 
is generally 6-F or 7-F. Ultrasound guided puncture of the artery reduces the number of 
attempts and time required for acquiring access especially in the radial approach(50). 
Selective angiography is performed with 15-20ml iodine contrast medium for both the 
CA and the SMA. The use of low-osmolar contrast agent such as Visipaque 320 mg I/
ml (GE Healthcare Inc., Medical Diagnostics, Princeton, New Jersey, USA) minimizes 
abdominal discomfort, but, again, has a nephrotoxic risk. The femoral access site is 
closed by manual hemostasis or a closure device such as Angioseal (St. Jude Medical, 
Austin, Texas). The radial access site is sealed using dedicated bandages.
Multiplane digital subtraction angiography of the abdominal aorta and its branches 
enables multiple oblique projections of the abdominal aorta and of the origin and 
outflow of the mesenteric arteries. At least antero-posterior and lateral views should 
be obtained. Selective angiography and views during ex- and inspiration are optional 
and of diagnostic importance in patients with MALS (Image 19 and 20). Early imaging 
is necessary for visualizing the origins of the CA and the SMA. Late imaging is required 
to evaluate the retrograde flow, delayed filling and collateral pathways(51). The 
dynamic imaging also provides information on flow direction, which may be valuable 
interpreting collateral circulation(52). Retrograde flow within the IMA, the arc of Riolan 
or common hepatic artery are indicative for stenosis of respectively the SMA and CA. 
Common collateral pathways are through the gastroduodenal arteries, arc of Riolan and 
Drummond. Well-established collaterals (grade 2) are clearly defined by non-selective 
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angiography (Image 21-23) however potential collaterals (prior to enlargement) (grade 1) 
may be more difficult to demonstrate but may be visible on more selective angiography 
(Image 24)(21, 53). Collaterals present during non-selective angiography are indicative 
for significant stenosis in contrast to selective angiography (grade 1)(21). A recent study 
shows a possible compensational role for type 2 collaterals as success rate after release 
of the CA in MALS was lower when type 2 collaterals were present(54).
Image 19. Non-selective DSA in a patient with MALS in expiration (black arrow indicates the 
compression of the CA).
Image 20. Non-selective DSA in a patient with MALS in inspiration (black arrow indicates the CA).
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Image 21. Non-selective DSA in a patient with CA stenosis showing gastroduodenal grade 2 
collaterals (white arrows indicate collaterals between SMA and CA with flow direction from 
large to small arrow).
Image 22. Non-selective DSA (anterior-posterior plane) in a patient with CA and SMA stenosis 
showing grade 2 collateral from IMA through the arc of Riolan (white arrows indicate collateral 
with flow direction from large to small arrow).
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Image 23. Non-selective DSA in a patient with CA stenosis (black arrow) and SMA stenosis (white 
arrow) in lateral plane (same patient as image 22).
Image 24. Selective DSA of SMA showing grade 1 collaterals through the gastroduodenal pathway 
(from SMA to CA) in a patient with CA stenosis (white arrows indicate collaterals between SMA 
and CA with flow direction from large to small arrow).
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Selective cannulation during angiography facilitates measurement of pressure gradients 
in case of doubtful stenosis(55). An alternative is fractional flow reserve (FFR) which is 
used for evaluation of the coronary circulation however its use in mesenteric arteries has 
yet to be established. Injection of a vasodilative drug such as priscoline or papaverine 
into the SMA may be used as a test to diagnose MALS(56). The vasodilator increases 
flow in the SMA, which in theory mimics a postprandial state with steal by decreasing 
the collateral flow to the CA bed with ischemic symptoms. Studies are needed to further 
determine the clinical significance of the visualization of collateral flow and FFR.
At present, angiography is mostly obtained in conjunction with a planned endovascular 
intervention, e.g. PTA or stent placement. Angiography however has its place in patients 
where other techniques provide insufficient information for example in case of extensive 
calcifications or presence of stents causing artefacts. Angiography also has its value in 
patients suspected for MALS, allowing more accurate imaging of the CA and its relation 
to the arcuate ligament during respiration.
CONCLUSION
Radiological imaging is essential for the diagnosis of mesenteric vascular disease. CTA 
and MRA are highly accurate vascular imaging modalities with high sensitivity and 
specificity for evaluation of the mesenteric vasculature and these imaging modalities 
have virtually replaced reference standard DSA as a diagnostic modality. However, 
DSA has a leading role in endovascular treatment of CMI and an emerging role in 
the treatment of AMI. CTA is the first-line approach in diagnosing acute and chronic 
mesenteric ischemia, because of its high spatial resolution and short acquisition time. 
The peripheral branches of the mesenteric vasculature and the IMA are assessed with 
greater accuracy compared to MRA and US. Moreover, CTA is lower in costs compared 
to MRA and more available in clinical practice. DUS is a non-invasive, non-radiating 
and non-nephrotoxic contrast agent exposing imaging modality, which is useful in the 
diagnosis of occlusive CMI and follow-up of revascularization therapy. Table 4 and 5 
show the compared sensitivity and specificity rates of US, CTA and MRA compared with 
DSA as reference standard and the advantages, disadvantages and recommendations 
of each of these modalities are given, respectively. Because of the fast developments 
in imaging techniques more detailed non-invasive imaging becomes available including 
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functional assessment. An up-do-date comparison of the performance of the current 
imaging modalities for the diagnosis of mesenteric vascular pathology is needed.
Table 4. Overview of report comparing US, CTA and/or MRA in detecting of mesenteric stenosis
US 
sensitivity
US 
specificity
CTA 
sensitivity
CTA 
specificity
MRA 
sensitivity
MRA 
specificity
Schaefer (48)
(2013)
stenosis ≥ 50%
CA 91%
SMA n.a.
CA 91%
SMA 96%
CA 100%
SMA n.a.
CA 95%
SMA 98%
CA 92%
SMA n.a.
CA 84%
SMA 96%
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ABSTRACT
Background and objective
The objective of this article is to externally validate and update a recently published 
score chart for chronic mesenteric ischemia (CMI).
Methods
A multicenter prospective cohort analysis was conducted of 666 CMI-suspected patients 
referred to two Dutch specialized CMI centers. Multidisciplinary consultation resulted 
in expert-based consensus diagnosis after which CMI consensus patients were treated. 
A definitive diagnosis of CMI was established if successful treatment resulted in durable 
symptom relief. The absolute CMI risk was calculated and discriminative ability of the 
original chart was assessed by the c-statistic in the validation cohort. Thereafter the 
original score chart was updated based on the performance in the combined original 
and validation cohort with inclusion of celiac artery (CA) stenosis cause.
Results
In 8% of low-risk patients, 39% intermediate-risk of patients and 94% of high-risk 
patients of the validation cohort, CMI was diagnosed. Discriminative ability of the 
original model was acceptable (c-statistic 0.79). The total score of the updated chart 
ranged from 0 to 28 points (low risk 19% absolute CMI risk, intermediate risk 45%, and 
high risk 92%). Discriminative ability of the updated chart was slightly better (c-statistic 
0.80).
Conclusion
The CMI prediction model performs and discriminates well in the validation cohort. 
The updated score chart has excellent discriminative ability and is useful in clinical 
decision making.
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INTRODUCTION
Chronic Mesenteric Ischemia (CMI) is defined as ischemic symptoms caused by 
insufficient blood supply the gastrointestinal tract(1). The most common cause is 
atherosclerotic stenosis of one or more supplying gastrointestinal arteries(1, 2). Other 
common causes for mesenteric artery stenosis are vasculitis, and the most common 
cause for isolated celiac artery (CA) stenosis is compression of the CA by the median 
arcuate ligament (median arcuate ligament syndrome (MALS)). Chronic non-occlusive 
mesenteric ischemia (NOMI) is caused by hypoperfusion or hypooxygenation as can be 
seen in underlying conditions as cardiac or pulmonary disease, shunting, microvascular 
occlusion, and autonomic dysfunction(3).
The exact incidence of CMI is unknown, since population-based studies are lacking. 
However, the number of CMI patients undergoing revascularization procedures is 
increasing significantly according data from the United States (1.8 per million in 2000 to 
5.6 per million in 2012 (p<0.01))(4). Considering the aging population and the increased 
prevalence of cardiovascular disease (CVD), the incidence of CMI is expected to increase 
in upcoming years.
Diagnosing CMI is important since untreated CMI may develop into acute-on-chronic 
mesenteric ischemia, which is associated with high morbidity and mortality. Since 
no gold-standard test for CMI is currently available, the diagnostic work-up consists 
of symptom assessment and radiological evaluation of the mesenteric arteries(3). 
Symptoms alone are associated with a low predictive value for CMI(2, 5, 6). If available, 
a functional test to assess mucosal ischemia as gastric-jejunal tonometry(7-9) or visible 
light spectroscopy (VLS)(10, 11) can enhance the diagnostic accuracy. A consensus 
diagnosis is established in a multidisciplinary meeting(1), an accepted method in the 
absence of one specific test(12). A definitive diagnosis of CMI is established when 
revascularization for occlusive mesenteric ischemia or medical therapy for chronic 
NOMI results in durable symptom relief.
The diagnostic work-up for CMI is cumbersome and time-consuming since multiple tests 
are required. This exposes patients to invasive diagnostic interventions and because of 
the need for successive investigations may lead to a delay in treatment for patients with 
CMI. This underlines the need for an easy-to-use tool to promptly and reliably assess 
the risk of CMI in patients suspected of having this diagnosis to guide clinical decision-
3
80
Chapter 3
making: 1) patients with low risk of CMI for which a wait-and-see policy is justified to 
save them from unnecessary diagnostics, 2) patients with intermediate risk of CMI 
for which further testing to assess mucosal oxygenation such as VLS or tonometry is 
indicated to establish the diagnosis and 3) patients with high risk of CMI for whom no 
additional test is indicated and require intermediate vascular intervention.
Recently, a CMI prediction model based on a large single-center prospective cohort 
was published by our study group that identifies low-risk, intermediate-risk and high-
risk patients(13). The score chart of this model consists of 5 predictors: female sex, 
presence of weight loss, presence of CVD, degree of CA stenosis, and degree of superior 
mesenteric artery (SMA) stenosis (Table 1). However, this CMI prediction model did not 
include the cause of the CA stenosis, such as MALS or atherosclerosis, which differ in 
patient presentation and patient characteristics(2). Since it was expected by experts in 
the field that the specific cause of CA stenosis would result in different predictive values 
for the risk of CMI, this variable was added to the updated model.
The current diagnostic work-up for CMI is extensive and cumbersome. A validated tool 
is much needed to stratify patients suspected of CMI in distinct risk groups to guide 
clinical decision making. Such a tool and corresponding strategy should result in a more 
optimal identification of patients with CMI whom may profit from treatment using 
tailored diagnostics and should lead to a decrease in patient-burden and reduced health 
costs. We aimed to externally validate the previously published CMI prediction model 
in a new multicenter cohort. Furthermore, we aimed to update the score chart based 
on the performance of the model by combining the original and validation cohort and 
by including the CA stenosis cause.
MATERIAL AND METHODS
Study design and setting validation cohort
A multicenter, prospective cohort study was conducted for all consecutive patients 
suspected of CMI referred to two Dutch centers specialized in functional testing for 
mucosal ischemia: Erasmus MC University Medical Center Rotterdam (inclusion January 
2014 to July 2016) and Medisch Spectrum Twente Enschede (inclusion May 2015 to 
January 2016). Patients were suspected of CMI based on the criteria for the original 
cohort of Harki et al(13). Patients without radiological evaluation of the mesenteric 
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arteries with computed tomography angiography (CTA) or magnetic resonance 
angiography (MRA) were excluded.
The medical research ethics committee of Erasmus MC University Medical Center 
approved that the Medical Research Involving Human Subjects Act does not apply to 
this study and that no informed consent was required according to the local directives 
(MEC-2013-317). The study complies with the Helsinki declaration on research ethics. 
To enhance transparency this article is written according to the STROBE checklist for 
cohort studies(14).
Data sources
All data was retrieved from the hospital records in the context of standard clinical care. 
Follow-up of patients was by means of outpatient clinic contact or by phone. Standard 
protocol visits were scheduled 1, 3, 6, 12, and 24 months after revascularization during 
which recurrent symptoms (i.e. similar to presenting symptoms before therapy) were 
assessed and body weight was documented.
Participants
All included patients underwent a standardized diagnostic work-up for CMI at baseline. 
This work-up consists of symptom assessment, physical examination, imaging of the 
mesenteric arteries with either CTA and MRA, and a functional test for mucosal ischemia 
detection with either 24-hour gastric-jejunal tonometry, gastric exercise tonometry or 
VLS(6-8, 10, 15-17).
All cases were discussed in a multidisciplinary meeting attended by gastroenterologists, 
vascular surgeons and interventional radiologists, all specializing in CMI. An expert-
based consensus diagnosis of CMI was established if two of the following three criteria 
were met: 1) typical clinical presentation of CMI (postprandial abdominal pain, weight 
loss, or diarrhea); 2) significant stenosis of at least the CA or SMA (≥ 50% diameter 
reduction(18-21)) on CTA or MRA and/or conventional catheter angiography; 3) 
mucosal ischemia as determined by 24-hour gastric-jejunal tonometry, gastric exercise 
tonometry or VLS(7, 10).
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The degree of stenosis of the mesenteric arteries was calculated on CTA or MRA using 
interactive vessel segmentation software. The stenosis degree was classified in <50% 
stenosis, 50%-70% stenosis or ≥70% stenosis.
Definitive diagnosis of CMI
Patients with a consensus diagnosis of CMI based on occlusive disease were scheduled 
for either endovascular or surgical revascularization. Patients with stenosis of one 
or more mesenteric arteries based on vascular disease were scheduled first for 
endovascular revascularization: percutaneous mesenteric artery stenting (PMAS). If 
patients were not eligible for PMAS or if patients had recurrent episodes of restenosis, 
they were treated with open surgical mesenteric artery repair (OSMAR).
In patients with a CA stenosis the diagnosis of MALS was established if CTA demonstrated 
focal narrowing of the proximal CA ≥50% with post-stenotic dilatation and eccentric 
indentation on the superior aspect of the CA, creating a hook-shaped contour of the 
CA. This characteristic kinking dependent on the respiratory cycle in the absence of 
calcifications distinguishes this condition from other causes of CA stenosis such as 
atherosclerosis(22). When CTA did not clarify the cause of CA stenosis, an additional 
catheter angiography of the CA in inspiration and expiration was performed. Patients 
with CA stenosis based on MALS were planned for surgical release (open or endoscopic) 
of the median arcuate ligament.
Patients with a consensus diagnosis of chronic NOMI were treated with vasodilatory 
medical therapy: oral nitrates (isosorbide mononitrate or isosorbide dinitrate). First, 
a low dose was prescribed (10-20 mg twice per day) and if symptoms preserved with 
the absence of side effects the dose was increased (to 40 mg twice per day). Nitrates 
were replaced by Ketansarin (selective α1-receptor antagonist) if side effects occurred 
and/or clinical improvement was absent, starting with a 10-20 mg twice per day and 
increased to 40 mg twice per day.
The treated patients were evaluated during follow-up visits. A definitive diagnosis of 
CMI was established if the patient reported relief of initial symptoms after successful 
therapy. This patient-reported outcome of symptom relief was classified into two 
groups: no or minimal symptom relief and major or complete symptom relief. A 
definitive diagnosis of no CMI was established when consensus diagnosis was no CMI 
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or when symptom relief did not occur after technically successful treatment. Patients 
with a consensus diagnosis of no CMI were discharged without further follow-up.
Variables
Patient characteristics that were collected included age, sex, past medical history, 
presenting symptoms such as abdominal pain, postprandial pain, diarrhea, nausea, 
weight loss (in kg, defined as >5% loss of body weight), body mass index (BMI) at 
presentation, and cardiovascular risk factors. Vascular lesions were specified for 
localization (CA, SMA or inferior mesenteric artery (IMA)) and cause (vascular disease, 
MALS, NOMI).
The primary outcome was definitive diagnosis: CMI or no CMI. The definitive diagnosis 
was compared with the total score of the score chart to validate this score chart. 
Secondary outcome was the cause of CMI (vascular disease versus MALS).
Score chart
The score chart (Table 1) was applied for each included patient. Based on the total 
score each patient was classified in one of three risk groups: low-risk (0-2 points), 
intermediate-risk (3-6 points) and high-risk (≥7 points).
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Table 1. Score chart for the prediction of CMI and the absolute CMI risk from Harki et al.(13). 
Predictor Scoring points
Sex
Male 0
Female 1
Weight loss
No 0
Yes 1
Cardiovascular disease
No 0
Yes 1
Celiac artery
50-70% stenosis 1
>70% stenosis 4
Superior mesenteric artery
50-70% 1
>70% stenosis 3
Total score Risk group Absolute CMI risk (%)
0-2 points Low 21%
3-6 points Intermediate 46%
7+ - High 79%
CMI = chronic mesenteric ischemia. 
Study size
There was a requirement to include minimally 215 patients suspected of having CMI 
assuming a CMI diagnosis rate of 47%(13) according to literature recommendations 
on sample size considerations for the external validation of a multivariable prognostic 
model(23, 24).
Statistical methods
Baseline characteristics were described for the validation cohort either as numbers and 
percentages for dichotomous variables, or as means and standard deviations or medians 
and interquartile ranges (IQR) for continuous variables. Multiple imputation (10 times) 
was used to impute missing values of the predictors from the score chart and cause 
of CA stenosis. Univariable and multivariable associations were estimated with logistic 
regression analysis as odds ratios (ORs) with a 95% confidence interval (CI). The added 
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value of cause of the stenosis of the CA (vascular disease versus MALS) was assessed 
by including the variable in the multivariable logistic regression.
Performance of the original score chart was studied by comparing the definitive 
diagnosis with the total score of the score chart. Discriminative ability of the score 
chart was assessed with the c-statistic. This measure of concordance is identical to the 
area under the receiver-operating characteristics (ROC) curve. C-statistic of 0.5 suggests 
no discrimination, c-statistic of 0.7-0.8 is considered as acceptable discrimination, 
c-statistic of 0.8-0.9 as excellent discrimination and c-statistic ≥0.9 as outstanding 
discrimination(25). Furthermore, calibration was assessed graphically with a calibration 
plot: a plot with the predicted risk of CMI on the X-axis and the observed proportion of 
CMI on the Y-axis. After validating the score chart in the validation cohort, the data of 
the validation cohort was combined with the data of the original cohort described by 
Harki et al(13). The original score chart was updated based on the performance of the 
score chart in the combined original cohort and validation cohort and with inclusion 
of the cause of the CA stenosis based on expert view. Scores for the updated score 
chart were calculated by dividing the regression coefficients of the predictors by 0.17. 
Calibration and discriminative ability were also tested for the updated score chart.
RESULTS
Patient characteristics of validation cohort
During the study period, 246 patients suspected of CMI were included in the validation 
cohort. A consensus diagnosis of CMI was established in 105/246 patients (43%). After 
treatment for CMI a definitive diagnosis of CMI was established in 93/105 patients 
(89%). A flow chart is shown in Figure 1. Mean age in the validation cohort was 61 years, 
the majority was female (70%) with a mean symptom duration of 2 years (Table 2). 
Table 3 lists the consensus diagnosis, definitive diagnosis, vascular lesions, and cause of 
stenosis for each risk group according the original score chart in the validation cohort. 
The majority of patients in the low-risk group did not have significant vascular lesions 
(75%) whereas all patients of the high-risk group had at least one significant mesenteric 
stenosis, 96% being atherosclerotic. Furthermore, the majority of the patients in the 
high-risk group had multi-vessel disease (88%).
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The follow-up period was 10.5±6.6 months for the patients with a consensus diagnosis 
of CMI and 3.7±6.6 months for the patients with a consensus diagnosis of no CMI.
Figure 1. Flowchart of validation cohort.
CMI = chronic mesenteric ischemia; MALS = median arcuate ligament syndrome.
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Table 2. Patient characteristics and presenting symptoms of validation cohort.
All patients
n=246
Definitive diagnosis 
of CMI 
n=93
No definitive diagnosis 
of CMI
n=153
Patient characteristics
Age (y) 60.9±16.6 65.8±14.4 57.9±17.2
Female 171 (69.5%) 58 (62.4%) 113 (73.9%)
Hypertension* 122 (49.6%) 62 (66.7%) 60 (39.2%)
Ever smoked 179 (73.7%) 79 (85.9%) 100 (66.2%)
Dyslipidemia# 123 (50.2%) 62 (67.4%) 61 (39.9%)
Diabetes 42 (17.1%) 25 (26.9%) 17 (11.1%)
BMI at presentation (kg/m2) 23.5±4.8 23.5±5.1 23.4±4.6
History of CVD 133 (54.1%) 68 (73.1%) 65 (42.5%)
Presenting symptoms
Symptom duration (months) 23.6±59.3 18.0±31.4 27.1±71.1
Abdominal pain 231 (93.9%) 88 (94.6%) 143 (93.5%)
Postprandial pain 166 (67.8%) 65 (70.7%) 101 (66.0%)
Exercise related pain 78 (35.0%) 23 (28.7%) 55 (38.5%)
Nausea 128 (57.9%) 51 (60.0%) 77 (56.6%)
Diarrhea 72 (30.6%) 32 (36.8%) 40 (27.0%)
Weight loss 169 (68.7%) 76 (81.7%) 93 (60.8%)
Data are presented as N (percentages) or as mean ± SD. *Hypertension was defined as a blood pressure 
of ≥140/90 mmHg or use of antihypertensive medication. #Dyslipidemia was defined as LDL-C >4.2 
mmol/L or HDL-C <0.9 mmol/L or use of lipid lowering medication.  
BMI = body mass index; CMI = chronic mesenteric ischemia; CVD = cardiovascular disease.
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Table 3. Diagnosis, vascular lesion, and cause of the vascular lesion specified for each risk group 
according the original score chart of the validation cohort.
Low-risk 
(0-2 pts)
n=92
Intermediate-risk 
(3-6 pts) 
n=106
High-risk 
(≥7 pts) 
n=48
Diagnosis
Consensus diagnosis CMI 10 (10.9%) 49 (46.2%) 46 (95.8%)
Definitive diagnosis CMI 7 (7.6%) 41 (38.7%) 45 (93.8%)
Cause of the vascular lesion
No sign. vascular lesion#, no ischemia 69 (75.0%) 13 (12.3%) 0 (0.0%)
Vascular disease 7 (7.6%) 57 (53.7%) 42 (87.5%)
MALS 7 (7.6%) 33 (31.1%) 2 (4.2%)
NOMI 6 (6.5%) 1 (0.9%) 0 (0.0%)
Atherosclerosis + NOMI 3 (3.3%) 0 (0.0%) 1 (2.1%)
Atherosclerosis + MALS 0 (0.0%) 1 (0.9%) 3 (6.3%)
MALS + NOMI 0 (0.0%) 1 (0.9%) 0 (0.0%)
Vascular lesion localization
No significant vascular lesion# 75 (81.5%) 14 (13.2%) 0 (0.0%)
Single vessel 16 (17.4%) 70 (66.0%) 6 (12.5%)
CA stenosis 10 (62.5%) 52 (74.2%) 5 (83.3%)
SMA stenosis 0 (0.0%) 17 (24.3%) 1 (16.7%)
IMA stenosis 6 (37.5%) 1 (1.4%) 0 (0.0%)
Multi vessel 1 (1.1%) 22 (20.8%) 42 (87.5%)
CA and SMA stenosis 0 (0.0%) 9 (40.9%) 16 (38.1%)
CA and IMA stenosis 0 (0.0%) 4 (18.2%) 1 (2.4%)
SMA and IMA stenosis 1 (100%) 6 (27.3%) 0 (0.0%)
CA, SMA and IMA stenosis 0 (0.0%) 3 (13.6%) 25 (59.5%)
# No significant vascular lesion = no stenosis or stenosis < 50% 
Data are presented as n (percentages). 
CA = celiac artery; CMI = chronic mesenteric ischemia; IMA = inferior mesenteric artery; MALS = median 
arcuate ligament syndrome; NOMI = non-occlusive mesenteric ischemia; pts = points; SMA = superior 
mesenteric artery. 
Performance original score chart
The original score chart performed good in the validation cohort with an absolute CMI 
risk of 8% in the low-risk group (original cohort: 21%(13)), 39% in the intermediate-
risk group (original cohort: 46%(13)) and 94% in the high-risk group (original cohort: 
79%(13)). Discriminative ability was acceptable with a c-statistic of 0.79 (original cohort: 
0.79). Calibration results of the original model in the combined cohort are shown in 
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Figure 2a. Perfect prediction of CMI would show when all points are on the 45° (dashed 
line) because of a slope of 1 and calibration intercept of 0.
Figure 2. Performance of the original score chart (a) and the updated score chart (b) based on 
the combined cohort (n=666).
Alb = intercept a, slope b = calibration slope, c stat = c-statistic.
Combined cohort
The observed frequencies of CMI in the original cohort, validation cohort and combined 
cohort are shown in Table 4 specified per hospital. The frequency of CMI was higher 
in the original cohort (47%) than in the validation cohort (38%). Table 5 shows the 
multivariable logistic regression analyses of the combined cohort with the 5 predictors 
of the original score chart and with interaction of the CA stenosis cause (vascular disease 
versus MALS). Sex showed no effect in the combined cohort (female OR=1.01, 95% CI 
0.68-1.52).
Table 4. Observed frequencies of CMI in the original, validation and combined cohort specified 
per hospital.
Center Original cohort 
n=420
Validation cohort
n=246
Combined data
n=666
Erasmus MC 196/420 (46.7%) 42/136 (30.1%) 238/556 (42.8%)
Medisch Spectrum Twente - 51/110 (46.6%) 51/110 (46.6%)
Total 196/420 (46.7%) 93/246 (37.8%) 289/666 (43.4%)
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Table 5. Results of the multivariable logistic regression analyses in the combined cohort; odds 
ratio (95% confidence interval).
Predictors Combined cohort
n=666
Female 1.01 (0.68-1.52)
Weight loss 2.22 (1.47-3.35)
CVD 1.40 (0.95-2.07)
50-70% CA stenosis - vascular disease 1.82 (0.96-3.44)
50-70% CA stenosis - MALS 1.94 (0.77-4.91)
> 70% CA stenosis - vascular disease 6.62 (3.95-11.09)
> 70% CA stenosis - MALS 4.53 (2.43-8.44)
50-70% SMA stenosis 2.02 (0.99-4.15)
>70% SMA stenosis 5.94 (3.42-10.31)
CA = celiac artery; CMI = chronic mesenteric ischemia; CVD = cardiovascular disease; MALS = median 
arcuate ligament syndrome; SMA = superior mesenteric artery.
Updated score chart
Table 6 shows the updated score chart with the absolute CMI risk. We included the 
interaction of the CA stenosis cause based on expert view, although not statistically 
significant (p=0.541). The score of the updated chart ranged from 0 to 28 points, with 0 
to 5 points indicating a low risk of CMI of 19% (low-risk original score chart in combined 
cohort: 22%), 6 to 18 points indicating an intermediate risk of 45% (intermediate-risk 
original score chart in combined cohort: 45%), and 19 points or more indicating a high 
risk of 92% (high-risk original score chart in combined cohort: 87%). The low-risk group 
consisted of 247 of the 666 patients of the combined cohort (37%), the intermediate-risk 
group of 305 (46%) patients, and the high-risk group consisted of 114 (17%) patients.
Figure 2b shows the calibration of the updated score chart. The updated model is based 
on the data of the combined cohort and resulted in a calibration intercept close to 0 
and calibration slope b (slope b) close to 1. The discriminative ability of the updated 
model is excellent with a c-statistic of 0.80.
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Table 6. Updated score chart for the prediction of CMI. 
Predictor Scoring points
Weight loss
No 0
Yes 5
Cardiovascular disease
No 0
Yes 2
Celiac artery
50-70% stenosis – vascular disease 4
50-70% stenosis – MALS 4
>70% stenosis – vascular disease 11
>70% stenosis - MALS 9
Superior mesenteric artery
50-70% stenosis 4
>70% stenosis 10
Total score Risk group Absolute CMI risk (%)
0-5 points Low 19.4%
6-18 points Intermediate 44.6%
19+ High 92.1%
CMI = chronic mesenteric ischemia; MALS = median arcuate ligament syndrome.
DISCUSSION
In this multicenter study, we performed an external validation of the recently developed 
score chart to predict the risk of CMI. Next, we developed an updated version of the 
score chart based on the performance of the score chart in the combined cohort and 
with inclusion of the CA stenosis cause. CMI predictors of the updated score chart are 
presence of weight loss, presence of CVD, the degree of CA stenosis combined with 
the cause of CA stenosis and the degree of SMA stenosis. The updated score chart is an 
easy-to-use and reliable tool to discriminate the risk of CMI (c-statistic 0.80).
The findings of our cohort analysis in 666 CMI suspected patients, the largest cohort 
described, correspond with the recently published clinical practice guidelines 
Management of the diseases of mesenteric arteries and veins(1) by the European 
Society of Vascular Surgery. Weight loss is an important symptom for the diagnosis 
of CMI according the guideline and the advice is given to perform additional analyses 
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for an alternative diagnosis in patients suspected of CMI without substantial weight 
loss. Our data confirm that weight loss is the only predictive clinical symptom in the 
prediction model. In accordance with the guidelines stating that patients with CMI have 
atherosclerotic involvement in other locations(26, 27) our score chart incorporated 
the presence of cardiovascular disease as a predictor of CMI. Finally, the guidelines 
recommends considering the diagnosis of CMI in patients with otherwise unexplained 
abdominal symptoms and occlusive disease of two or three mesenteric arteries. This 
corresponds with our findings that multi vessel disease is present in 88% of the high-risk 
patients as opposed to only 1% multi vessel disease in low-risk patients.
In contrast with the original score chart, female sex is not a predictor in the updated 
score chart. Female preponderance for CMI is reported in literature(26, 27) and we 
show that the majority (70%) of the patients with definitive CMI are female in the 
combined cohort. However, the majority of patients without CMI are also female (65%).
We recommend the updated model for clinical practice since it is based on a more 
heterogeneous data set from a multicenter cohort, which supports its generalizability. 
Its applicability is also boosted by inclusion of the cause of CA stenosis. Experts 
expressed reservations regarding the original score chart because it lacked the cause 
of CA stenosis while clinical presentation and patient characteristics differ between 
those with atherosclerotic CMI and CMI based on MALS. The updated score chart shows 
a higher predictive value for vascular disease in case of >70% CA stenosis.
Both the original and the validation cohort include patients with chronic NOMI. Patients 
with NOMI present with typical symptoms of CMI. Chronic NOMI patients however will 
not be readily identified as high risk using the score chart because of a maximum score 
of 7 points in the absence of mesenteric artery stenoses. Subsequently chronic NOMI 
patients are classified as low risk or intermediate risk. Based on symptom development 
they will undergo immediate or later additional testing to establish or negate the 
diagnosis of CMI.
We suggest a wait-and-see policy for the patients classified as low-risk by the updated 
score chart since the symptoms in this patient group are minor and immediate treatment 
is not required. According to the score chart, 19% of the patients in the low-risk group 
will have CMI and their CMI is caused by NOMI or single vessel disease. The delay in CMI 
diagnosis for the 19% patients suffering from CMI in the low-risk group can be defended 
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since these patients are under the control of a physician during the wait-and-see policy 
who may intervene when the clinical situation during follow-up worsens. With this 
wait-and-see strategy, on the other hand, patients without CMI in the low-risk group 
(81%) are spared unnecessary diagnostics procedures.
This study carries several limitations. An inevitable limitation is the absence of a gold-
standard clinical test for the diagnosis of CMI. A working diagnosis is established by 
multidisciplinary consensus opinion and a definitive diagnosis is established when 
treatment results in durable symptom relief(3). Symptom relief is considered to be 
the most important and relevant patient related outcome. This response was noted 
as a dichotomous variable to limit interpretation bias. However, the patients reported 
symptom relief to the same team which participated in the multidisciplinary meeting 
reaching the consensus diagnosis of CMI, for which reason reporting bias cannot be 
excluded. Patients with a consensus diagnosis of no-CMI were not selected for therapy 
and discharged without further follow-up. The results of our prediction model can be 
extrapolated only to patients suspected of having CMI. Therefore, this model should 
not be used for patients with gastrointestinal symptoms in general, but only for those 
with a clear suspicion of CMI after other causes have been excluded. Incorporation 
bias may have possibly led to overestimation of the diagnostic accuracy of the score 
chart for CMI(28). Finally, the original cohort described by Harki et al. consisted of 436 
patients(13). The data set used for the current combined cohort analysis consisted 
of 420 patients of the original cohort because of missing data. In view of the sizable 
number of 666 patients in the current analysis, we assume that the effect of missing 
data of these 16 patients is negligible.
In conclusion, we externally validated a previously published score chart to predict 
the risk of CMI. We also updated the original score chart and included the cause of CA 
stenosis based on expert view. The updated score chart shows a good performance 
and an excellent discriminative ability. This updated score chart is a useful-tool to be 
used in clinical practice to stratify CMI suspected patients in 3 groups: 1. wait-and-see 
policy justified, 2. additional functional testing indicated and 3. immediate vascular 
intervention justified.
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ABSTRACT
Background
Visible light spectroscopy (VLS) performed during upper gastrointestinal endoscopy 
allows measuring mucosal oxygen saturation levels to determine gastrointestinal 
ischemia. We aimed to determine the observer variability of VLS.
Research design and methods
This is a single-center prospective study of 24 patients planned for usual care upper 
endoscopy. To test intraobserver variability, VLS-measurements were performed in 
duplicate by a single endoscopist in 12 patients. For interobserver variability analysis, in 
another 12 patients VLS-measurements were repeatedly and independently performed 
by two endoscopists in the same patient during the same endoscopy session. Observer 
variability was assessed with intraclass correlation coefficient (ICC) and clinical 
disagreement defined as >5% difference between 1st and 2nd set VLS-measurements.
Results
The intraobserver reliability was excellent (ICC antrum 0.77, duodenal bulb 0.81 and 
duodenum 0.84) with clinical disagreement only in antrum (3% of all intraobserver 
measurements). The interobserver reliability was good for the duodenal bulb (ICC 0.70) 
without clinical disagreement, however interobserver reliability was fair for duodenum 
(ICC 0.49) and antrum (ICC 0.56) with clinical disagreement occurring in 11% of all 
interobserver measurements.
Conclusions
The observer reliability of VLS is fair to good with intraobserver reliability being 
better than interobserver reliability. This supports the use of VLS for detection of 
gastrointestinal ischemia.
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INTRODUCTION
Chronic Mesenteric Ischemia (CMI) is defined as ischemic symptoms caused by 
insufficient blood supply to the gastrointestinal tract(1). CMI affects the upper 
gastrointestinal tract, while colonic ischemia affects the lower gastrointestinal tract. 
Patients with CMI may present with a range of symptoms, including postprandial 
abdominal pain and weight loss, malabsorption, villous atrophy, and gastroduodenal 
ulceration. These result from insufficient mesenteric blood flow, usually caused by 
atherosclerotic stenosis of the supplying gastrointestinal arteries. For long, a diagnosis 
of CMI could only be based on symptoms, physical exam, and vascular imaging. The 
lack of a functional test was an important shortcoming, likely leading to underdiagnosis 
and overdiagnosis of CMI. In recent years, substantial research efforts led to two 
functional tests; tonometry(2, 3) and more recently Visible light spectroscopy (VLS)(4, 
5). VLS oximetry is a technique to determine the mucosal capillary hemoglobin oxygen 
saturation(6) by closely mimicking the widely used pulse oximetry. VLS performed 
during upper endoscopy allows measuring the oxygen saturation of the mucosa of the 
upper gastrointestinal tract. CMI is characterized by decreased mucosal saturation. 
Functional testing by means of VLS thus represents a tool for diagnosis of CMI and this 
technique is currently used in clinical practice for the diagnostic work-up of patients 
suspected of CMI(7).
VLS-measurements are noninvasive and performed during upper endoscopy using a 
fiberoptic probe passed through the accessory channel of the endoscope. This probe 
emits white light and detects differences in the absorption spectra of the oxygenated 
and deoxygenated hemoglobin molecules(6). The measured mucosal saturation reflects 
indirectly the adequacy of the gastro-intestinal blood flow. VLS-measurements are 
performed in clinical practice at three different locations during upper endoscopy: the 
antrum of the stomach, the duodenal bulb and the descending duodenum. Based on 
previously determined cut-off values (4) in CMI suspected patients, the outcomes are 
defined positive for ischemia if the measured saturation value is lower than 63% in the 
antrum, 62% in the duodenal bulb and 58% in the descending duodenum in fasting state.
The sensitivity and specificity rates for VLS for the diagnosis CMI are 90% and 60%, 
respectively(4). Given its ease of use, VLS has the capacity to become the standard 
for CMI assessment, both for initial diagnosis as well as for follow-up of patients after 
therapeutic intervention. Since VLS is a relatively new functional test, further validation 
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is needed. To validate a novel diagnostic test it is mandatory to establish its observer 
variability.
The rationale of this study was to determine the interobserver variability and 
intraobserver variability of the VLS-measurements in order to establish the reliability 
and reproducibility of this technique.
PATIENTS AND METHODS
Study design
A single center prospective study was performed to evaluate the intraobserver and 
interobserver variability of VLS. Patients, who were planned for upper endoscopy in 
our center from March 2017 till August 2017, were screened for eligibility for this study. 
The study was approved by the medical research ethics committee of the Erasmus MC 
University Medical Centre (NL59989.078.17) and informed consent was obtained for 
all participants.
Participants
All patients of 18 years or older and planned for usual care upper endoscopy were 
eligible. Exclusion criteria were: referral for suspicion of CMI, pregnancy, previous 
surgery of the upper gastro-intestinal tract including small bowel, and contra-indication 
for the use of butylscopolamine.
Upper endoscopy with VLS-measurements
All patients underwent an upper endoscopy for usual care with additional VLS-
measurements. If sedation was administered, this consisted of midazolam intravenously 
(dose 2.5-5 mg) combined with fentanyl (dose 0.05 mg). Peripheral oxygen saturation 
and heart rate were continuous monitored. Oxygen was administered intranasally if 
necessary to maintain peripheral saturation level ≥ 95% during the VLS-measurements.
The VLS-measurements were performed with a fiberoptic probe (Endoscopic T-Stat 
Sensor; Spectros, Portola Valley, California) passed through the accessory channel of 
the endoscope. This probe was placed just above the mucosa (1-5 mm) of the target 
area, after any bile remnants were removed. The light of the endoscope was switched 
off and the reading of the mucosal saturation started on the monitor connected with 
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the probe (T-Stat 303 Microvascular Oximeter; Spectros, Portola Valley, California). 
The reading showed small rapid variations due to true changes in saturation and 
due to small changes in the position of the probe. A reading was noted if a stable 
measurement was obtained which is a measurement that recurrences several times 
during the small rapid variations of a reading. The highest saturation was noted. The 
probe was repositioned within the measurement site and a new measurement was 
performed. Three repeated readings per site were noted with fewer than 5% variation 
and these 3 readings were averaged reflecting the most accurate mucosal saturation at 
that site. These saturation measurements were performed at three different locations: 
the antrum of the stomach, the duodenal bulb and the descending duodenum since the 
cut-off values are determined for these 3 locations(4). All VLS-measurements during 
this study were performed before any biopsy was executed or any contrast-agent 
was administered. In case intestinal spasms limited obtaining proper measurements, 
butylscopolamine (10-20 mg) was intravenously administered. Duration of the 1st set 
and 2nd set of VLS-measurements was noted.
Intraobserver variability
To test intraobserver variability, VLS-measurements were performed at the three 
respective locations and these measurements where thereafter duplicated by a single 
endoscopist. The endoscopist was blinded for all VLS outcomes.
Interobserver variability
For interobserver variability analysis, in another group of patients VLS-measurements 
were repeatedly and independently performed by two endoscopists in the same 
patient during the same endoscopy session. Both endoscopists were blinded for the 
VLS outcomes.
Follow-up
Follow-up data were gathered in the context of usual care. All patients were seen 
by a physician in the weeks following upper endoscopy. Complications of the upper 
endoscopy and of the VLS-measurements were reported.
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Variables
Baseline characteristics included age, gender, body mass index (BMI), smoking, 
indication of upper endoscopy and the complaints of the patient. Characteristics of the 
upper endoscopy included duration, administration of butylscopolamine and the aspect 
of gastro-intestinal mucosa. Characteristics of the endoscopists included experience, 
number of upper endoscopies performed, VLS experience in months, and number of 
VLS performed.
Primary outcome was interobserver variability and intraobserver variability quantified 
with the intraclass correlation coefficient (ICC) and percentage of clinical disagreement. 
VLS-measurements were noted in percentages. Secondary outcome were duration of 
VLS-measurements, procedure-related morbidity and mortality.
Statistics
Baseline characteristics and secondary outcomes were described as counts and 
percentages for
dichotomous variables, or means and standard deviations or medians and interquartile 
ranges (IQR) for continuous variables. For differences in baseline characteristics and 
variables χ2 test or Fisher’s exact test was used for dichotomous variables and Student’s 
t-test for continuous variables. Statistical significance was defined as p-value < 0.05.
First, the mean VLS-measurements of the first set of measurements were compared 
with the second set of measurements of the specific locations for the intraobserver and 
interobserver variability analysis using a paired t-test. Second, the ICC was computed 
for exact agreement. The ICC for the intraobserver and interobserver variability 
was calculated using the Two Way Random model with absolute agreement(8-10). 
However, the ICC did not take into account what may be viewed as clinically meaningful 
disagreement between individual ratings. Therefore, a value of 5% was set to define 
clinical disagreement and we calculated the percentage of ratings that differed at least 
5%. The ICC ranges used were defined according Cicchetti et al. (11) and were less 
than 0.40 (poor), 0.40-0.59 (fair), 0.60-0.74 (good) and 0.75-1.00 (excellent). The range 
of disagreement was visualized with a Bland-Altman plot(12). Statistical analysis was 
performed using the SPSS Statistics 23 (IBM Inc., Chicago, IL).
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Sample size
We determined an inclusion of 12 patients for the assessment of interobserver variability 
and another 12 patients for the intraobserver assessment to detect an acceptable ICC 
of 0.60-0.74 and a desirable ICC of 0.75 or larger for observer variability with an alpha 
of 0.05 and a power of 80%(13).
RESULTS
Twelve patients planned for upper endoscopy were included for the intraobserver 
analysis and another 12 patients planned for upper endoscopy were included for the 
interobserver analysis. Patient characteristics, indication of upper endoscopy and 
complaints of the included patients are specified in Table 1 and the characteristics of 
the upper endoscopy with VLS-measurements are specified in Table 2. Table 3 shows the 
characteristics of the endoscopist for the intraobserver analysis and the characteristics 
of the two endoscopists for the interobserver analysis.
Table 1. Patient characteristics, indication of upper endoscopy and complaints.
All
(n=24)
Intra-observer
(n=12)
Inter-observer
(n=12)
Patient characteristics
Male 12 (50%) 8 (66.7%) 4 (33.3%)
Age (y) 61.1 ± 12.5 63.3 ± 10.8 58.8 ± 14.0
BMI (kg/m2) 27.4 ± 5.7 24.9 ± 4.0 29.1 ± 6.9
Ever smoked 17 (70.8%) 7 (58.3%) 10 (83.3%)
Indication of upper endoscopy
Surveillance Barrett 4 (16.7%) 3 (25%) 1 (8.3%)
Surveillance varices 3 (12.5%) 1 (8.3%) 2 (16.7%)
Dysphagia/achalasia 5 (20.8%) 3 (25%) 2 (16.7%)
Unintentional weight loss 2 (8.3%) 1 (8.3%) 1 (8.3%)
GERD 3 (12.5%) 2 (16.7%) 1 (8.3%)
Suspicion of malignancy 2 (8.3%) 2 (16.7%) 0 (0.0%)
Helicobacter pylori 4 (16.7%) 0 (0%) 4 (33.3%)
Iron deficiency anemia 1 (4.2%) 0 (0%) 1 (8.3%)
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Table 1. Continued
All
(n=24)
Intra-observer
(n=12)
Inter-observer
(n=12)
Complaints
No complaints 8 (33.3%) 5 (41.7%) 3 (25.0%)
Dysphagia 3 (12.5%) 2 (16.7%) 1 (8.3%)
GERD complaints 6 (25.0%) 3 (25%) 3 (25.0%)
Epigastric pain 5 (20.8%) 1 (8.3%) 4 (33.3%)
Weight loss 2 (8.3%) 1 (8.3%) 1 (8.3%)
Categorical variables are presented as number (%). Continuous variables are presented as mean ± 
standard deviation. BMI=body mass index, GERD=gastro-esophageal reflux disease.
Table 2. Characteristics of upper endoscopy.
All
(n=24)
Intra-
observer
(n=12)
Inter-
observer
(n=12)
p-value
intra versus 
inter
Duration of upper endoscopy 
(min)
23.4 ± 5.7 21.1 ± 3.7 25.7 ± 6.5 0.05
Normal mucosa 23 (95.8%)* 11 (91.7%) 12 (100%) 0.31
Butylscopalamin administered 4 (16.7%) 0 (0%) 4 (33.3%) 0.09
Categorical variables are presented as number (%). Continuous variables are presented as mean ± 
standard deviation. * Mild antral gastritis.
Table 3. Endoscopist characteristics.
Intra-observer Inter-observer
VLS 1 & VLS 2 VLS 1 VLS 2
Endoscopy experience (months) 24 32 240
Upper endoscopies performed (n) 350 455 10.000
VLS experience (months) 3 0 19
VLS performed (n) 9 0 5
VLS = visible light spectroscopy
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Intraobserver variability
The mean VLS values for each specific location (descending duodenum, duodenal 
bulb or antrum) were not significantly different between the first set and second set 
of intraobserver measurements. Furthermore, the ICC was excellent for all locations 
(ICC antrum 0.77, ICC duodenal bulb 0.81 and ICC descending duodenum 0.84). Clinical 
disagreement between the first set and the second set of intraobserver measurements 
occurred only for the measurements of the antrum (descending duodenum 0.0%, 
duodenal bulb 0.0% and antrum 8.3%, overall intraobserver measurements 2.8%.). See 
Table 4 and see Figure 1A, B and C for the visualization of the range of disagreement.
The mean duration of the VLS-measurements differed not significantly between first set 
and second set of intraobserver measurements (duration first set of VLS-measurements 
6.4±1.3 minutes versus duration second set of VLS-measurements 5.7±1.0 minutes, 
p=0.074).
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Figure 1. Bland-Altman plots for the intraobserver variability of the A) descending duodenum, 
B) duodenal bulb and C) antrum and Bland-Altman plots for the interobserver variability of the 
D) descending duodenum, E) duodenal bulb and F) antrum.
Interobserver variability
The mean VLS values for each specific location (descending duodenum, duodenal bulb 
or antrum) were not significantly different between the first set and second set of 
interobserver measurements. Furthermore, the ICC was good for the duodenal bulb 
(ICC 0.70), the ICC was fair for the descending duodenum (ICC 0.49) and antrum (ICC 
0.56). Clinical disagreement between the first set and second set of interobserver 
measurements occurred in 16.7% of the measurements of descending duodenum and 
antrum and 0.0% in all measurements of the duodenal bulb (clinical disagreement all 
interobserver measurements 11.1%). See Table 5 and see Figure 1D, E and F for the 
visualization of the range of disagreement.
The mean duration of the VLS-measurements differed not significantly between first set 
and second set of interobserver measurements (duration first set of VLS-measurements 
8.2±2.2 minutes versus duration second set of VLS-measurements 6.3±1.7 minutes, 
p=0.062).
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Time between the end of the first set of VLS-measurements and the start of the second 
set of VLS-measurements was significantly longer for the interobserver measurements 
(intraobserver 0.71±0.36 minutes versus interobserver 4.53±4.52 minutes, p=0.014).
Follow-up
At the outpatient clinic visit after the upper endoscopy, no complications of the upper 
endoscopy or of the VLS-measurements were reported. All 24 patients were alive at 
the end of the follow-up period (mean follow-up duration 4.3±1.6 months).
DISCUSSION
The present study shows a fair to good observer reliability of endoscopic VLS-
measurements. The intraobserver reliability is, as expected, better than the 
interobserver reliability. VLS-measurements, currently used in the diagnostic work-up 
of CMI, are reproducible.
The diagnosis of CMI is challenging as chronic abdominal pain due to other causes 
is common and stenosis of the mesenteric arteries are often asymptomatic due 
to extensive collateral circulation(14, 15). Radiological imaging modalities as CT-
angiography can sufficiently detect the presence of a mesenteric artery stenosis, 
however the presence of a stenosis is not necessarily related with symptomatic disease. 
The European Society of Vascular Surgery (ESVS) recently published guidelines about 
‘Management of the Diseases of Mesenteric Arteries and Veins’(1). These guidelines 
underline the need of a functional test that indicates ischemia. Current available 
methods of functional testing need validation for widespread use in clinical practice. 
Therefore, we performed this study to determine the observer validity of endoscopic 
VLS-measurements.
To our knowledge, this is the first study assessing both the interobserver as intraobserver 
variability of endoscopic VLS-measurements. Others assessed the interobserver 
variability of an endoscopist experienced in VLS (>200 cases) versus an endoscopist with 
limited VLS-experience (<10 cases). Their study showed a good interobserver reliability 
with an average absolute difference of 2%(5). Their results suggest that endoscopic 
VLS-measurements are easy to perform without a steep learning curve.
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Our results show no significant difference between repeated VLS-measurements, 
neither by the same endoscopist nor between different endoscopists. The intraobserver 
reliability was excellent for all locations and clinical disagreement was seen in 3% of 
all intraobserver measurements. Possibly the intraobserver variation is partly probe-
related variation, however probe-related variation for VLS-measurements has never 
been described before. The interobserver reliability was fair to good. Subsequently, 
clinical disagreement was seen in 11% of all interobserver measurements. The time 
between the end of the first set of VLS-measurements and the start of the second set 
of VLS-measurements was significantly longer for the interobserver measurements due 
to the change for endoscopist in this group. It is not expected that mucosal saturation 
values change in this time period in these fasted patients. Although the interobserver 
reliability is less than the intraobserver reliability, we conclude that overall endoscopic 
VLS-measurements are reproducible with fair to good results.
VLS is a useful and minimally invasive tool to assess mucosal ischemia of the upper 
gastrointestinal tract. However, VLS is underutilized since the technique is not yet 
validated and widespread enough. This underlines the importance of this study of the 
observer validation of endoscopic VLS measurements. Directions for further research on 
the use of VLS for the diagnosis of CMI are VLS measurements after feeding in patients 
suspected of CMI and VLS measurements under various oxygenation levels.
This study carries several limitations. The endoscopists were blinded for the VLS-
measurements during endoscopy; however, the observer noting the VLS values was 
not blinded. We checked all noted values with the digital output of the VLS oximeter 
and all noted VLS values agreed with the (blinded) VLS values from the digital output. 
Furthermore, upper endoscopy experience differed between the endoscopists of the 
interobserver variability analysis. The influence of the endoscopy experience on the 
VLS measurements is unknown. We assume that upper endoscopy experience has no 
clinically significant influence on the VLS values and this is supported by the fact that 
the mean values of VLS 1 and VLS 2 were not significantly different.
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CONCLUSION
The observer reliability of endoscopic VLS-measurements is fair to good with 
intraobserver reliability being better than interobserver reliability. Endoscopic VLS-
measurements are reproducible in clinical practice, which supports the use of VLS as 
functional test for assessment of CMI.
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ABSTRACT
Background
Endoscopic visible light spectroscopy (VLS) enables measurement of mucosal oxygen 
saturation during upper gastro-intestinal endoscopy and is used in the diagnostic work-
up of chronic mesenteric ischemia (CMI). Currently, VLS is performed while the patient 
has fasted. We aimed to determine whether food challenge improves the diagnostic 
performance of VLS measurements for the diagnosis of CMI.
Methods
Single center prospective study in healthy controls and consecutive patients suspected 
of CMI and referred to a Dutch specialized CMI center for standardized diagnostic CMI 
work-up. Immediately after performance of conventional fasted VLS measurements, 
luminal feeding was administered and 45 minutes thereafter VLS measurements were 
performed again. Patients were classified as CMI if a multidisciplinary expert based 
consensus diagnosis of CMI was established and successful revascularization therapy 
resulted in symptom relief. Patients were classified as no-CMI when consensus diagnosis 
was not reached or when symptom relief did not occur after technically successful 
treatment.
Results
We included 60 CMI-suspected patients and 16 healthy controls. Duodenal oxygen 
saturation was significantly higher postprandially compared to fasting state in healthy 
controls (median (IQR) pre 54% (49-56), post 56% (53-58), p=0.02), no-CMI patients 
(pre 55% (51-57), post 57% (53-59), p>0.01), as well as CMI patients (pre 51% (48-
53), post 54% (50-58), p=0.01). Mucosal oxygen saturations did not significantly 
increase postprandially in the duodenal bulb or antrum of the stomach. Neither 
absolute postprandial oxygen measurements nor the absolute or relative difference 
between preprandial versus postprandial oxygen measurements provided additional 
discriminative ability for the diagnosis of CMI.
Conclusion
Postprandial VLS measurements have no added benefit for the diagnosis of CMI.
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INTRODUCTION
Endoscopic visible light spectroscopy (VLS)(1) enables targeted non-invasive catheter-
based measurement of mucosal oxygen saturation of the upper gastro-intestinal (GI) 
tract during upper GI endoscopy. VLS determines the microvascular hemoglobin oxygen 
saturation using a small catheter that is passed through the accessory channel of the 
endoscope. The oximeter probe tip is positioned just above the GI mucosa and emits 
white light. Any light returning from the GI mucosa is collected by the probe and reflects 
the differences in the absorption spectra of oxygenated and deoxygenated hemoglobin.
VLS is currently used in the diagnostic work-up of chronic mesenteric ischemia (CMI), 
adding functional measurements to radiological imaging and presenting symptoms(2). 
CMI is the result of insufficient blood supply to the GI tract and is mostly caused by 
atherosclerotic stenosis of one or more supplying mesenteric arteries(3, 4). Other 
causes of occlusive CMI are vasculitis or compression of the celiac artery (CA) by the 
median arcuate ligament (median arcuate ligament syndrome (MALS)). Chronic non-
occlusive CMI (NOMI) is caused by hypo-perfusion or hypo-oxygenation due to, for 
example, underlying cardiac or pulmonary disease.
The mucosal oxygen saturation measured by VLS during upper endoscopy is significantly 
lower in CMI patients than in patients without CMI(2). VLS measurements are performed 
in the antrum of the stomach, the duodenal bulb and the descending duodenum. The 
sensitivity of VLS measurements for the diagnosis of CMI is 90% with a specificity of 
60%(2).
Typical symptoms of CMI are postprandial abdominal pain and weight loss due to fear 
of eating. VLS measurements are however performed during upper GI endoscopy in 
fasting state. Since CMI is mostly provoked by a meal, VLS measurements performed 
during fasting could potentially underdiagnose CMI.
The aim of the current study therefore was to determine whether non-fasting VLS 
measurements increase the discriminative ability of the test to diagnose CMI. We 
hypothesized that VLS measurements in healthy controls and patients without CMI 
will increase after a food challenge due to postprandial hyperemia and that VLS 
measurements in CMI patients will decrease after a food challenge.
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PATIENTS AND METHODS
Study design and setting
A single center prospective study included healthy controls and consecutive patients 
suspected of CMI. Patients were referred to our tertiary referral center between 
September 2014 and March 2017 for a standardized diagnostic CMI work-up. This center 
is one of the two Dutch CMI referral centers that perform functional tests to detect 
mucosal ischemia.
Patients were suspected of CMI if at least two of the following criteria were fulfilled: 1) 
presence of postprandial pain, 2) otherwise unexplained weight loss, and 3) significant 
stenosis of >50% of at least one of the mesenteric arteries. Patients were excluded if 
they were known with cardiac arrhythmias or cardiac conduction disorders and/or if 
they had undergone gastric (bypass) surgery.
Healthy controls without GI complaints and without comorbidity, with an unremarkable 
medical history, not using acid-suppressive medication, and without cardiovascular or 
pulmonary disease were also included. Abdominal duplex ultrasound was performed 
to ensure patent mesenteric arteries.
The medical research ethics committee of Erasmus MC University Medical Center 
approved this study (NL43008.078.12). The study complies with the Helsinki declaration 
on research ethics. To enhance transparency, this article is written according to the 
STROBE checklist for cohort studies(5).
Participants
All patients underwent a standardized diagnostic work-up for CMI consisting of 
obtaining medical history and physical examination, imaging of the mesenteric arteries 
with either computer tomography (CTA), magnetic resonance angiography (MRA) and/
or conventional catheter angiography, and VLS(2, 6). Thereafter, patients were discussed 
in our multidisciplinary CMI team of vascular surgeons, interventional radiologists, 
and gastroenterologists, all specialized in CMI, leading to an expert-based consensus 
diagnosis. This consensus diagnosis was established if at least two of the three following 
criteria were met: 1) typical presentation of CMI (symptoms as postprandial pain, 
otherwise unexplained weight loss, diarrhea) 2) significant stenosis of at least the CA 
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or superior mesenteric artery (SMA) (≥50% diameter reduction(7-10)) on CTA or MRA 
and/or conventional catheter angiography, 3) mucosal hypo-oxygenation detected by 
VLS (fasted). Based on previous experience, hypo-oxygenation was defined as a mucosal 
oxygen saturation in the antrum <63%, and/or in the duodenal bulb <62%, and/or in the 
descending duodenum <58%(2). Patients with chronic NOMI were excluded in this study.
VLS measurements in healthy controls and patients were performed during upper 
endoscopy. If sedation was administered, this consisted of midazolam intravenously 
(dose 2.5-5 mg) combined with fentanyl (dose 0.05 mg). Peripheral oxygen saturation 
and heart rate were continuously monitored. Oxygen was administered intranasally <1 
minute before the introduction of the endoscope to maintain a peripheral saturation 
level ≥95% during the VLS-measurements. The VLS measurements were performed 
using a fiberoptic catheter-based VLS oximeter (T-Stat 303 Microvascular Oximeter; 
Spectros, Portola Valley, California) passed through the accessory channel of the 
endoscope. Mucosal saturation measurements were performed at three different 
locations: the antrum of the stomach, the duodenal bulb and the descending duodenum. 
After removal of any bile remnants at the target area, the catheter tip was positioned 
approximately 1-5 mm above the mucosa. The light of the endoscope was turned 
off and continuous readings of mucosal saturation were shown on the monitor. This 
reading showed small rapid variations due to true changes in saturation and due to 
small changes in the position of the probe. A study reading was started if a stable 
measurement was obtained. The highest value was noted. Three repeated readings per 
site were obtained with fewer than 5% variation and these 3 readings were averaged. 
All VLS-measurements were performed before any biopsy was taken or any stain was 
applied. When intestinal spasms prohibited obtaining proper VLS-measurements, 
butylscopolamine (10-20 mg) was administered intravenously.
For standardized work-up, VLS measurements are performed during upper endoscopy in 
persons who have fasted for at least 6 hours. The study subjects underwent additional 
VLS measurements after luminal feeding. For this, a guidewire was endoscopically 
placed in the antrum after conventional preprandial VLS measurements. The guidewire 
was used to insert a 10-F nasogastric tube (Wilson-Cook Medical, Cook Ireland Ltd, 
Limerick, Ireland) in the stomach. The study subject was placed in an upright position to 
prevent aspiration and 300 ml (1.5 kcal/ml) compound liquid food (Nutrison Energy©, 
Nutricia Koninklijke Numico N.V., WTC Schiphol, The Netherlands) was given by bolus 
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feeding using a 50cc syringe. Erythromycin 250 mg was given intravenously 15 minutes 
after the luminal feeding to stimulate motility and clear gastric contents. Forty-five 
minutes after luminal feeding a second upper endoscopy was performed. Redundant 
liquid food was aspirated. Postprandial VLS measurements were performed in the same 
manner as preprandial VLS measurements.
Follow-up and data sources
Patients with a consensus diagnosis of CMI based on occlusive disease were planned for 
either endovascular or surgical revascularization. Patients with stenosis of one or more 
mesenteric arteries based on atherosclerosis were primarily planned for endovascular 
revascularization: percutaneous transluminal angioplasty (PTA) combined with stent 
placement (percutaneous mesenteric artery stenting (PMAS)). If patients were not 
eligible for endovascular intervention or if patients had recurrent episodes of restenosis, 
they were treated with open surgical mesenteric artery repair (OSMAR). In patients with 
a stenosis of the CA the diagnosis of MALS was established if CTA demonstrated focal 
narrowing of the proximal CA ≥50% with post-stenotic dilatation and indentation on the 
superior aspect of the CA, creating a hook-shaped contour of the CA. This characteristic 
kinking in the absence of atherosclerotic plaques distinguishes this condition from other 
causes of CA stenosis such as atherosclerosis(11). Since these imaging features are 
dependent on the respiratory cycle, an additional catheter angiography of the CA in 
inspiration and expiration was performed in unclear cases. Patients with stenosis of 
the CA based on MALS were planned for surgical release (open or laparoscopic) of the 
median arcuate ligament.
Patients were evaluated during standard protocol visits at 1, 3, 6, 12, and 24 months 
after therapy. These visits were mostly in-clinic follow-up. All patients were minimally 
followed for a period of 6 months. A definitive diagnosis of CMI was established if 
the patient reported relief of presenting symptoms. This patient reported outcome of 
symptom relief was classified in two groups: no or minimal symptom relief and major 
or complete symptom relief. Standard protocol contains questions about recurrent 
symptoms (i.e. similar to presenting symptoms before revascularization therapy) and 
actual weight. No standard questionnaire was used.
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Patients with a consensus diagnosis of no-CMI were discharged without further follow-
up. The healthy controls were not followed after the preprandial and postprandial VLS 
measurement.
Variables
Baseline characteristics included age, gender, past medical history, presenting symptoms 
such as abdominal pain, diarrhea, nausea, and weight loss (kg), body mass index (BMI), 
smoking, and cardiovascular risk factors. Hypertension was defined as a blood pressure 
of ≥140/90 mmHg or use of antihypertensive medication. Dyslipidemia was defined as 
LDL-C >4.2 mmol/L or HDL-C <0.9 mmol/L or use of lipid lowering medication. Smoking 
status was defined as ever smoked or never smoked. Vascular lesions were specified for 
localization (CA, SMA or inferior mesenteric artery (IMA)) and cause (atherosclerosis, 
MALS, vasculitis).
The primary outcomes were the absolute postprandial VLS-measurements and the 
absolute and relative differences in preprandial and postprandial VLS-measurements 
in patients with CMI, patients without CMI and healthy controls. Secondary outcomes 
were complications and mortality.
Study size
We determined that 50 patients suspected of CMI needed to be included to detect a 
relative decrease of 10-15% in mucosal saturation per location with an alpha of 0.01, a 
power of 90% and with assumption of a CMI diagnosis rate of 50%.
Statistical methods
Baseline characteristics and secondary outcomes were described either as numbers 
and percentages for dichotomous variables, or as means and standard deviations or 
medians and interquartile ranges (IQR) for continuous variables. Differences in baseline 
characteristics and clinical response to treatment were determined by the χ2 test or 
Student’s t-test. Difference in BMI during follow-up was determined with the paired 
samples t-test.
Differences in absolute preprandial and postprandial VLS-measurements between CMI 
patients, no-CMI patients and healthy controls were determined with the Mann Whitney 
U-test. Differences between preprandial and postprandial VLS-measurements within 
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a patient group were determined with the Wilcoxon signed rank test. However, the 
normal VLS-measurements differ per location, as distal VLS-measurements are lower 
than proximal VLS-measurements. Therefore, relative differences between preprandial 
and postprandial measurements were calculated in percentages of the baseline VLS-
measurements. Differences in relative preprandial versus postprandial VLS differences 
between CMI patients, no-CMI patients and healthy controls were determined with 
the Mann Whitney U-test. Statistical significance was defined as a two-sided p<0.05. 
Statistical analysis was performed using the SPSS Statistics 23 (IBM Inc., Chicago, IL).
RESULTS
Patient characteristics
During the study period, 136 patients suspected of CMI were referred to our center of 
which 75 were eligible for inclusion. Of these 75 patients, 60 patients were eligible for 
analysis (Figure 1). Furthermore, 16 healthy controls were included. All patients and 
controls gave informed consent. Baseline characteristics, presenting symptoms and 
vascular lesions are presented in Table 1.
Treatment
In 28 patients (39%) a consensus diagnosis of CMI was established. All patients with 
a consensus diagnosis of occlusive CMI were treated with revascularization therapy. 
The 16 patients with CMI based on atherosclerosis were all treated with endovascular 
revascularization (15 patients stent placement, 1 patient PTA). Of the 7 patients with CMI 
based on MALS, 4 underwent laparoscopic surgical decompression and 3 underwent 
open surgical decompression.
Endovascular revascularization was initially technically successful in 15/16 patients 
(94%). A re-procedure in one patient resulted in technical success for all 16 endovascular 
treated patients. Endovascular approach was established in 9 procedures (56%) via the 
radial artery, in 5 procedures via the femoral artery (31%) and in 2 procedures (13%) 
via the brachial artery. Of the 7 surgical celiac artery release procedures, 6 procedures 
were technically successful (86%). One patient needed additional mesenteric bypass 
surgery for successful revascularization.
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After successful endovascular revascularization, 3 of the 16 patients (19%) developed 
symptomatic in-stent stenosis. Successful re-intervention was performed in all 3 cases 
resulting in relief of symptoms.
Figure 1. Flowchart.
CMI = chronic mesenteric ischemia; MALS = median arcuate ligament syndrome; NOMI = non-occlusive 
mesenteric ischemia; VLS = visible light spectroscopy.
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Table 1. Baseline characteristics, presenting symptoms and vascular lesions.
All patients
(n=60)
CMI 
patients
(n=23)
no-CMI 
patients
(n=37)
Healthy 
controls
(n=16)
Patient characteristics
Age (y) 59.7±14.1 60.7±15.6 59.1±13.2 35.2 ± 8.1
Female 53.3% 47.8% 56.8% 43.8%
Caucasian 100% 100% 100% 93.8%
Hypertension 51.7% 65.2% 43.2% 6.3%
Smoking 80.0% 78.3% 81.1% 43.8%
Dyslipidemia 47.5% 59.1% 40.5% 0.0%
Diabetes 18.3% 26.1% 13.5% 0.0%
BMI at presentation (kg/m2) 24.0±4.5 24.0±4.6 23.9±4.5 23.3 ± 2.8
History of CVD 45.0% 60.9% 35.1% 0.0%
Presenting symptoms
Abdominal pain 88.3% 91.3% 86.5% 0.0%
Postprandial abdominal pain 83.3% 91.3% 78.4% 0.0%
Exercise related abdominal 
pain
33.9% 36.4% 32.4% 0.0%
Nausea 43.3% 39.1% 45.9% 0.0%
Diarrhea 16.7% 17.4% 16.2% 0.0%
Weight loss 61.7% 56.5% 64.9% 0.0%
Abdominal bruit 18.4% 31.3% 12.1% 0.0%
Classic triad of CMI 3.3% 5.3% 2.8% 0.0%
Gastric ulcer 3.3% 8.7% 0.0% 0.0%
Duration of symptoms 
(months)
18.1±26.0 21.3±36.8 16.0±16.0 0.0±0.0
Vascular lesions
No stenosis 41.7% 0.0% 67.6% 100.0%
Single vessel stenosis# 36.7% 47.8% 29.7% 0.0%
Multivessel stenosis 21.7% 52.2% 2.7% 0.0%
CA stenosis 30.0% 39.1% 21.6% 0.0%
SMA stenosis 6.7% 8.7% 5.4% 0.0%
IMA stenosis 1.7% 0.0% 2.7% 0.0%
CA and IMA stenosis 3.3% 13.0% 0.0% 0.0%
CA and SMA stenosis 5.0% 13.0% 0.0% 0.0%
SMA and IMA stenosis 1.7% 0.0% 2.7% 0.0%
CA, SMA and IMA stenosis 10.0% 26.1% 0.0% 0.0%
Data are presented as percentages or as mean ± SD.
# solitary stenosis of CA, SMA or IMA.
BMI = body mass index; CMI = chronic mesenteric ischemia; CVD = cardiovascular disease; Classic triad of 
CMI is postprandial abdominal pain, bruit and weight loss; CA = celiac artery, SMA = superior mesenteric 
artery, IMA = inferior mesenteric artery.
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Definitive diagnosis
A definitive diagnosis of CMI was established in 23 patients. Nine patients had a 
significant solitary CA stenosis, 2 patients a significant solitary SMA stenosis, 3 patients 
a significant stenosis of both CA and SMA, 3 patients a significant stenosis of both SMA 
and IMA and 6 patients a significant stenosis of CA and SMA as well as IMA. Solitary 
CA stenosis was caused by MALS in 7 patients. All other stenoses were caused by 
atherosclerosis (Table 1). BMI 6 months after revascularization was significantly higher 
than BMI before revascularization in CMI patients (BMI at diagnosis 24.0±4.6 versus 
BMI 6 months after revascularization 26.0±5.2 kg/m2, p=0.008).
 Alternative diagnoses were established in 22 of 37 patients (59%) without a definitive 
diagnosis of CMI: alcohol abuse, radiation damage, chronic pancreatitis, polycystic 
kidney disease with hepatic involvement, diarrhea after chemotherapy, tuberculosis, 
gastroparesis, Anterior Cutaneous Nerve Entrapment Syndrome (ACNES), obstipation, 
lung cancer with peritoneal and mesenteric metastases, proctitis, primary sclerosing 
cholangitis (PSC), sliding hiatal hernia, and diverticulosis. In 6 patients the presenting 
symptoms spontaneously resolved.
None of the patient characteristics or presenting symptoms differed significantly 
between patients with CMI and patients without CMI (Table 1). The healthy volunteers 
were significantly younger (p<0.01), were less often smokers (p<0.01), had less 
hypertension (p<0.01), dyslipidemia (p<0.01), and cardiovascular disease (p<0.01) than 
the patients suspected of CMI. BMI did not significantly differ between the healthy 
volunteers and the CMI suspected patients.
Preprandial mucosal oxygen saturations
Sedation was administered at the start of the upper GI endoscopy in 56 of the 60 (93%) 
patients suspected of CMI and in 2 of the 16 (12.5%) healthy controls. Preprandial 
mucosal oxygen saturations were significantly lower in CMI patients than in no-CMI 
patients in all three locations. Furthermore, preprandial mucosal oxygen saturations 
were significantly lower in CMI patients than in healthy controls for the antrum of the 
stomach and for the duodenal bulb. Preprandial mucosal oxygen saturations did not 
significantly differ between no-CMI patients and healthy controls in all three locations 
(antrum of the stomach p=0.35, duodenal bulb p=0.50 and descending duodenum 
p=0.14 (Figure 2)).
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Figure 2. Preprandial oxygen saturations antrum, duodenal bulb and descending duodenum 
for CMI patients, no-CMI patients and healthy controls. Preprandial oxygen saturations of CMI 
patients were significantly lower than preprandial oxygens saturations of no-CMI patients in all 
three locations. Preprandial oxygen saturations of CMI patients were significantly lower than 
preprandial oxygens saturations of healthy controls in antrum and duodenal bulb. CMI = chronic 
mesenteric ischemia. * = p<0.05 Mann Whitney U-test
Postprandial mucosal oxygen saturations
Postprandial duodenal bulb mucosal oxygen saturations were significantly lower in 
CMI patients than in no-CMI patients. Postprandial antral mucosal oxygen saturations 
were significantly lower in both CMI patients and no-CMI patients compared to healthy 
controls. Postprandial antral and duodenal mucosal oxygen saturations were not 
significantly different between CMI patients and no-CMI patients (Tabel 2 and Figure 3).
Figure 3. Postprandial oxygen saturations in antrum, duodenal bulb and descending duodenum 
for CMI patients, no-CMI patients and healthy controls. The postprandial oxygen saturation was 
only significantly decreased in CMI patients compared to no-CMI patients in the duodenal bulb. 
In the antrum of the stomach the postprandial oxygen saturation was significantly decreased 
in both the CMI patients and no-CMI patients compared to the healthy controls. CMI = chronic 
mesenteric ischemia. * = p<0.05 Mann Whitney U-test.
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Table 2. Preprandial and postprandial oxygen saturations.
CMI patients
(n=23)
no-CMI patients
(n=37)
Healthy controls
(n=16)
Antrum preprandial (%) 59 (55-62) 61 (60-63) 62 (60-65)
Antrum postprandial (%) 59 (57-63) 60 (58-62) 63 (60-65)
p-value 0.10 0.03* 0.86
Duodenal bulb preprandial(%) 54 (51-58) 58 (55-60) 58 (54-63)
Duodenal bulb postprandial(%) 55 (52-59) 59 (57-61) 60 (55-62)
p-value 0.16 0.30 0.93
Descending duodenum preprandial (%) 51 (48-53) 55 (51-57) 54 (49-56)
Descending duodenum postprandial (%) 54 (50-58) 57 (53-59) 56 (53-58)
p-value 0.01* <0.01* 0.02*
Data are presented as median (IQR).
* p < 0.05 pre-prandial versus post-prandial oxygen saturations .
CMI = chronic mesenteric ischemia.
Preprandial versus postprandial mucosal oxygen saturations
Enteral feeding was associated with a significant increase in duodenal mucosal 
oxygen saturations in all CMI and no-CMI patients, as well as healthy controls (Table 
2). Furthermore, the absolute difference of preprandial versus postprandial antral 
mucosal oxygen saturations differed significantly between CMI patients and no-CMI 
patients (CMI patients absolute difference median (IQR) 0.00 (-1.0-3.0) versus no-CMI 
patients -0.5 (-3.0-1.0) p=0.02). However, the absolute difference of preprandial versus 
postprandial mucosal oxygen saturations did not significantly differ in the duodenal 
bulb or descending duodenum between CMI patients and no-CMI patients. In addition, 
there was no significant difference between CMI patients and healthy controls in any 
of the three locations.
The relative difference in preprandial and postprandial mucosal oxygen saturations was 
only significantly different between no-CMI patients and CMI patients in the antrum of 
the stomach, but not in the duodenal bulb or descending duodenum (Table 3 and Figure 
4). The relative difference in preprandial and postprandial mucosal oxygen saturations 
did not differ significantly between CMI patients and healthy controls.
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Table 3. Relative differences in preprandial and postprandial oxygen saturations.
CMI patients
(n=23)
no-CMI patients
(n=37)
Healthy controls
(n=16)
Antrum (%) 0.00 (-1.67-5.26) 0.00 (-4.05-1.65) -0.77 (-3.05-4.42)
Duodenal bulb (%) 1.72 (-1.85-7.41) 1.67 (-3.36-5.46) 0.86 (-5.61-3.42)
Descending duodenum (%) 6.67 (0.00-12.72) 3.64 (0.86-6.29) 6.39 (-1.32-12.57)
Data are presented as median (IQR).
CMI = chronic mesenteric ischemia.
Figure 4. Relative differences in preprandial versus postprandial oxygen saturations in antrum, 
duodenal bulb and descending duodenum for CMI patients, no-CMI patients and healthy con-
trols. The relative differences in preprandial versus postprandial oxygen saturations were not 
significantly different in any of the three locations and between any of the three groups except 
for CMI patients versus no-CMI patients in the antrum of the stomach. CMI = chronic mesenteric 
ischemia. * = p<0.05 Mann Whitney U-test.
Complications & mortality
No complications related to the preprandial or postprandial VLS measurements or 
the upper endoscopy were observed. Mean follow-up was 15.3±10.3 months for CMI 
patients and 6.7±7.1 months for no-CMI patients. Overall, 1 patient (CMI, 1/60=2%) died 
during follow-up due to liver failure unrelated to mesenteric ischemia. All 16 healthy 
controls were alive at the end of the study.
DISCUSSION
Our study shows that food administration is associated with an increase in duodenal 
mucosal oxygen saturation in CMI patients, no-CMI patients and healthy controls. 
However, neither postprandial oxygen saturation levels nor their absolute or relative 
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difference with preprandial levels provide additional discriminative ability for the 
diagnosis of CMI.
The diagnosis of CMI is a clinical challenge since a gold standard test is absent. Symptoms 
alone are not specific predictors for CMI(3, 12, 13). The prevalence of mesenteric artery 
stenosis ranges between 7-18% in the asymptomatic general population, increasing with 
age(14-17). Additional functional testing may increase the likelihood of the diagnosis, 
especially in those patients with significant solitary mesenteric artery stenosis(18). 
Therefore, diagnosis is generally based on the combination of symptoms, imaging of 
the mesenteric vasculature and a functional test to assess mucosal ischemia as VLS or 
gastric-jejunal tonometry(19, 20). Such a consensus approach is an accepted method 
in the absence of one specific test(21). A definitive diagnosis of CMI is established if 
symptom relief is reported after technically successful treatment. Functional assessment 
with VLS is performed during upper GI endoscopy. VLS has a sensitivity of 90% and a 
specificity of 60%, which leaves room for optimization. Furthermore, VLS requires that 
the mucosal surface is free of bile or food remnants since these can disturb the light 
reflectance.
In this study, the diagnostic value of fasted VLS measurements for the diagnosis of 
CMI as reported by van Noord et al.(2) is confirmed by showing significant decreased 
mucosal oxygen saturations in CMI patients versus no-CMI patients. Endoscopic VLS 
measurements in healthy controls have not been reported in literature before. We 
showed that fasted mucosal oxygen saturations did not significantly differ between 
no-CMI patients and healthy controls.
Mesenteric blood flow increases after a meal. Duplex ultrasound of the SMA in healthy 
volunteers has been shown to significantly increase in blood flow after a food challenge, 
whereas after water ingestion no significant increase of the SMA blood flow was 
demonstrated(22). In another duplex study blood flow measurements in the SMA in 
patients with a 70-99% SMA stenosis significantly less increased after a meal than the 
SMA blood flow in healthy volunteers and patients with SMA stenosis <70%(23). This 
suggests a lack of postprandial blood flow increase in patients with occlusive CMI. A 
decrease in blood flow to the GI tract results in decreased oxygen delivering. VLS could 
therefore potentially discriminate the patients with CMI from the patients without CMI 
based on the difference of preprandial versus postprandial mucosal oxygen saturation 
measurements.
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Blood flow in the CA increases less than the blood flow in the SMA after a meal(3). The 
CA provides blood to the stomach, liver, part of the pancreas and the proximal part of 
the duodenum. The SMA provides blood to the distal part of the duodenum, the small 
bowel and the proximal part of the colon. Our results confirm the large postprandial 
blood flow increase in the SMA, since the largest relative increase of preprandial versus 
postprandial blood flow in CMI patients, no-CMI patients as well as in healthy controls 
is demonstrated in the descending duodenum.
This study has some limitations. First, the study was designed to simulate the natural 
digestion process and metabolic challenge of food ingestion. To ensure the intake of the 
same amount of calories in every patient, luminal feeding was given over a feeding tube. 
Needless to say that this is only an approximation of the natural digestion process as 
the physiological process of digestion normally starts with smelling, seeing and chewing 
food including the production of saliva. Moreover, postprandial hyperemia starts about 
10 minutes after food ingestion to reach a maximum after 30 minutes(24). In this study, 
the second upper endoscopy started 45 minutes after the food challenge to minimize 
the risk of aspiration. Furthermore, postprandial VLS measurements could be hampered 
by liquid food remnants. To minimize the risk of aspiration and faulty measurements 
the delay of 45 minutes was chosen to allow for passage of the liquid food. As extra 
safety precaution measures we administered erythromycin intravenously to stimulate 
gastric food evacuation and also aspirated remnant liquid food via the gastric tube and 
the endoscope. As a result of this 45 minute delay in the administration of the caloric 
challenge and the VLS-measurements the possibility exist that we missed the peak 
postprandial increase in mucosal oxygenation, especially in antrum of the stomach 
and duodenal bulb.
Second, the sample size was calculated assuming a CMI diagnosis rate of 50%. The CMI 
diagnosis rate in this cohort was 38%. As a result, we included 2 CMI patients less than 
the 25 CMI patients determined by sample size calculation. Even if two more included 
patients would have the most extreme outcomes, they would not change the outcome 
of this study.
Assessment of the presence and time of onset of CMI symptoms after luminal feeding 
would be of interest. However, this was not performed, since the upper GI endoscopies 
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are often performed under conscious sedation which would influence the reliability and 
interpretation of abdominal pain scores.
In conclusion, this is the first study of VLS measurements after a food challenge. Duodenal 
mucosal saturation values of the upper GI tract increase after food administration in 
healthy controls, no-CMI patients, as well as in CMI patients. However, postprandial 
VLS-measurements do not provide additional discriminative ability for the diagnosis of 
CMI. Postprandial VLS measurements have no added benefit for the diagnosis of CMI.
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ABSTRACT
Background
Visible light spectroscopy (VLS) is a technique used to measure the mucosal oxygen 
saturation during upper gastrointestinal endoscopy to evaluate mucosal ischemia, 
however in vivo validation is lacking. We aimed to compare VLS measurements with a 
validated quantitative microvascular oxygen tension (μPO
2
) measurement technique.
Methods
Simultaneous VLS measurements and μPO
2 
measurements were performed on the small 
intestine of five pigs. First, simultaneous measurements were performed at different 
FiO
2
 values (18%-100%). Thereafter, the influence of bile was assessed by comparing 
VLS measurements in the presence of bile and without bile. Finally, simultaneous VLS 
and μPO
2 
measurements were performed from the moment a lethal dose potassium 
chloride intravenously was injected.
Results
In contrast to μPO
2 
values that increased with increasing FiO
2, 
VLS values decreased. Both 
measurements correlated poorly with R2= 0.39, intercept 18.5, slope 0.41 and a bias 
of -16%. Furthermore, the presence of bile influenced VLS values significantly (median 
(IQR)) before bile application 57.5% (54.8-59.0%) versus median with bile mixture of 
the stomach 73.5% (66.8-85.8), p=<2.2*10-16; median with bile mixture of small bowel 
47.6% (41.8-50.8) versus median after bile removal 57.0% (54.7-58.6%), p=<2.2*10-16). 
Finally, the VLS mucosal oxygen saturation values did not decrease towards a value of 
0 in the first 25 minutes of asystole in contrast to the μPO
2 
values.
Conclusions
These results suggest that VLS measures the mixed venous oxygen saturation rather 
than mucosal capillary hemoglobin oxygen saturation. Further research is needed 
to establish if the mixed venous compartment is optimal to assess gastrointestinal 
ischemia.
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BACKGROUND
Visible light spectroscopy (VLS) is a technique used to measure the mucosal capillary 
hemoglobin oxygen saturation based on reflectance spectrophotometry(1). The 
mucosal oxygen saturation can be calculated by the marked difference in the absorption 
spectra of oxygenated and deoxygenated hemoglobin. Endoscopic VLS measurements 
are performed during upper GI endoscopy(2-4). As determined previously by van Noord 
et al., measurements are defined positive for ischemia if the measured saturation is 
lower than 63% in the antrum of the stomach, lower than 62% in the duodenal bulb 
and 58% in the descending duodenum(4).
VLS is used in clinical practice in the work-up of the diagnosis of chronic mesenteric 
ischemia (CMI). CMI is defined as ischemic symptoms caused by insufficient blood 
supply to the gastrointestinal (GI) tract(5). The main cause of CMI is stenosis of one or 
more mesenteric arteries due to atherosclerosis(6). Other occlusive causes are external 
compression of the celiac artery and/or celiac ganglion by the median arcuate ligament 
and diaphragmatic crura (median arcuate ligament syndrome (MALS)) and mesenteric 
artery stenosis due to vasculitis. However, CMI can exist in the absence of mesenteric 
artery stenosis. Non-occlusive mesenteric ischemia (NOMI) is caused by hypo-
oxygenation due to underlying conditions such as cardiac and pulmonic insufficiency, 
spasms of small arteries, shunts, occlusion of smaller arteries e.g. by micro-emboli, and 
autonomic dysfunction(7).
The diagnosis of CMI is a clinical challenge because of the diverse presentation of 
CMI. Symptoms overlap largely with many other disorders and the high prevalence of 
asymptomatic mesenteric artery stenosis in the general population of (3-29%(8, 9)) 
due to the existence of an extensive collateral circulation. However, mesenteric artery 
stenosis can become symptomatic if this collateral circulation is not sufficient and/or the 
extent of the stenosis becomes significant. Accurate identification of patients with CMI 
is important to select those patients who will benefit of therapy, but to withhold invasive 
therapy from those who will not. Treatment consists of endovascular revascularization 
with expandable metal stents or surgical revascularization of obstructed vessels, both 
methods that are invasive, costly and not without side-effects. A functional test to 
determine mucosal ischemia of the GI tract is therefore essential.
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In the absence of one specific test for the diagnosis of CMI(10), the diagnosis is 
established by consensus in a multidisciplinary meeting attended by gastroenterologists, 
vascular surgeons and interventional radiologists. Symptoms alone do not accurately 
predict the diagnosis of CMI(7, 11, 12). Therefore, consensus diagnosis is based on 
the combination of symptoms, imaging of the mesenteric vasculature and functional 
assessment of mucosal ischemia with gastric-jejunal tonometry(13, 14) or VLS(1, 4). The 
diagnosis is confirmed if successful therapy results in symptom relief. This method for 
the diagnosis of CMI has an acceptable diagnostic yield(15) and this method is excepted 
in absence of a gold standard test(10).
Endoscopic mucosal oxygen saturation measurements with VLS are already used in 
clinical practice to evaluate CMI, however no extensive validation studies have been 
performed for this intended use. In the current study, VLS mucosal oxygen saturation 
is compared with a validated microvascular oxygen tension (μPO
2
) measurement 
technique(16, 17)
The microvascular oxygen tension technique used in this study is a Palladium (Pd) 
porphyrin phosphorescence lifetime technique that measures oxygen tension, 
introduced by Van der Kooi at the end of the 1980s(18). Palladium porphine (Pd-
porphyrin) bound to albumin, has become a standard phosphorescent dye for μPO
2
 
measurements in vivo(16, 17). This quantitative measurement is also located in the 
microcirculation making it a convenient comparison to mucosal oxygen saturations 
measured with VLS.
The objective of this study was to validate the VLS technique. This validation consisted 
of 3 experiments in a porcine model: 1) comparison of VLS mucosal oxygen saturation 
and μPO
2 
measurements at different levels of FiO
2
, 2) VLS mucosal oxygen saturation 
measurements in the presence of bile and 3) comparison of VLS mucosal oxygen 
saturation and μPO
2 
measurements during asystole.
METHODS
Ethical statement
This study was approved by the local Animal Research Committee of the Erasmus MC 
University Medical Center in accordance with the National Guidelines for Animal Care 
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and Handling (protocol number DEC 129-13-06 EMC3185). To enhance transparency 
this article is written according to the ARRIVE guidelines for animal research(19).
Experimental animals
In total, 5 female crossbred Landrace x Yorkshire pigs, with mean body weights 
of 28.1±0.6 kg (mean±standard error of mean), age 2-3 months were used for the 
experiments. Sample size calculation determined that 5 animals were sufficient to 
detect a difference of at least 5% in mucosal saturation measured with VLS before and 
after bile per location with an alpha of 0.05 and a power of 90%(20).
Experimental procedures
After an overnight fast with free access to water, the animals were sedated with an 
intramuscular injection of tilatamine/zolazepam (6/6 mg/kg; Virbac Laboratories, Carros, 
France), xylazine (2 mg/kg; AST Farma B.V., The Netherlands) and atropine sulfate 
(0.5 mg/animal; Centrafarm Services BV, Etten-Leur, The Netherlands). After a 15 min 
induction period, anesthesia was induced with tilatamine/zolazepam (50-100 mg/animal) 
through a cannula (20G Venflon (Becton, Dickinson and Company, USA) in an auricular 
vein. Tracheal intubation was performed with a size 7.0 Portex® endotracheal tube 
(Smiths Medical International Ltd., United Kingdom). For maintenance of anesthesia, 
the animals received continuous infusion of ketamine (5 mg kg−1 h−1; Alfasan Nederland 
B.V., The Netherlands), midazolam (1.5 mg kg−1 h−1; Atavis Group PCT, Iceland), sufentanil 
(4 μg kg−1 h−1; Janssen-Cilag B.V., The Netherlands), and rocuroniumbromide (4 mg 
kg−1 h−1; Fresenius Kabi Austria GmbH, Austria). All animals received 500 ml of colloid 
solution (Voluven®; Fresenius Kabi AG, Germany) at start and a continuous infusion of 
crystalloid (Sterofundin® ISO 10 ml kg−1 h−1; B. Braun, Germany). Each pig received a 
bolus of magnesium sulfate (500 mg; Pharmachemie BV, Haarlem, The Netherlands), 
as arrhythmia prophylaxis, added to the first bag of crystalloid solution. To prevent 
infections during the experiment, Cefazolin (1000 mg/animal; Kefzol ® EuroCept BV, 
Ankeveen, The Netherlands), an antibiotic used for the treatment of a widespread of 
bacteria was given intravenous.
Pressure-controlled mechanical ventilation (Servo 300; Siemens-Elema, Solna, Sweden) 
was performed with a FiO
2
 between 24% and a positive end-expiratory pressure of 
5 cmH
2
O while no intervention was done. Normothermia, measured nasal, was 
maintained between 38° and 39°C, with two heating pads underneath and an electric 
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heating blanket above the animal. Furthermore, hearth rate, mean arterial pressure, 
SpO
2
 and temperature were monitored continuously throughout the entire experiment. 
Arterial blood samples were collected to determine the arterial oxygen pressure and 
arterial oxygen saturation (ABL 800Flex (Radiometer, Denmark)).
A 4F thermodilution catheter (Pulsion Medical Systems AG München, Germany) was 
placed in the left femoral artery for arterial blood sampling. An 9Fr introducer sheath 
(Arrow International Inc., USA) was placed in the right jugular vein for infusion of 
palladium porphyrin. Both catheters were placed using the Seldinger technique. A lower 
midline abdominal incision was made to insert a cystostomy tube into the urinary 
bladder with purse-string sutures for urine collection.
The animals were placed in supine position and an incision was made to open the 
abdomen. A small intestinal loop was dissected and a small incision was made at the 
non-vascularized side to expose the intestinal mucosa (Figure 1). Mucosal oxygen 
saturation measurements were performed with a fiberoptic probe (Endoscopic T-Stat 
Sensor; Spectros, Portola Valley, California, USA) connected to the VLS oximeter (T-Stat 
303 Microvascular Oximeter, Spectros, Portola Valley, California).
Figure 1. Set-up of the experiment of the VLS-probe (blue) and the μPO
2 
probe fixated together 
positioned 1 to 5 mm above the mucosa of the small intestinal loop.
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Microvascular oxygen tension measurements were done with oxygen dependent 
phosphorescent dye palladium porphine (Pd-porphyrin). Palladium porphyrin is a large 
molecule with optical properties that can absorb energy and react with oxygen. In the 
absence of oxygen it will release the absorbed energy from an excitation source via 
phosphorescent light with a specific decay time, i.e. lifetime. The lifetime is related to 
the amount of oxygen surrounding the Pd-porphyrin described by the Stern-Volmer 
relation(18). It has been tested for pH, temperature and diffusivity dependency(17). 
Calibration experiments are done and determine the O
2
 accuracy of 5% independent 
of phosphorescence intensity itself(17).
For the laboratory experimental setup of the μPO
2 
measurements the excitation source 
was an Opolette 355-I tunable laser (Opotek, Carlsbad, CA, USA) set to a wavelength 
of 524nm. An optical fiber developed by TNO and produced by Light Guide Optics was 
used that would fit through the working channel of a gastroduodenal endoscope. It has 
one central located excitation fiber with several surrounding detection fibers.
The phosphorescence was collected with a gated micro channel plate photomultiplier 
tube (MCP-PMT R5916U series, Hamamatsu Photonics, Hamamatsu, Japan). 
Phosphorescence lifetime analysis was done with a self-written software program in 
Labview (version 13.0, National Instruments, Austin, TX, USA). For the detailed setup 
description we refer elsewhere(21).
The probe palladium porphyrin was Pd(II) meso-Tetra (4-carboxyphenyl)porphine (80 
mg/animal) (Frontier Scientific, Logan, USA) dissolved in 1ml DMSO and TRIS Trisma® 
Base (Sigma, St. Louis, MO) was combined with a 4% bovine serum albumin solution 
solved in phosphate buffered saline. This method has been validated in vitro and in 
vivo(17). Pd-porphyrin bound to albumin, forms a high-molecular-weight complex, 
confining it mainly to the vascular compartment when infused intravenously.
Both optical fibers were fixated together to perform stable simultaneous mucosal 
oxygen saturation and μPO
2 
measurements of the same mucosal spot of the small 
intestine (Figure 1).
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Mucosal oxygen saturation versus μPO2 measurements at different FiO2 
values
Simultaneous VLS mucosal oxygen saturation and μPO
2 
measurements were performed 
at different FiO
2
 values ranging from 18%-100%. The mucosal oxygen saturation and 
μPO
2 
measurements were simultaneously performed for two minutes at a specific FiO
2
 
value. When a new FiO
2
 value was set, the start of a set of new measurements was 
awaited for the first two minutes. To compare the two measurement techniques the 
μPO
2 
was converted into a corresponding saturation. For the μPO
2
 conversion, for every 
measured value in mmHg the corresponding % was calculated called micro-vascular 
oxygen saturation converted (μSO
2
.converted). The conversion can be found in Figure 2.
Figure 2. Conversion of μPO
2
 into saturation according to the found relationship by Serianni et 
al.(22).
Influence of bile on mucosal oxygen saturation
Furthermore, the influence of bile on mucosal oxygen saturation values measured 
with VLS was assessed. Mucosal oxygen saturation measurements were performed of 
the small intestine mucosa in presence of bile. Two different types of bile were used: 
fluid obtained during upper GI endoscopy from the stomach of the animal and fluid 
obtained from the small intestine of the animal. The sticky viscosity of the bile ensured 
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the fixation of the bile on the measurement area and continuous visual confirmation 
ensured that the bile measurements were performed on surface covered with bile. The 
amount of bile applied to the mucosa, the thickness of the bile applied and the exact 
content of the bile applied were not controlled. The mucosal oxygen saturations in 
presence of bile were compared with the mucosal oxygen saturations before the bile 
was applied to the mucosa (baseline) and the mucosal oxygen saturations every time 
after the bile was removed with saline fluid as control. For every step approximately 
30 measurements were done.
Mucosal oxygen saturation versus μPO2 during asystole
Finally, simultaneous mucosal oxygen saturation and μPO
2 
measurements were 
performed from the moment a lethal dose potassium chloride was intravenously 
injected. A measurement period of 25 minutes after injection was considered long 
enough to ensure a steady state since Benaron. et al. showed detection of local ischemia 
with VLS within 120 seconds(23).
Experimental outcomes
Mucosal oxygen saturation values were defined in percentage tissue hemoglobin 
saturation. The μPO
2
 measurements were defined in mmHg.
Analytical and Statistical methods
Statistical analysis was performed with R Statistics software (v3.2.4). Normal distribution 
was assessed visually and with the Shapiro-Wilk normality test. Normal distributed 
data is presented as mean±standard deviation (SD) and abnormally distributed data 
is presented as median with interquartile range (IQR). A linear regression model was 
used for the FiO
2
, mucosal oxygen saturations, and μPO
2
. A scatter plot was used to 
show the mucosal oxygen saturation versus the μPO
2 
measurements at different FiO
2
 
values. To compare the two measurement techniques, the μPO
2
 was converted from 
mmHg to % porcine hemoglobin saturation. To determine the saturation a porcine-
specific hemoglobin saturation formula published by R. Serianni et al. was used(22): 
(%/100) = (0.13534 · P
O2
)3.02/[(0.13534 _ P
O2
)3.02 + 91.2]. The formula was derived from 
213 data point at pH7.4 and 37 degrees with an excellent fit.
To compare the saturation, the difference in measurement frequency had to be 
overcome. The mucosal oxygen saturation has a fixed measurement interval whereas 
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the μPO
2
 is measured on demand. To equally compare the two measurements the 
mucosal oxygen saturation was averaged over same period as one μPO
2
 was done. 
Thereafter these results were visualized with linear regression and with a Bland-Altman 
comparison plot(24).
The Wilcoxon signed-rank test was used to compare the measurement before, with 
and after application of bile. A two-tailed p value of <0.05 was considered significant. 
After the potassium chloride injection mucosal oxygen saturation measurements were 
compared with μPO
2
. Because VLS measures every second, a symmetrical moving 
average of 20 samples was taken to smooth the data, for example the eleventh sample 
is an average of sample [1-21].
RESULTS
Baseline data
All 5 animals were in good clinical condition before the start of the experiment.
Mucosal oxygen saturation versus μPO2 measurements at different FiO2 
values
The mucosal oxygen saturation levels versus the μPO
2
 levels different values of FiO
2
 in 
5 animals were measured. The mucosal oxygen saturation decreased with increasing 
FiO
2
 in contrast to the μPO
2 
values that increased with increasing FiO
2.
 The spread of 
the mucosal oxygen saturation levels and the FiO
2
 levels was large, shown in Figure 3.
Figure 4a shows the correlation between mucosal oxygen saturation and the converted 
μPO
2
 saturation. There is a poor linear correlation with an r2=0.39, an interception of 
18.5% and a slope of 0.41. In the Bland-Altman plot (Figure 4b) also a poor correlation 
is seen with a mean difference of -16%. If the saturation increases the mucosal oxygen 
saturation undervalues the saturation even more.
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Figure 3. Scatter plot n=5 of mucosal oxygen saturation versus μPO
2 
measurements at different 
FiO
2
 values. VLS (R^2 =-0.01, Intersect=42.19, Slope=-0.07), μPO
2
 (R^2=0.06, intersect=35.56, 
slope=0.14).
Figure 4. A) Correlation between mucosal oxygen saturation and the converted μPO
2
 saturation. 
R2= 0.39, intercept 18.5 slope 0.41. B) Blant-Altman plot of the mucosal oxygen saturation and 
the converted μPO
2
 saturation. VLS – μPO
2
_saturation: -16.00974, 2.5% limit: -52.83358 , 97.5% 
limit: 20.81410, SD(diff): 18.41192
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Influence of bile on mucosal oxygen saturation
Figure 5 shows the mucosal oxygen saturation measurements without the presence of 
bile, with the presence of a bile mixture from the stomach and with the presence of a 
bile mixture from the small bowel and measurements without any of the bile mixtures 
measured in a total of 2 animals. The mucosal oxygen saturation measurements before 
application of the bile mixtures and after the bile mixtures were removed were not 
significantly different (mucosal oxygen saturation before application of bile mixture 
median (IQR) 57.5% (54.8-59.0%) versus mucosal oxygen saturation after removal bile 
mixture 57.0% (54.7-58.6%), p= 0.2743). However, a significant increase of the mucosal 
oxygen saturation was seen when the bile mixture from the stomach was applied 
compared to the mucosal oxygen saturation before application of the bile mixtures 
(median mucosal oxygen saturation with mixture of the stomach (IQR) 73.5% (66.8-
85.8) p= <2.2*10-16). When the bile mixture from the small bowel was applied, the 
mucosal oxygen saturation was significantly lower with a median (IQR) 47.6% (41.8-
50.8), p=<2.2*10-16 compared to mucosal oxygen saturation measurements with bile 
mixture form the stomach and the mucosal oxygen saturation increased significantly 
after the bile mixtures had been removed (p=<2.2*10-16).
Figure 5. Mucosal oxygen saturation measurements without the presence of bile, with the pres-
ence of a bile mixture from the stomach, with a bile mixture from the small bowel and mea-
surements without any of the bile mixtures. The baseline mucosal oxygen saturations did not 
significantly differ from the mucosal oxygen saturations after the bile had been removed shown 
as “after bile”. *** = p <2.2*10-16
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Mucosal oxygen saturation versus μPO2 during asystole
The mucosal oxygen saturation measurements and μPO
2 
measurements during the 
minimally first 25 minutes of asystole in 5 animals are shown in Figure 6. In all 5 animals 
the μPO
2 
measurements decreased towards a value of 0. The mucosal oxygen saturation 
measured with VLS decreased and increased variably during the measurement period 
and the mucosal oxygen saturation never reached a stable state around 0%.
Figure 6. Average mucosal oxygen saturation measurements measured by VLS (black) over 21 
data points (gray) and μPO
2 
measurements (red) during the minimally first 20 minutes of asystole 
in 5 pigs. Green vertical dashed line represents the time a lethal potassium dose was injected.
Adverse events
No adverse events occurred during the 5 porcine experiments.
DISCUSSION
In this study we validated mucosal oxygen saturation measurements by comparing 
VLS with calibrated μPO
2 
measurements. This study showed that the mucosal oxygen 
saturation values decreased with increasing FiO
2
 in contrast to the μPO
2 
values that 
increased with increasing FiO
2
 with a large spread of the measured mucosal oxygen 
6
146
Chapter 6
saturation levels and FiO
2
 levels and a poor linear correlation. Furthermore, a significant 
influence of bile on the mucosal oxygen saturation values was shown. Finally, this study 
showed that the mucosal oxygen saturation values, in contrast to the μPO
2 
values, did 
not decrease towards a value of 0 in the first 25 minutes of asystole.
The found inverse relationship of the mucosal oxygen saturation measurements 
by VLS with FiO
2
 is remarkable. Mucosal oxygen saturations measured with VLS 
are expected to increase with increasing FiO
2
 if VLS measures the capillary oxygen 
saturation level. However, VLS measures not only arterial saturation but also a large 
venous compartment. If a large mixed venous saturation determines the overall 
saturation value the influence of FiO
2
 is expected to be minimal. Potentially due to 
hyperoxic vasoconstriction the actual venous saturation can decrease more compared 
to normoxic situations. The high FiO
2
 values will be measured by the μPO
2
. Furthermore, 
the measured values, both VLS as μPO
2 
values, have a great spread. Possibly, the oxygen 
tension was very variable in the gastrointestinal vessels as intestinal ischemia is also 
patchy and heterogenic distributed(5). During the experiment the hemodynamic state 
of the animals worsened by all experimental handlings, also contributing to a great 
spread of measured values.
Significant influence of bile on the mucosal oxygen saturation values measured with 
VLS was confirmed. Therefore it is advised and mentioned in the prescription to 
remove any bile remnants before the start of the VLS measurements. The bile has 
its own absorption spectrum of light. It also absorbs light in the same wavelengths as 
oxyhemoglobin and deoxyhemoglobin(25), and influences the result to determine the 
mucosal oxygen saturation. The amount of bile applied to the mucosa, the thickness 
of the bile applied and the exact content of the bile applied were not controlled in this 
experiment. However, these factors contribute to the light absorption by the bile and 
thus influence its effects on the VLS signal. Therefore, we advise to remove any fluid 
on the measuring area of the GI mucosa before the VLS measurements.
The idea that VLS measures mixed venous oxygen saturation is further confirmed by the 
fact that VLS measured still a reasonable oxygen saturation 25 minutes after asystole. 
The saturation in the capillaries is decreased towards zero over time due to diffusion of 
oxygen towards the still oxygen consuming cells. However, in the venous compartment 
the oxygen will desaturate slowly by the large buffer capacity. Therefore, the oxygen 
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saturation will not decrease towards zero immediately after asystole. Dips in oxygen 
saturation are seen in the mixed venous compartment measured by VLS as shown in 
Figure 6 due to spasm in the supplying arteries. After such a peristaltic contraction the 
blood flow stabilizes and no decrease in saturation is seen.
VLS is a powerful technique to measure oxygen saturation at a microvascular level. In 
the microvasculature oxyhemoglobin/deoxyhemoglobin is proportional mainly located 
in the venous compartment of the microvasculature. Therefore the saturation measured 
by the VLS is mainly represented by the venous compartment. For detection of an 
oxygen transport problem that results in ischemia, the microvascular arterial saturation 
is of importance, a part that is underexposed by VLS. This is endorsed by the fact that 
after a lethal potassium chloride the saturation does not drop in comparison to μPO
2
, 
which is an exaggerated model of instant ischemia.
This study has some limitations. First, the experiments performed in this study were 
designed to enable generalizability in humans. However, to enable stable oxygen 
saturation measurements with VLS and μPO
2
 of the mucosa of the small intestine of 
a pig, the abdomen had to be opened to open the small intestinal loop. The mucosa 
of this small intestinal loop was exposed to room air and room temperature. This will 
result in oxygen diffusion into the tissue and rapid decrease in temperature for the 
exposed tissue. Furthermore, the abdominal anatomy of a pig is different from the 
human abdominal anatomy. The GI tract of a pig is monogastric like the human GI tract, 
however the colon lies in a spiral. The mesenteric vascularization in humans consists 
of individual variable, mesenteric vessel formations with arcades, lateral branches and 
anastomoses in the bowel wall(26). The mesenteric vascularization in pigs consists of 
bundles of vessel branched of the main stem arising from the mesentery and passing 
directly into the bowel wall without any branching of arcades(26).
CONCLUSION
This study showed that VLS measures the mixed venous hemoglobin oxygen saturation 
and not the mucosal capillary hemoglobin oxygen saturation. The presence of bile 
significantly influences the oxygen saturation levels measured with VLS. VLS is currently 
used in clinical practice in the clinical work-up of CMI. Further research is needed 
to establish if the mixed venous compartment is optimal for mucosal hemoglobin 
saturation measurements to assess GI ischemia.
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ABSTRACT
Protoporphyrin IX-triplet state lifetime technique (PpIX-TSLT) is a method used to 
measure oxygen (PO
2
) in human cells. The aim of this study was to assess the technical 
feasibility and safety of measuring oxygen-dependent delayed fluorescence of 
5-aminolevulinic acid (ALA)-induced PpIX during upper gastrointestinal (GI) endoscopy.
Endoscopic delayed fluorescence measurements were performed 4 hours after oral 
administration of ALA in healthy volunteers. The ALA dose administered was 0,1,5 or 
20mg/kg. Measurements were performed at three mucosal spots in the gastric antrum, 
duodenal bulb and descending duodenum with the catheter above the mucosa and 
while applying pressure to induce local ischemia and monitor mitochondrial respiration. 
During two endoscopies, measurements were performed both before and after 
intravenous administration of butylscopolamine.
Delayed fluorescence measurements were successfully performed during all 10 upper GI 
endoscopies. ALA dose of 5 mg/kg showed adequate signal-to-noise ratio (SNR) values 
>20 without side effects. All pressure measurements showed significant prolongation of 
delayed fluorescence lifetime compared to measurements performed without pressure 
(p<0.001). Measurements before and after administration of butylscopolamine did not 
differ significantly in the duodenal bulb and descending duodenum.
Measurements of oxygen-dependent delayed fluorescence of ALA-induced PpIX in the 
GI tract during upper GI endoscopy are technically feasible and safe.
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GRAPHICAL ABSTRACT AND TEXT
Oxygen tension (PO
2
) can be measured in human cells by delayed fluorescence lifetime 
quenching of 5-aminolevulinic acid-induced protoporphyrin IX. This study aimed to 
assess the technical feasibility and safety of this technique during upper gastrointestinal 
endoscopy in the gastrointestinal (GI) tract. The endoscopic delayed fluorescence 
lifetime measurements in the GI tract were technically feasible and safe. Local mucosal 
ischemia was introduced temporarily by applying pressure with the probe on the 
mucosa. The lifetime prolongation demonstrated the oxygen-dependence of the signal.
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INTRODUCTION
Protoporphyrin IX (PpIX) is an endogenous compound synthesized in active mitochondria 
which can be induced by administration of its precursor 5-aminolevulinic acid (ALA). 
PpIX exhibits oxygen-dependent delayed fluorescence after photoexcitation(1). The 
fluorescence lifetime depends directly on oxygen concentration, since oxygen acts 
as a quencher of excited PpIX molecules. In other words, upon collision of oxygen 
with an excited PpIX molecule energy transfer to oxygen will relax PpIX to the ground 
state without emission of a photon. More oxygen leads to more collisions and 
quenching, thereby shortening the delayed fluorescence lifetime. This phenomenon 
is described quantitatively by the Stern-Volmer relationship(2), relating the lifetime 
to the amount of oxygen (e.g. oxygen concentration or oxygen tension). A detailed 
description of the principles of the PpIX-triplet state lifetime technique (PpIX-TSLT) can 
be found in the article written by Harms et al.(3). Introduction of the COMET monitor 
(Photonics Healthcare BV, Utrecht, The Netherlands) made PpIX-TSLT clinically available 
for measurements on the skin(4). The main goal of this study was to investigate the 
technical feasibility of delayed fluorescence measurements in the gastrointestinal (GI) 
tract during endoscopy.
Oxygen tension (PO
2
) measurements in cells of the GI tract during endoscopy could be 
of great value, e.g. for the diagnostic work-up of patients suspected to be suffering from 
chronic mesenteric ischemia (CMI). CMI is the result of insufficient blood supply to the 
GI tract caused by obstruction of mesenteric arteries and/or veins(5). CMI is in >90% 
caused by atherosclerosis of minimally one mesenteric artery. Typical symptoms of CMI 
are postprandial abdominal pain and weight loss, however more atypical symptoms 
as nausea, constant abdominal discomfort, vomiting, diarrhea or constipation are also 
reported(5). Symptoms alone are of limited value for the diagnosis of CMI(6). Mesenteric 
artery stenosis can be detected by CT-angiography, however the presence of mesenteric 
artery stenosis will not necessarily result in symptomatic disease (CMI) due to an 
abundant collateral mesenteric network. The prevalence of mesenteric artery stenosis 
in the asymptomatic general population is high (3-29%), increasing with age(7, 8). CMI 
occurs when extensive mesenteric artery stenosis and/or an insufficient collateral 
network is present. Therefore, a functional test detecting GI ischemia is highly desired. 
Currently, visible light spectroscopy (VLS) and tonometry are used as functional tests 
for the diagnostic work-up of patients suspected to be suffering from CMI.
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VLS measures the mucosal capillary hemoglobin oxygen saturation during upper GI 
endoscopy(9, 10) and is less invasive than tonometry measuring luminal pCO
2
 with a 
nasogastric and nasojejunal catheter connected to a capnography(10, 11). However, 
the sensitivity of VLS for CMI is 90% and the specificity is 60%(12), indicating the need 
to improve the accuracy of the diagnostic workup. Since in the original reports of 
PpIX-TSLT the lifetimes were shown to be related to mitochondrial oxygen levels(1, 
13) this technique shows promise for diagnosing CMI. The COMET monitoring device 
was designed for cutaneous measurements and has been adapted for endoscopic 
delayed fluorescence lifetime measurements. Therefore the primary aim of this study 
was to assess the technical feasibility of delayed fluorescence measurements of the GI 
tract during upper GI endoscopy. Secondary aims were: 1. to determine the dose of 
5-aminolevulinic acid (ALA) needed for endoscopic measurements; 2. to determine the 
specific measurements locations; 3. to demonstrate oxygen-dependent signal and, 4. 
to determine the influence of butylscopolamine on the measurements.
METHODS
Study design and setting
This work describes a single center study in healthy volunteers. The institutional 
review board of the Erasmus MC University Medical Center approved this study 
(NL59177.078.16, NL63050.078.17). The study complies with the Helsinki declaration 
on research ethics.
Participants
Healthy volunteers were recruited by distributing information leaflets. Before inclusion 
the medical history and existence of GI complaints were evaluated. Blood samples were 
taken to detect impaired renal function, and liver test abnormalities, defined as eGFR 
<90 ml/min/m3 or liver test abnormalities >1.5 times upper limit of normal. Healthy 
volunteers were eligible if they were able to give written informed consent, had an 
unremarkable medical history, and had no GI complaints. Volunteers were excluded 
in case of pregnancy, acute or chronic porphyria, and a known ALA or porphyrin 
hypersensitivity.
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Study procedures and setup
The healthy volunteers were fasted for at least 6 hours and ALA (Gliolan, Medac GmbH, 
Wedel, Germany) was administered orally 4 hours before the upper GI endoscopy. The 
volunteers were discharged after the endoscopy. They were instructed to report any 
side effects. Furthermore, they were instructed to avoid exposure to sunlight as much 
as possible, and take precautions (e.g. sunglasses, long sleeves) during the first 24 hours 
after administration of ALA, since phototoxicity after sunlight exposure is a known side 
effect of ALA. Adverse events were collected during 7 days.
A probe that could be passed safely through the accessory channel of the endoscope 
was used for endoscopic detection of fluorescence light (designed by TNO, produced 
and CE-marked by LightGuideOptics, Mechenheim, Germany). The diameter of the 
accessory channel of the endoscope is 3.2 to 4.2 mm and therefore the tip of the 
probe is slightly smaller than 3.2 mm. The probe is a fiber optic assembly with one 
excitation fiber in the middle directly surrounded by seven detection fibers. The used 
detection fibers all have a diameter of 365 μm, and the excitation fiber is 470 μm in 
diameter. The fibers have a numerical aperture (NA) of 0.22±0.2. The tips of the fibers 
are fixed together in a ferrule. The position of the fiber tips within the ferrule and 
distance compared to each other is fixed and does not change when pressure is applied 
on the mucosa with the probe tip or while passing the probe tip through the accessory 
channel of the endoscope. The excitation fiber of the probe was connected to the 
light source in the COMET, a pulsed 515nm laser. The detection fiber was connected 
to the photomultiplier detection system of the COMET. To protect the highly sensitive 
detection system from indirect laser light a long pass filter (575nm with OD 4, Edmund 
Optics, Barrington, NJ, USA) was introduced in the optical path of the detection branch. 
During endoscopy peripheral saturation was continuously monitored and oxygen was 
administered intranasally to maintain a saturation level ≥95%. See Figure 1 for the setup.
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Figure 1. The setup for upper GI endoscopic delayed fluorescence measurements: A) Schematic 
setup, B) Probe in the descending duodenum during upper GI endoscopy, and C) Probe in the 
descending duodenum during endoscopic measurement (endoscopic light is switched off).
Delayed fluorescence lifetime measurements were performed similar to VLS 
measurements at three anatomical locations in the descending duodenum, duodenal 
bulb, and antrum of the stomach(12). The fiber was positioned approximately 1-5 mm 
above the mucosa of the target area. A perpendicular angle of the fiber tip and the target 
area is optimal for the signal quality, however this is not an important parameter for the 
outcome of the lifetime measurements. To minimize interference by background noise 
the light of the endoscope was switched off during the measurements. Raw delayed 
fluorescent traces were stored with an external computer connected via the serial 
(rs-232) port. A python script written to store the raw data in a comma-separated file 
was used to read the serial buffer. The raw data was analyzed with software written in 
LabVIEW (version 13.0, National Instruments, Austin, TX, USA). Lifetimes were calculated 
using a rectangular distribution fit, taking into account the heterogeneity in lifetimes 
underlying the measured delayed fluorescence signal(13) unless stated otherwise. The 
mitochondrial oxygen tension (mitoPO
2
) reading by COMET was not used since COMET 
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is developed and tested for measurement on skin and links the measured lifetimes 
to the calibration constants for skin cells. Because this is the first report on delayed 
fluorescence measurements via an endoscope, we judged to exercise some restraint 
in reporting absolute values of PO
2
. Therefore all delayed fluorescence measurements 
are represented as reciprocal lifetimes  (with t in microseconds) in order to obtain 
a positive association between oxygen and lifetime. According to the Stern-Volmer 
relationship the reciprocal lifetime is linearly related to the actual oxygen tension. Based 
on our current understanding of the technology, PO
2 
measurements with a reciprocal 
lifetime >0.1 μs-1 should be considered as non-physiological in humans with a normal 
arterial oxygen tension(1).
Determination necessary ALA dose
The appropriate dose of ALA was determined by performing delayed fluorescence 
lifetime measurements with different doses of ALA. Since PpIX is endogenously present 
and accumulates in metabolic active cells, such as mucosal cells, measurements 
were performed during one upper GI endoscopy without administration of ALA. In 
neurosurgery 20mg/kg ALA is used to induce enough PpIX to visually determine the 
tumor fluorescence under blue light(14). This was expected to be an abundant dose for 
detection of delayed fluorescence in the duodenal region because of the high cellular 
turnover and metabolic rate compared to neurological tissue. Therefore, five upper 
GI endoscopies were performed using a dose of 20mg/kg, two upper GI endoscopies 
were performed after administration of 1mg/kg ALA and two using a dose of 5mg/kg. 
Optimal dosage was based on signal quality and adverse events. Quality is expressed 
as signal-to-noise ratio (SNR). A SNR >20 is considered adequate(4).
Determining measurement locations and demonstrating oxygen-dependent 
signal
Measurements were obtained at each anatomical location with the probe hovering 
1-5 mm above the mucosal surface. In order to confirm that the measured delayed 
fluorescence lifetimes depend on the oxygen concentration, measurements were 
performed while inducing local mucosal ischemia. Temporary ischemia was achieved 
by applying pressure to the mucosa with the probe. The oxygen supply to the tissue 
under the probe is compromised by compression of the capillaries. Because the oxygen 
is used within the cells, and the supply compromised, a prolongation of lifetime was 
expected due to the decrease in PO
2
 during application of pressure. After minimally 
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two seconds of pressure, three consecutive measurements were taken while pressure 
was applied. This process was repeated at two more sites within each anatomical 
location. In the situation without pressure the tip of the probe was positioned under 
view in close proximity of the tissue or just on the tissue without visible deformation 
of the mucosa. While providing pressure the probe is pushed on the tissue and caused 
tissue deformation similar to the procedure performed when obtaining tissue biopsies 
for diagnostic purposes. The exact amount of pressure applied was not controlled or 
measured. Measurements started in the descending duodenum and subsequently 
measurements with and without applying pressure were performed in the duodenal 
bulb and gastric antrum.
An oxygen consumption curve was made in two volunteers who received 5mg/kg ALA 
by taking repeated measurements with an interval of one second. Measurements were 
performed without applying pressure for minimally five seconds; the next 20 seconds 
measurements were performed while applying pressure to visualize mitochondrial 
respiration(15). SNR and reciprocal lifetime were used to determine appropriate 
locations for measurements.
It is known that local oxygen tension will be heterogeneously distributed within the 
tissue(16). Further analysis was done on the raw fluorescent traces to determine the 
effect of local applied pressure on the reciprocal lifetime and its distribution, caused 
by e.g. oxygen heterogeneity. By assuming the PpIX to be homogenous distributed 
among the GI tract the underlying lifetime distribution can be obtained with a method 
described by Golub et al.(17). The trace can be described by a sum of rectangular 
distributions and the fractional contribution per reciprocal lifetime can be recovered. 
This method was successfully used by our group to recover oxygen distribution 
histograms (16, 18, 19) and is used on specific traces in this study to determine the 
distribution of (reciprocal) lifetimes in the signal as a measure of heterogeneity in 
the tissue. The fractional distribution within a trace describes the heterogeneity on 
a microvascular and cellular scale. To investigate the heterogeneity on a larger tissue 
scale all data recorded above the tissue is combined in a histogram and the individual 
contributions are visualized by color.
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Determining influence of butylscopolamine
Intravenous administration of butylscopolamine is commonly used during upper GI 
endoscopy to reduce intestinal contractions. Since butylscopolamine is known to induce 
tachycardia causing increased cardiac output, GI tract tissue oxygen levels could be 
influenced. This possible influence was evaluated in two volunteers receiving 5mg/
kg ALA. All measurements mentioned before were performed in the descending 
duodenum, duodenal bulb and gastric antrum. After intravenous administration of 20 
mg butylscopolamine the measurements were repeated in exactly the same manner.
Statistical analyses
The SNR and reciprocal lifetime were not normally distributed and therefore described 
as medians and interquartile ranges (IQR). Differences in reciprocal lifetimes with 
and without pressure and before and after administration of butylscopolamine were 
determined using the Wilcoxon-Mann-Whitney Test. A two-tailed p value of <0.05 was 
considered significant. Statistical analysis was performed using R (version 3.4.2) (20).
RESULTS
Participants
Ten upper GI endoscopies were performed in six healthy volunteers. Nine out of ten 
upper GI endoscopies were performed in females, with a median age of 30.0 years 
(IQR 28.5-34.0 years). All endoscopies were performed in non-smokers and all healthy 
volunteers gave informed consent. No oxygen or sedatives were administered during 
endoscopy. Delayed fluorescence lifetime measurements were successfully performed 
during all ten endoscopies.
Determining necessary ALA dose
The SNR for each specific location and dose of ALA are presented in Table 1 and Figure 
2. The endogenous amount of PpIX showed to be insufficient to measure delayed 
fluorescence, since SNR was below 20 at all locations. The dose of 1mg/kg ALA also 
showed to be insufficient with SNR values of the first quartile reaching maximal 18 in 
the descending duodenum and a median SNR of 29 just above the lower limit of 20.
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Table 1. Signal-to-noise ratio (SNR) for measurements with probe position 1-5mm above tissue, 
data presented as median [IQR], total of 10 upper GI endoscopies.
Dose 0 mg/kg 1 mg/kg 5 mg/kg 20 mg/kg
SNR Antrum 2 [1-3] 4 [3-6] 6 [4-13] 19 [8-37]
SNR Duodenal bulb 3 [2-7] 233 [165-533] 702 [179-900] 617 [269-921]
SNR Descending duodenum 6 [5-6] 29 [18-56] 215 [156-684] 110 [77-248]
Adverse Events 0/1 0/2 0/2 3/5 phototoxicity
Figure 2. Signal-to-noise ratio (SNR) sorted by oral dose ALA combined for all measurement 
locations (gastric antrum, duodenal bulb, descending duodenum). Measurements are performed 
without pressure applied. Outliers are not presented since SNRs in 5 and 20mg/kg go up to 6000.
SNR in duodenal bulb and descending duodenum were adequate in the 5 and 20mg/
kg group, however phototoxic side effects occurred in three out of five volunteers in 
the 20mg/kg group (Table 1). The phototoxicity was observed on the skin of the face 
exposed to sunlight after the experiment in all three volunteers with phototoxicity 
and looked similar to a sunburned like reaction. Side effects resolved within 24 hours 
in all volunteers. Phototoxicity was not observed in the GI tract and volunteers did not 
experience abdominal complaints.
It was concluded that 5mg/kg was the best dose with sufficient SNR values and without 
reported side effects. This dose leaves a margin for suboptimal circumstances, for 
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example less conversion of PpIX in patients and losses in the detection system due 
to the use of adaptors needed to couple the measuring probe to the COMET system.
Determining measurement locations
The SNR at the gastric antrum location was low compared to the SNR of the duodenal 
bulb and descending duodenum. Only in the 20mg/kg group the upper quartile of 
the values reached a SNR >20 in the gastric antrum, therefore the signal quality in the 
gastric antrum showed insufficient for reliable measurements. The lifetime calculation 
became more inaccurate if the SNR dropped below 20, resulting in a scatter of lifetimes 
with a tendency to non-physiological lifetimes, see Figure 3. Since the SNR values in the 
gastric antrum were too low and caused non-physiological lifetimes, measurements in 
gastric antrum were not included in the analysis of the influence of butylscopolamine.
Figure 3. Reciprocal lifetimes (with lifetime  tau in microseconds) versus signal-to-noise ratio 
(SNR) of all measurements without pressure applied specified for each measurement location.
Demonstrating oxygen-dependent signal
Raw delayed fluorescence lifetime traces were recorded. When the probe was “loose” 
hovering above the GI tissue short lifetimes were measured. While pressure was applied 
the lifetime increased, shown in the Bulbus in Figure 4.
165
Endoscopic delayed fluorescence of protoporphyrin IX
Fi
gu
re
 4
. A
) T
he
 n
or
m
al
iz
ed
 d
el
ay
ed
 fl
uo
re
sc
en
ce
 tr
ac
es
 r
ec
or
de
d 
in
 th
e 
B
ul
bu
s 
w
it
h 
5m
g/
kg
 A
LA
. T
he
 tr
ac
es
 r
ep
re
se
nt
 3
 lo
os
e 
fo
llo
w
ed
 b
y 
3 
m
ea
su
re
-
m
en
ts
 w
hi
le
 p
re
ss
ur
e 
w
as
 g
iv
en
 w
it
h 
th
e 
pr
ob
e 
on
 t
he
 ti
ss
ue
 t
o 
in
du
ce
 lo
ca
l i
sc
he
m
ia
. T
hi
s 
se
qu
en
ce
 w
as
 r
ep
ea
te
d 
fo
r 
a 
se
co
nd
 ti
m
e.
 F
or
 t
he
 d
is
tr
ib
u-
ti
on
 a
na
ly
si
s 
(h
is
to
gr
am
s)
 a
 b
as
e 
of
 1
5 
re
ci
pr
oc
al
 li
fe
ti
m
es
 e
qu
al
ly
 d
is
tr
ib
ut
ed
 o
ve
r 
a 
co
rr
es
po
nd
in
g 
ph
ys
io
lo
gi
ca
l P
O
2 
ra
ng
e 
(0
-1
50
 m
m
H
g)
 a
ss
um
in
g 
a 
qu
en
ch
in
g 
co
ns
ta
nt
 o
f 8
30
 m
m
H
gs
-1
 a
nd
 li
fe
ti
m
e 
of
 s
po
nt
an
eo
us
 r
el
ax
ati
on
 o
f 8
00
 m
ic
ro
se
co
nd
s 
w
as
 t
ak
en
(1
). 
H
is
to
gr
am
s 
sh
ow
 r
ec
ip
ro
ca
l l
ife
ti
m
e 
di
st
ri
bu
ti
on
s 
of
 t
ra
ce
s 
of
 t
he
 fi
rs
t 
pa
ne
l. 
B 
an
d 
D
) A
ve
ra
ge
 o
f 3
 lo
os
e 
m
ea
su
re
m
en
ts
. C
 a
nd
 E
) A
ve
ra
ge
 o
f 3
 m
ea
su
re
m
en
ts
 w
hi
le
 p
re
ss
ur
e 
w
as
 a
pp
lie
d 
on
 t
he
 ti
ss
ue
 w
it
h 
th
e 
op
ti
ca
l p
ro
be
. H
is
to
gr
am
 d
at
a 
pr
es
en
te
d 
as
 m
ea
n±
SE
M
.
7
166
Chapter 7
For the lifetime distribution analysis a base of 15 reciprocal lifetimes equally 
distributed over a corresponding physiological PO
2
 range (0-150 mmHg) assuming a 
quenching constant of 830 mmHgs-1 and lifetime of spontaneous relaxation of 800 
microseconds was taken(1). The distribution analysis was done on the 2 times 3 
loose and 2 times 3 pressure traces. The averaged distributions of both the loose and 
pressure measurements are shown in Figure 4. While pressure was applied a fraction 
of 0.55 of the signal fell in the bin with central reciprocal lifetime 0.005 μs-1. Such 
lifetimes around 200 µs and even longer, as in this bin, indicate that a large part in the 
measurement volume is ischemic. The decrease in oxygen resulted in a distribution that 
has shifted to the left (lower PO
2
) compared to the loose situation(3). To analyze the 
heterogeneity between different spots of mucosal tissue, all “loose” data was combined 
into a histogram. To visualize the contribution of individual volunteers the data is color 
categorized per subject, shown in Figure 5.
Figure 5. Histogram, 16 bins distributed over physiological reciprocal lifetimes, of the two mea-
surement locations, included data is 5 and 20mg/kg ALA administration. The presented data is 
from two measurement location, a) Descending duodenum, b) Duodenal bulb, with the mea-
surement probe hovering 5mm above the tissue. The colors indicate the individual measurement 
subjects.
All measurements performed while applying pressure on the mucosa were significantly 
lower compared to measurements performed without pressure at all measurements 
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locations (Table 2). Figure 6 displays a decrease of reciprocal lifetime when pressure is 
applied with values decreasing further when pressure is maintained for a longer period 
of time. The oxygen disappearance curve (Figure 7) supports this finding and shows a 
decrease of reciprocal lifetime over time, demonstrating disappearance of oxygen due 
to ongoing oxygen consumption, while temporary ischemia is induced.
Table 2. Reciprocal lifetime (in units, 1/τ ms-1) of GI tissue PO
2 
measurements with and without 
pressure applied for each measurement location. ALA dose is 5mg/kg and 20mg/kg, total of 
seven upper GI endoscopies.
Location
1/τ loose
median [IQR]
1/τ pressure
median [IQR]
p-value
Antrum 0.092 [0.061-0.132] 0.052 [0.032-0.069] <0.001
Duodenal bulb 0.041 [0.032-0.049] 0.013 [0.010-.0.022] <0.001
Descending duodenum 0.016 [0.011-0.026] 0.009 [0.008-0.011] <0.001
Figure 6. A) Measurements in the descending duodenum. X-axis shows measurements just 
above tissue (loose) and three consecutive measurements during pressure application (pres-
sure 1, pressure 2, pressure 3). B) Measurements in the duodenal bulb. X-axis shows measure-
ments just above tissue (loose) and three consecutive measurements during pressure applica-
tion (pressure 1, pressure 2, pressure 3).
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Figure 7. Oxygen consumption curve performed in the duodenal bulb.
Determining influence of butylscopolamine
Delayed fluorescence before and after administration of butylscopolamine did not differ 
significantly in the duodenal bulb (Figure 8). In the descending duodenum, reciprocal 
lifetimes before administration of butylscopolamine were significantly lower than 
after administration of butylscopolamine (Figure 8). Measurements before and after 
administration of butylscopolamine did no longer differ significantly (p=0.281) when 
the lowest duodenal values before administration of butylscopolamine are excluded. 
These measurements were performed while unintended pressure was applied to the 
mucosa due to intestinal contractions.
169
Endoscopic delayed fluorescence of protoporphyrin IX
Figure 8. A) measurements with 5mg/kg ALA in duodenal bulb without butylscopolamine versus 
measurements with butylscopolamine and B) measurements with 5mg/kg ALA in descending 
duodenum without butylscopolamine versus measurements with butylscopolamine.
DISCUSSION
This study showed that delayed fluorescence measurements of ALA-induced PpIX in the 
GI tract during upper GI endoscopy are technically feasible and that the measured signal 
is oxygen-dependent. We determined an optimal dose of 5mg/kg ALA and duodenal 
bulb and descending duodenum as suitable measurement locations. Administration of 
butylscopolamine during upper GI endoscopy did not influence the measured GI delayed 
fluorescence signal (reciprocal lifetimes).
ALA-induced enhancement of mitochondrial PpIX provided the first method to measure 
mitochondrial PO
2
 in living cells(1). In a time window of some hours after administration 
of ALA the PpIX is confined in the mitochondria as shown in animal studies in rat liver(18) 
and rat heart(19). Since PpIX diffuses slowly out of the mitochondria, it will not solely 
remain in the mitochondria, making the localization of the signal less specific over time. 
The COMET system provides the clinical parameter “mitoPO
2
”, in order to distinguish the 
measurement from e.g. hemoglobin-based “tissue oxygen” measurements, since such 
parameters provide other information from different tissue compartments(4). However, 
the reader should keep in mind that the origin of the PpIX delayed fluorescence signal 
7
170
Chapter 7
is not only mitochondrial and depends on tissue type, and the amount of time after 
ALA administration.
Administration of ALA is needed for reliable endoscopic delayed fluorescence lifetime 
measurements since the amount of endogenously present PpIX is not sufficient for 
measurements using the current setup. The optimal dose of ALA is a compromise 
between sufficient signal quality and no or few side effects. The signal quality was 
high for a dose of 20mg/kg ALA, however phototoxicity was reported in 60%. Measured 
reciprocal lifetime values were disproportionally high at a dose of 1mg/kg ALA compared 
to the values measured with 5 or 20mg/kg ALA. This finding suggests the occurrence 
of disproportional high reciprocal lifetime values at low SNRs due to insufficient ALA 
dose. An explanation may be the occurrence of PpIX photobleaching, caused by the 
white xenon light source of the endoscope plus the potential photobleaching effect of 
the green laser light. The total amount of light exposure depends on the endoscopic 
observation time. But despite the endoscopic light source the measurements could 
be performed with sufficient signal quality. With technical and medical considerations 
in mind we advise an ALA dose of 5mg/kg for endoscopic oxygen-dependent 
delayed fluorescence measurements, since we showed reliable delayed fluorescence 
measurements without any side effects after administration of this dose.
The COMET device determines mitoPO
2
 by the delayed fluorescence lifetime of PpIX 
after excitation with a laser pulse. The measurement has been calibrated for skin and 
in that case reciprocal lifetime is linear proportional to oxygen tension in mmHg(1). 
The calibration constants in the human gastro-duodenal tract are unknown, as a 
consequence all data is represented in reciprocal lifetimes 1/τ (μs-1). The measured 
lifetimes in the gastric antrum were short, with a median value of 10.8 μs, that would 
have corresponded with non-physiological high PO
2
 values if the current available 
calibration constants were used(1). The reason why the gastric antrum has short delayed 
fluorescent lifetimes has not been studied. We consider the histological composition 
and function of the mucosa could interfere with the excitation light of the delayed 
fluorescent signal itself. It could be that the ability of these cells to accumulate PpIX is 
lower, e.g. due to a relatively slow cellular turnover, resulting in low SNRs and unreliable 
short lifetimes.
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We determined the influence of administration of butylscopolamine on the endoscopic 
delayed fluorescence signal since butylscopolamine is commonly administered 
intravenously in clinical practice if intestinal contractions hamper the endoscopy. 
Delayed fluorescence lifetimes before and after administration of butylscopolamine did 
not differ significantly in the duodenal bulb, however in the descending duodenum the 
reciprocal lifetimes before administration of butylscopolamine were significantly lower 
than after administration. These lower values were due to unintended application of 
pressure during measurements, caused by peristaltic movements of the bowels. During 
the endoscopic GI delayed fluorescence measurements the green light emitted by the 
laser is visible when the endoscopic light is switched off. When peristaltic movements 
of the bowels were present we frequently observed fading or even disappearance of 
the green light when the GI mucosa pressed against the fiber. At the same time, lower 
reciprocal lifetime values were noted. Since the endoscopic light has to be switched off 
during GI delayed fluorescence measurements, correcting the position of the probe in 
order to avoid contact with the mucosa is difficult in contractile bowels. After excluding 
the low values caused by unintended application of pressure, no significant differences 
in reciprocal lifetime before and after butylscopolamine remained. Therefore we 
conclude that butylscopolamine does not influence the endoscopic GI tissue reciprocal 
lifetime values, however when intestinal contractions are present measurements 
can be affected by unintended application of pressure. We advise to administer 
butylscopolamine during duodenal delayed fluorescence measurements when intestinal 
contractions are present, to increase the reliability of the measurements. Furthermore, 
future design of the probe with development of pressure sensors on the probe tip to 
avoid measurements during unintended application of pressure with the probe tip on 
the GI mucosa could be a solution for this problem.
This study has some limitations. First, the measured GI tract delayed fluorescence 
measurements in this study are presented as reciprocal lifetime since the calibration 
constants for the mucosa of the GI tract are unknown yet. Second, during the GI tissue 
measurements the light of the endoscope has to be switched off to minimize background 
noise. Furthermore, the probe tip currently consists of sharp edges, which can possibly 
damage the GI mucosa. Finally, the amount of endogenous PpIX is far from sufficient to 
measure GI delayed fluorescence using COMET. Necessity to administrate ALA causes a 
delay between oral intake and the first measurement opportunity, aside from potential 
phototoxic effects. Fortunately we did not register any adverse events with 5mg/kg 
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ALA. The use of a commercial device limited our choice to an excitation wavelength of 
515nm, since this is the excitation wavelength of the COMET device, which is designed 
for cutaneous delayed fluorescence measurements after topical application of ALA(4). 
This wavelength is a tradeoff between melatonin and hemoglobin absorption, topical 
applied ALA penetration depth, and measurement volume depth. The penetration 
depth of green light in the gut is very limited(21), and in our application the use of 515 
nm excitation light likely limits the measurement depth to the mucosa. However, since 
ALA is systemically administered in this application, other excitation wavelengths could 
provide more efficient photo excitation and improve SNR, or alter the penetration depth 
and increase measurement volume.
For the interpretation of the signal in terms of quantitative oxygen measurements 
additional research into the localization of PpIX and the photo-physical properties of 
the delayed fluorescence would be very helpful. For example, Vinklárek et al. described 
a Singlet Oxygen Feedback-Induced mechanism (SOFDF) that influences the delayed 
fluorescence of PpIX under certain non-physiologic circumstances(22). It is currently 
unknown to what extent other mechanisms than T-type delayed fluorescence, like this 
SOFDF mechanism, contribute to the in vivo delayed fluorescence signal. Although 
we are determined to improve our measurement and eventually hope to be able to 
convert the measured lifetimes to PO
2
 levels this in itself is not necessary for successful 
clinical application. The only relevant question here is whether the measured lifetimes 
in healthy subjects differ from patients with e.g. CMI. Sensitivity and specificity of the 
technique could equally well be studied and calculated on reciprocal lifetimes instead 
of oxygen tensions.
In conclusion, measurement of oxygen-dependent delayed fluorescence of ALA-induced 
PpIX during upper GI endoscopy is feasible and safe. Further research is needed for 
the clinical applicability of this technique in the diagnostic work-up of CMI, starting 
with endoscopic GI delayed fluorescence measurements in patients suspected of CMI 
to determine its discriminative ability and to determine cut-off values for the inverse 
lifetime measurements for mucosal ischemia. Further research has to determine 
whether a more accurate diagnosis of CMI can be established when the presence of 
mucosal ischemia detected by endoscopic delayed fluorescence measurements is 
combined with the symptoms and imaging of the mesenteric arteries, and ultimately 
whether its use results in less patients treated for suspected CMI (with the associated 
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risks and costs of revascularization therapy) who will not experience relief of symptoms 
since they are false positively diagnosed by current standards.
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ABSTRACT
Background
Chronic mesenteric ischemia (CMI) is the result of insufficient blood supply to 
the gastrointestinal tract and is caused by atherosclerotic stenosis of one or more 
mesenteric arteries in >90% of cases. Revascularization therapy is indicated in patients 
with a diagnosis of atherosclerotic CMI to relieve symptoms and to prevent acute-on-
chronic mesenteric ischemia, which is associated with high morbidity and mortality. 
Endovascular therapy has rapidly evolved and has replaced surgery as first choice 
of treatment in CMI. Bare-metal stents (BMS) are standard care currently, although 
retrospective studies suggested significantly higher patency rates for covered stents 
(CS). The CoBaGI trial is designed to prospectively assess the patency of CS versus BMS 
in patients with atherosclerotic CMI.
Methods
The CoBaGI trial is a randomized controlled, parallel group, patient and investigator 
blinded, superiority, multicenter trial conducted in 6 centers of the Dutch Mesenteric 
Ischemia Study group (DMIS). Eighty-four patients with a consensus diagnosis of 
atherosclerotic CMI are 1:1 randomized to either a balloon-expandable BMS (Palmaz 
Blue with rapid exchange delivery system, Cordis Corporation, Bridgewater, NJ, USA) 
or balloon-expandable CS (Advanta V12 over-the-wire, Atrium Maquet Getinge Group, 
Hudson, NH, USA). Primary endpoint is primary stent patency rate at 24 months 
assessed with CT-angiography. Secondary endpoints are primary stent patency at 6 
and 12 months and secondary patency rates, freedom from restenosis, freedom from 
symptom recurrence, freedom from re-intervention, quality of life according the EQ-
5D-5L and SF-36 and cost-effectiveness at 6, 12 and 24 months.
Discussion
The CoBaGI trial is designed to assess the patency rates of CS versus BMS in patients 
treated for CMI caused by atherosclerotic mesenteric stenosis. Furthermore, the 
CoBaGI trial will provide insights in the quality of life of these patients before and after 
stenting and its cost-effectiveness. The CoBaGI trial is the first randomized controlled 
trial performed in CMI caused by atherosclerotic mesenteric artery stenosis.
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BACKGROUND
Chronic mesenteric ischemia (CMI) is the result of insufficient blood supply to the 
gastrointestinal (GI) tract and is caused by atherosclerotic stenosis of one or more 
mesenteric arteries in >90% of cases(1, 2). The mesenteric arteries are the celiac 
artery (CA), superior mesenteric artery (SMA) and inferior mesenteric artery (IMA). 
Classic symptoms of CMI are postprandial abdominal pain and weight loss due to fear 
of eating. However, CMI may present atypically with constant abdominal discomfort, 
nausea, vomiting, diarrhea or even constipation(1). The “classic triad” of CMI consisting 
of postprandial abdominal pain, weight loss and abdominal bruit is present in only 
16-22% of patients(3, 4).
The diagnosis of CMI is established by consensus in a multidisciplinary meeting joined 
by vascular surgeons, gastroenterologists and interventional radiologists(1). Consensus 
is an accepted method of diagnosing if a gold standard test is absent(5). Symptoms 
alone do not predict the diagnosis of CMI accurately(4, 6, 7). Therefore consensus 
diagnosis is based on the combination of clinical symptoms, radiological evaluation 
of the mesenteric vasculature and if available, assessment of mucosal ischemia with a 
functional test such as gastric-jejunal tonometry(3, 8, 9) or visible light spectroscopy 
(VLS)(10, 11). A definitive diagnosis of CMI is established if successful therapy of patients 
with CMI consensus diagnosis results in a durable relief of presenting symptoms.
Revascularization therapy is indicated in patients with a diagnosis of atherosclerotic CMI 
to relieve symptoms and to prevent acute-on-chronic mesenteric ischemia, which is 
associated with high morbidity and mortality. Endovascular revascularization has largely 
replaced open surgical revascularization (1, 12, 13). Endovascular revascularization of 
mesenteric arteries is achieved by means of stent placement. The SMA and CA are 
target vessels for therapy because of their larger diameter compared to the IMA. 
Furthermore, a protective collateral network ensures blood supply when the IMA is 
occluded as shown in patients with an aortic stent occluding the IMA. Literature on 
revascularization of the IMA is scarce. A study reported successful stenting of the IMA 
in 4 patients who were not candidates for CA or SMA revascularization(14). The classic 
percutaneous approach for mesenteric endovascular procedure is trans-brachial and 
trans-femoral, but a trans-radial approach is currently gaining popularity(15).
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Endovascular revascularization is associated with a significant decreased risk of in-
hospital complications compared to open mesenteric surgical revascularization(16). 
Despite the advantages of endovascular revascularization short term, re-stenosis is 
a common event occurring in 28-55% of patients within 2 years after endovascular 
mesenteric stenting(13, 17) whereas 0-25% of surgically treated patients develop 
re-stenosis(2, 18). The primary patency rate of open surgical revascularization is 
significantly higher than that of endovascular revascularization (cumulative OR 3.57, 
95% CI 1.82-6.87, p=0.0002)(19).
Currently, balloon-expendable bare-metal stents (BMS) are standard care for 
mesenteric endovascular revascularization(1, 20). Retrospective data however, showed 
significantly higher primary patency rates of balloon-expendable covered stents (CS) 
at 3 years for mesenteric artery stenosis(21). Furthermore, patients treated with CS 
had less restenosis, symptom recurrence and re-intervention than patients treated 
with BMS(21). The Covered versus Balloon Expandable Stent Trial (COBEST) showed 
significantly higher patency rates of CS than BMS for aortoiliac arterial disease 18, 24, 
48 and 60 months after stent placement(22, 23). Possibly, the membrane that covers the 
vascular atherosclerotic lesion functions as a physical barrier for intimal hyperplasia and 
is therefore associated with less restenosis in contrast with BMS. The performance of 
CS for mesenteric artery stenosis is promising, but prospective confirmation is lacking. 
The CoBaGI trial is a multicenter randomized controlled patient and investigator blinded 
clinical trial designed to compare patency rates of the CS versus standard care therapy 
with BMS in patients with CMI based on atherosclerosis.
Study hypothesis
CS have a significantly higher patency rate than BMS in patients with CMI due to 
atherosclerotic origin stenosis of the CA and/or SMA.
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METHODS/DESIGN
This study protocol is written according to the SPIRIT 2013 statement for study protocols 
of clinical trials(24). The SPIRIT diagram is shown as Table 1.
Table 1. Schedule of enrollment, interventions and assessments for the CoBaGI trial acoording 
to SPIRIT(24).
Study 
period
Enrolment Allocation Post-
allocation
Close-
out
Time point -t
1
0 t
1
t
2
t3 t4 tx
Enrollment:
Eligibility screen X
Informed consent X
Allocation X
Interventions:
Intervention CS X
Intervention BMS X
Assessments:
CTA X X X X
EQ-5D-5L X X X X
SF-36 X X X X
Cost-effectiveness X X X X
SAE X X X X
Mortality X X X X
-t
1
 = screening and enrollment; t
1 = 
endovascular stent placement; t
2
 = 6 months; t3 = 12 months; t4 = 24 
months after intervention; t
x
 = end of follow-up 24 months. BMS = bare-metal stent; CS = covered stent; 
CTA = computed tomography angiography; SAE = serious adverse event.
Study design
The CoBaGI trial is a randomized controlled, parallel group, patient and investigator 
blinded, superiority, multicenter trial conducted in 6 centers of the Dutch Mesenteric 
Ischemia Study group (DMIS). Patients with atherosclerotic CMI will be randomly 
allocated for standard care therapy using a BMS (Palmaz Blue with rapid exchange 
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delivery system, Cordis Corporation, Bridgewater, NJ, USA) or a CS (Advanta V12 over-
the-wire, Atrium Maquet Getinge Group, Hudson, NH, USA).
Study setting
The CoBaGI trial is conducted within the framework of the DMIS. Six Dutch centers 
participate in the CoBaGI trial. Initiating center is the Erasmus MC University Medical 
Center, an academic hospital in Rotterdam together with Medisch Spectrum Twente 
in Enschede which serves as a CMI specialized referral center. Furthermore, 4 other 
Dutch tertiary referral centers participate in the study: Maasstad Hospital in Rotterdam; 
St. Antonius Hospital in Nieuwegein; Bernhoven Hospital in Uden, and Jeroen Bosch 
Hospital in ‘s-Hertogenbosch.
Eligibility criteria
Patients with a consensus diagnosis of atherosclerotic CMI eligible for endovascular 
stent placement will be included in this trial.
Inclusion criteria are:
• Consensus diagnosis of CMI based on atherosclerotic mesenteric artery stenosis 
of the origin of the CA and/or SMA established in a multidisciplinary meeting 
attended by a gastroenterologist, interventional radiologist and vascular surgeon. 
This consensus diagnosis is based on:
 κ Typical symptoms (presence of postprandial pain, unexplained weight loss)
 κ Significant stenosis of >50% of at least one of the mesenteric arteries on previous 
computed tomography angiography (CTA)*
 κ Functional assessment of mucosal ischemia with VLS or tonometry
• ≥18 years old
• Signed informed consent
• Total length of mesenteric stenosis <25 mm.
* Requirements for CTA are: CTA not older than one year, maximum slice thickness 1 
mm, enhancement in aorta 300HU).
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Exclusion criteria are:
• Absence of informed consent
• <18 years old
• No stenosis detected during angiography
• Renal insufficiency (glomerular filtration rate (GFR) below 30 ml/min or GFR below 
60 ml/min in presence of comorbidities relevant to renal function)
• Previous stent placement in the target vessel
• Pregnancy
• Stenosis based on median arcuate ligament syndrome (MALS)
• Stenosis based on vasculitis
• Other criteria which the physician considers not compatible with inclusion in this trial.
Recruitment and consent
Patients with CMI based on atherosclerotic mesenteric artery stenosis are eligible for 
the CoBaGI trial. A gastroenterologist, surgeon or research physician will screen the 
patient according to the inclusion and exclusion criteria. When the patient is eligible 
for study inclusion, the treating physician will inform the patient about the possibility 
to participate in the CoBaGI trial and will hand-out the patient information form. 
Furthermore, the treating physician will inform the patient that study participation is 
voluntary and that participation may be withdrawn at any time without the need of 
having to provide a reason. At the return visit, the patient is given the opportunity to 
ask questions. If the patient consents to participate in the CoBaGI trial, written informed 
consent is obtained.
Randomization
Patients are 1:1 randomized for a BMS or CS with a web-based randomization module 
(9 Knots Business Solutions Ltd, Mansfield, UK) in random blocks of four or six stratified 
by center.
Interventions
At the start of the endovascular procedure patients are randomized for either a 
BMS or CS. The approach of the intervention is at the discretion of the attending 
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interventionalist (femoral, brachial, radial or retrograde). During the angiography the 
stenoses are assessed and if a suspected stenosis is not significant, this vessel will not 
be treated. If the stenosis is detected significant during angiography and the stenosis 
length is <25 mm the stenosis will be treated with the allocated stent. In case multiple 
stenosis are present and eligible for inclusion (i.c. CA and SMA), the same allocated 
stent type is used. After completion of the intervention various procedural details such 
as duration, approach, stent length, treated vessels and complications are entered in 
web-based case record forms by the interventionalist. The antiplatelet regimen in the 
CoBaGI trial consists of aspirin and clopidogrel combined for 12 months followed by 
aspirin lifelong and applies for both treatment arms. Table 1 presents the schedule of 
enrollment, interventions and assessments for the CoBaGI trial and Figure 1 presents 
the study flowchart according to CONSORT(25).
Figure 1. Flow of participants in the CoBaGI trial according to CONSORT(25).
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Follow-up
After the endovascular procedure, the patients are followed-up at 6, 12 and 24 months 
with CTA to assess stent patency and with a visit to the outpatient clinic to assess 
symptoms and bodyweight. The patients also receive questionnaires to assess quality 
of life and cost-effectiveness before stent placement and 6, 12 and 24 months after 
stent placement.
Outcome
The primary endpoint is the primary patency rate 24 months after stent placement 
based on intention-to-treat analyses.
The secondary endpoints are (definitions are shown in Table 2):
• Primary patency rates at 6 and 12 months
• Secondary patency rates at 6, 12 and 24 months
• Freedom from restenosis at 6, 12 and 24 months
• Freedom from symptom recurrence at 6, 12 and 24 months
• Freedom from re-intervention at 6, 12 and 24 months
• Quality of Life at 6, 12 and 24 months
• Cost-effectiveness at 6, 12 and 24 months
Table 2. Definitions.
Definition
Restenosis >50% intra-stent stenosis regardless whether the patient had clinical 
symptoms
Symptom recurrence Occurrence of presenting symptoms regardless of stent patency
Re-intervention Intervention due to symptom occurrence in the presence of >50% 
intra-stent stenosis, either a reimplantation of stent or a surgical 
procedure
Blinding
The patient, investigator and the treating physician at the outpatient clinic are blinded 
for the treatment allocation (BMS or CS). For the duration of the trial the allocated 
stent will not be disclosed unless there is a medical need (i.e. restenosis, stent fracture).
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Sample size
The sample size calculation for this randomized controlled superiority trial is based on 
the retrospective data of Oderich et al(21). Assuming that CS improves the patency 
rate of BMS after 24 months from 63% to 95%, and accounting for a 20% dropout rate, 
42 participants are required per arm to achieve 80% power with a two-sided alpha of 
0.05. The sample size calculation is performed using the Comparison of Independent 
proportions test (SAS Power and Sample size, SAS Institute Inc, Cary, NC, USA).
Data collection methods
Clinical data are collected using web-based case record forms (9 Knots Business 
Solutions Ltd, Mansfield, UK). Quality of life is assessed by the validated EQ-5D-5L(26, 
27) and SF36(28, 29) questionnaires. The cost-effectiveness questionnaire deals with 
work omission, hospital visits and use of healthcare. All trial documents are kept for 
15 years after study completion.
Data management
Data entry is performed by local study personnel or personnel of the initiating study 
center. Data-entry is anonymized replacing all patient names with a code. Only these 
codes are used as reference in reports and publications about this investigation. The 
web-based case record forms contain range checks for data values. The handling of 
personal data is compliant with the Dutch Personal Data Protection Act, the Code of 
Good Behavior and the General Data Protection Regulation effective since May 2018.
Data monitoring
Institution of a data monitoring committee (DMC) was waived by the ethical committee 
because the added risk of the interventional study arm is considered to be negligible. 
An interim analysis will not be performed. The initiating center Erasmus MC University 
Medical Center is responsible for the data monitoring activities to ensure data quality.
Statistical methods
Descriptive analyses will be provided regarding patient characteristics before 
randomization. Because this is a randomized controlled trial, statistical tests to detect 
differences in these baseline characteristics between both intervention arms will not 
be performed. The following patient characteristics before randomization will be 
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provided: age, gender, body mass index (BMI), smoking, comorbidity as hypertension, 
dyslipidemia, diabetes, and cardiovascular disease. Furthermore presenting symptoms 
will be described as abdominal pain, postprandial pain, exercise related pain, nausea, 
diarrhea, weight loss and symptom duration. Patient characteristics will be described 
as numbers and percentages for dichotomous variables, or as means and standard 
deviations for continuous variables with normal distribution or medians and interquartile 
ranges (IQR) for continuous variables if not normally distributed.
The primary analysis will be performed according the intention-to-treat principle. A 
per-protocol analysis will also be performed for the primary outcome of stent patency 
for those patients who were treated according to the treatment protocol.
The primary endpoint of stent patency will be analyzed with a ‘two-sample z-test’ for 
comparison of two proportions. Furthermore, a predictive model for time-to-event 
will be obtained by proportional hazards regression and Kaplan-Meier analysis to 
compare patency rates of CS versus BMS. All other continuous outcome measures will 
be reported as difference in mean improvement between CS versus BMS group. Change 
in quality of life assessed by the validated questionnaires EQ-5D-5L(26, 27) and SF-36(28, 
29) will be compared between the CS and BMS group. Furthermore, the costs of both 
groups will be compared. All costs will be estimated based on actual input in terms of 
resource use, personnel and indirect costs from loss of productivity assessed by the 
cost-effectiveness questionnaire.
Harms
Adverse events are defined as any undesirable experience occurring to a subject during 
the study, whether or not considered related to the implantation of a BMS or CS. A 
serious adverse event is any untoward medical occurrence or effect that at any dose:
• results in death;
• is life threatening (at the time of the event);
• requires hospitalization or prolongation of existing inpatients’ hospitalization;
• results in persistent or significant disability or incapacity;
• is a congenital anomaly or birth defect;
• Any other important medical event that may not result in death, be life threatening, 
or require hospitalization, may be considered a serious adverse experience when, 
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based upon appropriate medical judgement, the event may jeopardize the subjector 
and may require an intervention to prevent one of the outcomes listed above.
All physicians who are involved in the trial are asked to report all adverse events to the 
coordinating investigator. The coordinating investigator will report the SAEs through 
the web portal ToetsingOnline (https://www.toetsingonline.nl) of the Dutch Central 
Committee on Research involving human subjects to the accredited Institutional Review 
Board that approved the protocol, within 15 days after the coordinating investigator 
has first knowledge of the serious adverse reactions. SAEs that result in death or are 
life threatening should be reported expedited. The expedited reporting will occur not 
later than 7 days after the responsible investigator has first knowledge of the adverse 
reaction. This is for a preliminary report with another 8 days for completion of the 
report.
Auditing
Representatives of the initiating center Erasmus MC University Medical Center audit 
the participating centers during the course of the study. All protocol modifications are 
communicated to the relevant parties.
Research ethics approval
The CoBaGI trial is performed in accordance with declaration of Helsinki and the Dutch 
law regarding research involving human subjects (Wet Medisch wetenschappelijk 
Onderzoek met mensen (WMO)). The Institutional Review Board of the Erasmus MC 
University Medical Center, Rotterdam, the Netherlands approved the study protocol 
on 15th of October, 2013. The boards of the other 5 Dutch participating centers gave 
permission for conducting the trial in their center. The CoBaGI trail is registered on 29th 
of April, 2015 in ClinicalTrials.gov with identification number NCT02428582.
Protocol amendments
Five protocol amendments were approved after initial approval of the CoBaGI protocol 
by the Institutional Review Board. The subjects of these amendments were the addition 
of new inclusion centers, addition of one inclusion criterion and adjustment of the 
patient information form. The contents of these amendments are incorporated in this 
protocol.
191
Covered stents versus bare-metal stents study protocol
Confidentially
The investigators and the study staff will keep all information about the study patients 
during and after the trial in strict confidence. All study data is saved in the web-based 
case record forms. This study database is anonymized, the names of the enrolled study 
patients are replaced with a patient study number.
Ancillary and post-trial care
Compensation for post-trial care, for those patients who suffered harm from trial 
participation, is covered by trial health insurance.
Dissemination policy
Study protocol and study results will be presented at scientific conferences and in 
peer-reviewed publications. Authorship eligibility follows the common standards of 
author responsibility, conflict of interest, transparency and the recommendations of 
the International Committee of Medical Journal Editors (http://www.icmje.org). There 
are no limitations or restrictions for publication.
DISCUSSION
The CoBaGI trial is designed to compare the patency rate of BMS (standard care) with CS 
in patients with CMI based on an atherosclerotic mesenteric stenosis. Besides, the study 
will provide insights into the change in quality of life of patients induced by both stents 
and their cost-effectiveness. The CoBaGI trial is the first randomized controlled trial 
to compare BMS with CS in patients with CMI based on an atherosclerotic mesenteric 
stenosis.
The recently published clinical practice guidelines of the European Society of Vascular 
Surgery (ESVS) recommend with a low level of evidence (C: expert opinion and/or small 
studies, retrospective studies) to consider CS over BMS for patients requiring mesenteric 
artery stenting based a single retrospective study of Oderich et al.(21). A stronger, level 
A recommendation can only be issued based on the results of randomized controlled 
trials. The optimal design would be a double-blinded controlled trial. Since the physician 
who performs the endovascular procedure cannot be blinded, the CoBaGI trial is 
designed as a patient and investigator blinded randomized controlled trial.
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The primary endpoint of the CoBaGI trial is primary stent patency assessed with 
CTA. The primary endpoint is a hard endpoint which can be assessed objectively. The 
secondary endpoint of symptom recurrence is dependent on reports of patient and 
investigator. In order to ensure unbiased collection and an objective assessment of the 
endpoints, blinding of the patient and investigator is important.
To perform a fair comparison between the two stent designs all participating centers 
will use the same brand/type of BMS as standard of care in the CoBaGI trial. The 
initiating center Erasmus MC University Medical Center had already ample experience 
with the BMS Palmaz Blue from Cordis for mesenteric stenting and therefore this stent 
was chosen to be used in all participating centers. BMS from different manufacturers 
are considered comparable in use and outcome although studies comparing BMS from 
different manufacturers are lacking.
Of note is the inclusion criterion that the length of the stenosis cannot exceed 24 mm 
because all stenoses needing stent extension had to be excluded in the CoBaGI trial 
since a CS will obstruct blood flow when a side-branche is over-stented in contrast to 
a BMS. The longest available Palmaz Blue BMS during the inclusion of the CoBaGI trial 
had a length of 24 mm and the longest CS had a length of 59 mm.
A pivotal inclusion criterion for the CoBaGI trial is a consensus diagnosis of CMI based 
on atherosclerotic mesenteric artery stenosis which is established in a multidisciplinary 
meeting joined by gastroenterologists, interventional radiologists and vascular 
surgeons. Medisch Spectrum Twente and Erasmus MC University Medical Center are 
specialized CMI referral centers. All patients eligible for the CoBaGI trial therefore, will 
be discussed during a CMI multidisciplinary meeting in one of these two centers. If 
functional assessment of mucosal ischemia is required to reach a consensus diagnosis, 
especially in case of single-vessel disease, the patient is referred to the Erasmus 
MC University Medical Center (VLS)(10, 11) or Medisch Spectrum Twente (24-hours 
tonometry)(3, 8, 9).
After endovascular revascularization for CMI, antiplatelet therapy is recommended 
and dual antiplatelet therapy might be considered for 3-12 months(1). Exact dose and 
duration schedules are lacking for mesenteric revascularization. All stented patients 
in the CoBaGI trial regardless of allocation will receive aspirin and clopidogrel for 12 
months after stenting followed by aspirin lifelong.
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The true incidence of atherosclerotic CMI is unknown. It is expected that in the 
upcoming years the incidence of atherosclerotic CMI will increase, mainly because 
of the aging population and the increasing prevalence of cardiovascular disease. The 
predicted increase in the prevalence of atherosclerotic CMI, the significant patient 
burden in terms of pain and loss of quality of life, and in particular risk of an acute 
ischemic events with an exceedingly high mortality risk, underscore the importance of 
the CoBaGI trial. The CoBaGI trial aimed to improve the patient outcome in terms of 
pain relief, improvement of quality of life and prevention of acute ischemic events. The 
fact that the CoBaGI trial is carried out within the framework of the DMIS with patients 
being recruited from multiple academic and community hospitals should facilitate the 
generalizability of the study outcomes.
In conclusion, the CoBaGI trial is a multicenter randomized controlled patient and 
investigator blinded superiority trial comparing BMS (standard of care) with CS in 
patients with CMI caused by an atherosclerotic mesenteric artery origin stenosis.
Trial registration
ClinicalTrials.gov Identifier, NCT02428582, registered on 29 April 2015. https://
clinicaltrials.gov/ct2/show/NCT02428582
Trial status
The CoBaGI trial has started inclusion in May 2015. In September 2018 71 patients of 
the 84 (85%) patients were included. Inclusion is expected to be completed at the end 
of 2018. Follow-up duration is two years. Latest protocol version is version 5, date 28th 
June 2017.
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ABSTRACT
Objective
An isolated stenosis of the celiac artery (CA) or the superior mesenteric artery (SMA) 
is frequently detected in patients with abdominal complaints. The dilemma is whether 
these patients suffer from chronic mesenteric ischemia (CMI) and whether they benefit 
from revascularization. We evaluated the long-term clinical success rates for single CA 
or SMA revascularization in patients with gastrointestinal symptoms and confirmed 
mucosal ischemia.
Methods
Retrospective cohort analysis of 59 consecutive patients with gastrointestinal symptoms 
and a single atherosclerotic mesenteric artery stenosis who were referred to our 
tertiary care institution between 2006 and 2010 for standardized diagnostic work-up 
of CMI, including measurement of mucosal ischemia with visible light spectroscopy or 
gastric-jejunal tonometry. Patients with multidisciplinary consensus diagnosis of CMI 
underwent surgical or endovascular revascularization. The primary outcome was clinical 
response to revascularization, defined as relief of presenting symptoms as experienced 
by the patient.
Results
Consensus diagnosis of CMI was obtained in 37/59 patients. Isolated CA stenosis was 
present in 30/37 patients (81%) and isolated SMA stenosis in 7 patients. After a mean 
follow-up of 5.0±3.0 years, 27/37 patients (73%) experienced sustained symptom relief 
after revascularization. Response was not related to lesion localization (CA 73% versus 
SMA 71%, p=0.919).
Conclusion
Revascularization of the CA or SMA provides persistent symptom relief in 73% of 
patients diagnosed with CMI due to single atherosclerotic mesenteric artery stenosis.
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INTRODUCTION
The medical evaluation of patients with abdominal pain is frequently a process of 
elimination. When common causes of pain such as gastritis, gastric ulcer disease, 
gallstones, inflammatory bowel disease or pancreatitis are ruled out with the proposed 
diagnostic algorithms(1-3), a majority of patients is diagnosed with a functional 
gastrointestinal syndrome, including functional dyspepsia or irritable bowel syndrome 
(IBS). Failure to respond to empirical treatment or the presence of alarm features such 
as unintentional weight loss often trigger further imaging studies to identify chronic 
mesenteric ischemia (CMI) as a potential underlying cause.
Isolated stenosis of the celiac artery (CA) or the superior mesenteric artery (SMA) is 
frequently detected during the work-up of patients with abdominal symptoms. Imaging 
studies have demonstrated prevalence rates for isolated CA stenosis up to 15% and for 
isolated SMA stenosis of approximately 1% in the asymptomatic general population(4-7, 
and even higher rates in patients with peripheral or coronary artery disease(8). Isolated 
CA stenosis due to external compression by the median arcuate ligament (median 
arcuate ligament syndrome, MALS) occurs in about 7% of the population(5, 9, 10). 
However, single mesenteric artery stenosis rarely gives rise to symptoms due to the 
abundant collateral circulation of the splanchnic vascular bed. Symptoms of CMI, 
including postprandial pain, are nonspecific and no single symptom can predict who 
will respond to revascularization(11). Furthermore, the correlation between severity of 
abdominal symptoms, degree of stenosis, and number of affected mesenteric arteries 
is poor(12-15).
The challenge is to identify the subset of patients with abdominal complaints due to 
mesenteric ischemia who might benefit from revascularization of a solitary mesenteric 
artery stenosis. Assessment of mucosal ischemia with a functional test, either gastric-
jejunal tonometry or visible light spectroscopy (VLS), enhances the diagnostic accuracy 
for mesenteric ischemia(12, 13, 16, 17). In the present study, we evaluated the long-term 
clinical success rates for single mesenteric artery revascularization of either CA or SMA 
in patients with chronic gastrointestinal symptoms and confirmed mucosal ischemia.
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METHODS
Study design and setting
Retrospective cohort analysis was conducted for all consecutive patients with 
gastrointestinal symptoms and an isolated atherosclerotic stenosis of either CA or SMA 
who were referred to our tertiary referral center between January 2006 and October 
2010 for a standardized diagnostic work-up of CMI. This center is one of the two Dutch 
centers that perform functional tests to detect mucosal ischemia. During the inclusion 
period, a consensus diagnosis of CMI was established in approximately 50% of the 450 
patients who underwent evaluation for suspected CMI.
Patients with a significant stenosis of the inferior mesenteric artery were excluded from 
this study, as were patients with MALS. The diagnosis of MALS was established if CTA 
demonstrated focal narrowing of the proximal CA ≥50% with post-stenotic dilatation 
and indentation on the superior aspect of the CA, creating characteristic kinking in the 
absence of calcifications(18). In unclear cases additional catheter angiography of the 
CA in inspiration and expiration was performed.
Follow-up data was retrieved from the medical records in the context of routine clinical 
care. The medical research ethics committee of Erasmus University Medical Centre 
approved that the Medical Research Involving Human Subjects Act does not apply to this 
study and that no informed consent was required according to the local directives for 
retrospective studies (MEC-2012-336). The study complies with the Helsinki declaration 
on research ethics. To enhance transparency this article is written according to the 
STROBE checklist for cohort studies(19).
Participants
All referred patients underwent a standardized diagnostic work-up at baseline in our 
specialized CMI center, including medical history and physical examination, imaging 
of the mesenteric arteries with either computed tomography angiography (CTA) or 
magnetic resonance angiography (MRA) and/or conventional catheter angiography, 
and a functional test for mucosal ischemia detection with either 24-hour gastric-jejunal 
tonometry or VLS(11, 16, 20-22). All patients also underwent upper endoscopy with 
standard biopsies of the duodenum, gastric corpus, and antrum to rule out Helicobacter 
205
Single artery chronic mesenteric ischemia
pylori colonization and celiac disease. Psychiatric evaluation is not included in the 
routine diagnostic work-up.
All referred cases were discussed in a multidisciplinary meeting attended by vascular 
surgeons, interventional radiologists, and gastroenterologists, all specialized in CMI, 
leading to an expert based consensus diagnosis. The diagnosis of CMI was established 
if the following three criteria were met: 1) at least one of the following symptoms: 
(postprandial) abdominal pain, weight loss, or diarrhea; 2) significant stenosis (≥ 50% 
diameter reduction (23-26)) on CTA or MRA and/or conventional catheter angiography 
of either the CA or SMA while the other two mesenteric arteries were patent; and 3) 
mucosal ischemia as determined by 24-hour gastric-jejunal tonometry or VLS. The 24-
hour gastric-jejunal tonometry was considered to be positive for ischemia when three 
or more (standard) meals were followed by a pathologic response or when one or two 
pathologic responses after (standard) meals were combined with a median PCO
2
 >8.0 
kPa between meals. A pathologic response was defined as PCO
2
 >12.1 kPa for breakfast, 
>11.4 kPa for dinner, >11.3 kPa for compound solution meals in the stomach and PCO
2
 
>12.0 kPa for breakfast, >13.6 kPa for dinner and >10.6 kPa for compound solution meals 
in the jejunum(21). VLS measurements were considered to be positive for ischemia 
when the mucosal oxygen saturation measurements in the antrum were <63%, and/or 
in the duodenal bulb were <62%, and/or in the descending duodenum were <58%(16).
Patients with a consensus diagnosis of CMI were treated with either surgical or 
endovascular revascularization. Patients with atherosclerotic single mesenteric artery 
stenosis were primarily treated with an endovascular intervention: percutaneous 
transluminal angioplasty (PTA) combined with bare metal stent placement (Palmaz 
Blue, Cordis Cooperation), as part of standard care. The post-stenting medical regimen 
consisted of lifelong acetylsalicylic acid combined with clopidogrel for the first 12 
months post-procedure. In-stent restenosis was initially treated with PTA and/or stent 
placement. Medical management of atherosclerotic risk factors consisted of antiplatelet 
drugs, statin treatment, and treatment of diabetes and hypertension if indicated; 
smokers were advised to quit smoking. Patients who were not eligible for endovascular 
intervention, including those with recurrent in-stent restenosis, were treated with 
mesenteric bypass surgery. Patients not meeting the criteria for the consensus diagnosis 
of CMI were discharged without further follow-up.
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Variables
Baseline characteristics included age, gender, past medical history, presenting symptoms 
such as abdominal pain and weight loss (kg), body mass index (BMI) at presentation, 
abdominal bruit, cardiovascular risk factors, ulcer observed at upper endoscopy, and 
routine blood tests. Exercise induced abdominal pain was defined as abdominal pain 
during any form of exercise, including walking and stair climbing. Hypertension was 
defined as a blood pressure ≥140/90 mmHg or use of antihypertensive medication. 
Dyslipidemia was defined as LDL-C >4.2 mmol/L or HDL-C <0.9 mmol/L or use of lipid 
lowering medication. Smoking status was defined as current, former or non-smoker. 
Obesity was defined as a BMI ≥30 kg/m2.
The primary outcome was the clinical response to revascularization, defined as patient-
reported relief of the presenting symptoms, which was classified into two groups: 
symptom relief or no symptom relief. The presence or absence of symptom relief was 
initially evaluated at 3-month intervals following treatment with decreasing frequency 
over time. Stent patency was routinely evaluated with duplex ultrasound 3 to 6 months 
after the primary revascularization procedure. In case of recurrent symptoms after 
technical and clinical successful revascularization therapy, the date of recurrence 
was registered and patients were further evaluated with CTA. Recurrent symptoms 
were similar to presenting symptoms. Secondary outcomes were intervention-related 
morbidity and mortality.
Data sources
Patients attended the outpatient clinic in our center and/or were contacted by phone 
for clinical follow-up. Standard protocol visits were 1, 3, 6, 12, and 24 months after 
revascularization. These visits were mostly in-clinic follow-up. After two years, follow-
up was annually and mostly done by phone, unless the patient’s clinical condition 
changed. Standard protocol contains questions about recurrent symptoms (i.e. similar to 
presenting symptoms before revascularization therapy) and actual weight. No standard 
questionnaire was used. Survival status was obtained from the civil registry database. 
All other data was retrieved from the hospital records in the context of usual care.
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Statistical methods
Baseline characteristics and secondary outcomes were described either as numbers 
and percentages for dichotomous variables, or as means and standard deviations or 
medians and interquartile ranges (IQR) for continuous variables. Differences in baseline 
characteristics and clinical response to treatment were determined by the χ2 test or 
student’s T-test. Statistical significance was defined as p < 0.05.
RESULTS
Patient characteristics
During the study, 59 consecutive patients with abdominal complaints and/or unexplained 
weight loss and a single atherosclerotic mesenteric artery stenosis were referred to our 
center and underwent a standardized diagnostic work-up for CMI (Figure 1). Baseline 
characteristics are shown in Table 1. CTA was the diagnostic vascular imaging modality 
in the majority of patients (55/59 patients, 93%). MRA was performed in 9/59 patients 
(15%) and correlated with CTA, DSA and/or duplex ultrasound in 7/9 patients. A minority 
of 2 patients underwent only MRA for vascular imaging.
In 37 patients (63%) a consensus diagnosis of CMI was established. Single vessel CMI 
was caused by CA stenosis in 30 patients (81%) and by SMA stenosis in 7 patients (19%). 
Patients with CMI more often presented with exercise related abdominal pain, normal 
blood pressure, and a lower BMI then those without CMI. Alternative diagnoses were 
established in 12/22 patients (55%) without a consensus diagnosis of CMI: 3 obstipation, 
2 Helicobacter Pylori infection, 2 decreased cardiac function, 1 IBS, 1 abdominal pain 
due to adhesions, 1 Cronkhite Canada syndrome, 1 dyspepsia, and 1 obstructive sleep 
apnea.
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Table 1. Baseline characteristics.
All patients
(n=59)
CMI
(n=37)
No-CMI
(n=22)
Patient characteristics
Age (y) 66.2 ± 10.1 65.3 ± 10.9 67.9 ± 8.6
Female 59.3% 54.1% 68.2%
Caucasian 98.3% 97.3% 100%
Hypertension 44.1% 29.7% 68.2%*
Smoking 56.9% 63.9% 45.5%
Dyslipidemia 35.2% 27.8% 50.0%
Diabetes 8.5% 8.1% 9.1%
BMI at presentation (kg/m2) 22.4 ± 5.6 20.7 ± 5.0 25.4 ± 5.4*
History of CVD 54.2% 48.6% 63.6%
Presenting symptoms
Abdominal pain
      Postprandial
      Exercise related
91.5%
66.1%
35.6%
94.6%
70.3%
48.6%
86.4%
59.1%
13.6%*
Nausea 47.5% 45.9% 50.0%
Diarrhea 18.6% 18.9% 18.2%
Constipation 10.2% 8.1% 13.6%
Weight loss 67.8% 73.0% 59.1%
Abdominal bruit 20.3% 18.9% 22.7%
Classic triad of CMI 15.3% 16.2% 13.6%
Gastric ulcer 5.2% 5.6% 4.5%
Duration of symptoms (months) 32.1 ± 58.2 35.3 ± 67.8 26.6 ± 37.8
Vascular lesions
CA stenosis 84.7% 81.1% 90.9%
SMA stenosis 15.3% 18.9% 9.1%
Functional test
Tonometry positive 78.8% 100% 25.0%*
VLS positive 63.6% 100% 20.0%*
Data are presented as percentages or as mean ± SD.
* p < 0.05 CMI versus no-CMI
CVD = cardiovascular disease; Classic triad of CMI is postprandial abdominal pain, bruit and weight loss.
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Figure 1. Flowchart consensus diagnosis.
Treatment
All 37 patients diagnosed with CMI were treated with solitary mesenteric artery 
revascularization. The 7 patients with SMA stenosis were all treated with endovascular 
stent placement. The 30 patients with CA stenosis underwent endovascular 
revascularization (n=26 bare metal stent placement and n=2 PTA only) or bypass surgery 
(n=2).
Endovascular treatment was technically successful in 33/35 patients (94%). The 
endovascular approach was in 25/35 primary endovascular procedures (71%) via the 
brachial artery and in 10/35 endovascular procedures (29%) via the femoral artery. 
Stenting was discontinued in one patient who developed a stroke during the procedure. 
Stent placement was technically unfeasible in the other patient. The two surgical 
procedures were technically successful.
Overall, 16% of patients developed symptomatic restenosis during follow-up. Following 
primary endovascular treatment, 5/35 patients (14%) underwent a secondary procedure 
for symptomatic restenosis: endovascular revascularization in 3 patients (9%) and 
surgical revascularization in 2 patients (6%). Following primary surgical treatment, 
9
210
Chapter 9
1/2 patients (50%) underwent a secondary endovascular procedure for restenosis. All 
secondary procedures resulted in recurrent relief of symptoms.
Clinical response to revascularization
Symptom relief categorized by vascular lesion is shown in Table 2. After a mean follow-
up of 5.0±3.0 years of the initial intervention (median 5.9, IQR 1.6-7.6 years, 10.8% 
lost to follow-up in 2016), 27/37 patients (73%) experienced sustained symptom relief.
Table 2. Clinical response to treatment.
Symptom relief No symptom relief
All patients 27/37 (73%) 10/37 (27%)
CA stenosis 22/30 (73%) 8/30 (27%)
SMA stenosis 5/7 (71%) 2/7 (29%)
Response to revascularization was not related to lesion localization (symptom relief in 
73% of CA stenosis versus 71% of SMA stenosis, p=0.919). No baseline characteristics 
differed significantly between responders and non-responders. Particularly, there was 
no significant difference in symptom duration, use of pain medication or narcotics, 
and previous abdominal trauma or abdominal surgery between responders and non-
responders to revascularization.
Of the 10 patients who did not experience long-term benefit after technically successful 
revascularization, five patients l50%) did not experience any symptom relief after 
treatment, whereas five patients (50%) had initial symptom relief after treatment but 
had recurrent symptoms during follow-up despite three patent mesenteric arteries. 
Persistent or recurrent symptoms were similar to presenting symptoms in these 
patients. Alternative diagnoses were established in 5/10 non-responders (50%: 1 chronic 
pancreatitis, 3 IBS and 1 abdominal pain due to adhesions).
Complications
The overall complication rate for all 43 revascularization procedures was 26%. In 
8/35 primary endovascular procedures an access site complication occurred with a 
major access site complication rate of 11% (2 pseudoaneurysms and 2 thromboses, all 
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requiring intervention) and a minor access site complication rate of 11% (3 hematomas 
and 1 arteriovenous fistula not requiring intervention). In 1/35 primary endovascular 
procedures a patient developed a stroke. In 1/2 primary surgical procedures a 
patient developed pneumonia. No complications occurred after secondary surgical 
therapy, whereas 1/4 secondary endovascular therapy procedures was complicated 
by pseudoaneurysm. Overall, 13/37 patients died during follow-up (35.1%, mean age 
73.2±7.5years). Causes of death were heart failure (n=1), sepsis due to urinary tract 
infection and pneumonia (n=1), metastasized lung cancer (n=3), euthanasia (n=1), end-
stage COPD (n=2). The cause of death was irretrievable in 5 patients.
DISCUSSION
The present study shows that 73% of patients with longstanding abdominal complaints 
and single, atherosclerotic CA or SMA stenosis experience sustained long-term symptom 
relief after revascularization.
To our knowledge, the current study is the first report on the long-term clinical outcome 
with a median follow-up of 5.9 years for revascularization of either CA or SMA in 
patients with abdominal symptoms attributed to CMI. Apart from a previous report 
from our research group of a 64% short-term (median follow-up 13 months) clinical 
success rate for revascularization in patients with single artery CMI(22), the outcomes 
of treatment for single vessel CMI are not specified in the majority of prior studies(13, 
17, 27-29). The long-term clinical benefit was not related to lesion localization, i.e. CA or 
SMA, in spite of the differences in blood flow distribution between these two arteries. 
The prevalence of single SMA stenosis was substantially lower than CA stenosis in our 
cohort, which is in line with population-wide studies(4, 6).
The diagnosis of single vessel CMI and the selection of patients for revascularization are 
challenging. The existence of single artery mesenteric ischemia is a topic of continuous 
clinical debate. Sceptics argue that stenosis of one of the mesenteric arteries is a 
common finding in the general -asymptomatic- population and is often incidentally 
discovered on imaging studies. Furthermore, given the extensive collateral network, 
they dispute that stenosis of one mesenteric artery leads to CMI and, hence, gives 
rise to abdominal symptoms. Revascularization of a single mesenteric artery stenosis 
without confirming mucosal ischemia first would lead to overtreatment. We found no 
differentiating characteristics in demographics, comorbidities, presenting symptoms, 
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physical findings, or vascular lesions between patients with and those without a 
consensus diagnosis of CMI, except for a higher frequency of exercise-related abdominal 
pain, normal blood pressure, and a lower BMI in patients with CMI. Furthermore, 
neither baseline characteristics nor the localization of the mesenteric artery lesions 
were associated with a clinical response to treatment. In this cohort study, patients 
were selected for revascularization therapy if mucosal ischemia was confirmed with 
a functional test in addition to the presence of a significant stenosis of the CA or SMA 
and a history of symptoms suggestive of CMI. Objective confirmation of mucosal 
ischemia in the diagnostic work-up for patients suspected of CMI is important(11, 17, 
20, 30). Tests for mucosal ischemia include gastric exercise tonometry(17), 24-hour 
tonometry(21) and VLS(16) with sensitivities of 78%, 76%, and 90% and specificities of 
92%, 94%, and 60%, respectively. Our findings stress the importance of 1) extensive 
diagnostic gastro-intestinal work-up to rule out common causes of chronic abdominal 
pain, and 2) assessment of mucosal ischemia using a functional test to select patients 
for revascularization. The topic of chronic mesenteric ischemia is an evolving field 
in vascular surgery and gastroenterology. The European Society of Vascular Surgery 
(ESVS) recently published guidelines about ‘Management of the Diseases of Mesenteric 
Arteries and Veins’(31).
The overall technical success rates in the current study were 94% for endovascular and 
100% for surgical procedures with an overall complication rate of 26%. Overall, 16% 
of patients developed symptomatic restenosis during follow-up, which is in line with 
previous reports(32-34). All patients with symptomatic restenosis were revascularized, 
resulting in recurrent relief of symptoms in all. In the absence of randomized controlled 
trials and given the limited number of patients in the available cohort studies, there 
are no evidence-based recommendations for a preferred revascularization strategy for 
mesenteric ischemia. Endovascular revascularization in this cohort consisted of stent 
implantation in the majority of patients. Only bare metal stents were used, in line 
with the common practice at the time of inclusion. Current evidence suggests a lower 
restenosis rate for covered stents for treatment of mesenteric artery stenosis(32). Yet, 
these findings still await randomized controlled confirmation. The minimally invasive 
character and the effectiveness of novel technologies to prevent restenosis, including 
covered stents, drug-eluting stents, and drug-coated balloons, are promising for 
a primary endovascular approach to the splanchnic vascular bed in the majority of 
patients.
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This study carries the limitations inherent to its retrospective cohort design. Moreover, 
the results obtained in our tertiary referral center may not be representative for 
the general gastroenterology practice. Although we attempted to define whether 
any clinical characteristics factors are predictive of treatment response, the limited 
sample size is susceptible to false negative findings. Furthermore, the optimal follow-up 
would include functional testing before and after revascularization and again in case of 
recurrent symptoms. Although a post-interventional mucosal ischemia test could have 
supported our data, functional testing was not performed after revascularization and 
for recurrent symptoms for reasons of costs and patient burden. Since the presence 
or absence of symptom relief following revascularization was considered the most 
important and relevant patient reported outcome, “sustained symptom relief’’ was used 
as the primary outcome measure. Although it might be argued that a patient reported 
outcome in this non-randomized, non-blinded study may be subject to a placebo effect, 
the sustained clinical benefit rate of revascularization of 73% is significantly higher 
than the reported effects of either surgical sham interventions (18-32%)(35, 36) or 
placebo medical treatments (30-38%)(37-39) for functional gastrointestinal disorders 
in randomized controlled trials. Although every attempt was made to contact the 
patients for follow-up, 10.8% of the patients were lost to follow-up in 2016; recurrence 
of symptoms in these patients may have been missed.
In conclusion, it is generally accepted that an asymptomatic or incidentally discovered 
stenotic or occluded mesenteric artery does not warrant intervention. However, in 
case of gastrointestinal symptoms and mucosal ischemia, revascularization of a solitary 
atherosclerotic mesenteric artery stenosis provides persistent symptom relief in 73% 
of patients with otherwise unexplained, refractory abdominal pain.
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ABSTRACT
Purpose
To assess the feasibility and safety of trans-radial access (TRA) compared to trans-
femoral access (TFA) and trans-brachial access (TBA) for mesenteric arterial 
endovascular procedures.
Material and Methods
A retrospective cohort analysis was performed including all consecutive patients who 
underwent a mesenteric arterial procedure in a tertiary referral center between May 
2012 and February 2018. Exclusion criteria were absence of data and lost to follow-up 
within 24 hours after the procedure. During the study period, 103 patients underwent 
a total of 148 mesenteric arterial procedures (TBA n=52, TFA n=39 and TRA n=57). 
The mean patient age was 64.3±13.3 years and 91 patients (62%) were female. The 
primary outcomes were vascular access specified technical success rate and access site 
complication rate, as reported in the hospital records.
Results
The technical success rate specified for the vascular access technique differed not 
between the three approaches (TBA 96%, TFA 87%, TRA 91%, TRA-TBA p=0.295, 
TBA-TFA p=0.112, TRA-TFA p=0.524) and the overall access site complication rate 
was not different between the three approaches (TBA 42%, TFA 23%, TRA 35%, TRA-
TBA p=0.439, TBA-TFA p=0.055, TRA-TFA p=0.208). However, more major access site 
complications were reported for TBA than for TRA or TFA (TBA 17%, TFA 3%, TRA 2%, 
TRA-TBA p=0.005, TBA-TFA p=0.026, TRA-TFA p=0.785).
Conclusion
TRA is a safe and feasible approach for mesenteric arterial procedures comparable to 
TFA, but with a significant lower major access site complication rate than TBA.
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INTRODUCTION
Trans-brachial access (TBA) and trans-femoral access (TFA) are distinct approaches 
for endovascular mesenteric arterial procedures according the recently published 
‘Quality Improvement Guidelines for Mesenteric Angioplasty and Stent Placement 
for the Treatment of Chronic Mesenteric Ischemia’ of the Society of Interventional 
Radiology (SIR)(1). For coronary artery interventions, trans-radial access (TRA) has been 
shown to be associated with less major access-site complications than TBA and TFA with 
similar procedural and clinical outcomes(2). No recommendations are issued in the SIR 
guideline on the use of TRA for mesenteric arterial procedures since the efficacy and 
feasibility of this approach has not been established yet for this specific indication(1).
Potential advantages of TRA are the patient friendly compression device for TRA 
enabling fast mobilization after the procedure leading to shorter hospital stay, reduced 
costs, and fewer bleeding and vascular complications in coronary interventions(2-6). In 
addition, when performing mesenteric endovascular procedures, the vessels generally 
arise at a steep acute angle from the aorta making retrograde TFA potentially technically 
more difficult compared to an antegrade approach. Posham et al.(7) described 1,512 
non-coronary endovascular procedures, including mesenteric arterial procedures, using 
TRA, showing that TRA is feasible for non-coronary procedures, with a technical success 
rate of 98%, and a low major complication rate of only 0.1% and a minor complication 
rate of 2.4%. Thakor et al.(8) described 749 non-coronary TRA procedures and reported 
that 98% of the patients who had a previous TFA procedure would choose TRA over TFA. 
However, there is a deficiency of studies comparing TRA, TFA and TBA for non-coronary 
endovascular procedures and, more specifically, there is a lack of studies comparing 
these three approaches for mesenteric arterial procedures.
The aim of this study was to assess the feasibility and safety of TRA compared to TFA 
and TBA for mesenteric arterial endovascular procedures.
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MATERIAL AND METHODS
Study design and setting
A retrospective cohort analysis was conducted for all consecutive patients who 
underwent an endovascular procedure of the mesenteric vessels in a tertiary referral 
center between May 2012 and February 2018. Inclusion criteria were: endovascular 
procedure of the celiac artery (CA), superior mesenteric artery (SMA) and/or inferior 
mesenteric artery (IMA)) and all types of endovascular procedures were eligible: 
diagnostic angiography, percutaneous transluminal angioplasty (PTA), stenting 
procedures, and thrombolysis. Exclusion criteria were absence of data and lost to follow-
up within 24 hours after the procedure. The local medical research ethics committee 
concluded that the Medical Research Involving Human Subjects Act does not apply to 
this study (MEC-2017-461). The study complies with the Helsinki declaration on research 
ethics. To enhance transparency, this article is written according to the STROBE checklist 
for cohort studies(9).
In total, 148 mesenteric arterial procedures (TBA n=52, TFA n=39 and TRA n=57) 
performed in 103 patients were reviewed (Figure 1). Twenty-eight patients underwent 
two or more procedures of the mesenteric vessels due to development of re-stenosis or 
new mesenteric stenosis during follow-up. Four patients needed a repeated procedure 
on the same vessel(s) on a later date due to technical failure of a previous procedure. One 
patient underwent 6 mesenteric procedures during the inclusion period, and two other 
patients each 5 procedures. Eight interventionalists of in total 10 interventionalists who 
performed the included procedures, performed TRA procedures. All interventionalists 
had minimally two years of experience and performed his/her first TRA procedure 
within this study, none of the interventionalists were experienced in TRA procedures 
before start of this study. See Table 1 for the specifications of each interventionalist.
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Figure 1. Flowchart.
PTA = percutaneous angioplasty; TBA = trans-brachial access; TFA = trans-femoral access; TRA = trans-
radial access.
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Data sources
Cases were included by searching the radiology reports on the terms “radial”, “brachial” 
and “femoral” and all found reports were manually checked for eligibility. In addition, 
all mesenteric multidisciplinary meeting reports were screened for patients that were 
planned to undergo a diagnostic or therapeutic endovascular procedure. Data were 
retrieved from the hospital records in the context of standard clinical care. Since 
November 2014 TRA procedures were performed in the study center and the TBA and 
TFA procedures were included backwards until a comparable number of TFA and TBA 
procedures were included. Follow-up of patients was by outpatient clinic contact and 
by phone. A standard protocol visit was scheduled within 24 hours after the mesenteric 
arterial procedure at the ward and one month after the procedure at the outpatient 
clinic during which symptoms and complications were assessed.
Participants
Since November 2014 endovascular procedures of the mesenteric vasculature in the 
study center are performed by means of TRA, when either a normal modified Allen 
test or Barbeau test result of A, B or C and sufficient radial artery diameter is present: 
RA diameter > 2.0 mm for 4-F sheath, > 2.2 mm for 5-F sheath, and > 2.4 mm for 
6-F sheath(10). If TRA is not possible, the procedure is performed per TBA or TFA 
according to the vessel anatomy of the patient: TBA is first approach but TFA is used 
when the angle of the culprit mesenteric artery with the aorta is obtuse (towards 90 
degrees, decided by the interventionalist). Before November 2014, mesenteric arterial 
procedures were performed per TBA or TFA according to the vessel anatomy of the 
patient (mesenteric anatomy-driven).
All access techniques used local anesthesia with 2% lidocaine and all punctures were 
ultrasound guided. TRA procedure was performed as follows: the RA was punctured and 
a dedicated RA sheath (Prelude; Merit Medical Systems, Inc, South Jordan, Utah) was 
introduced. A solution containing 200 μg nitroglycerin, 2.5 mg verapamil, and 5,000 IU 
heparin was slowly injected intra-arterially. Thereafter a 110-cm Flexor sheath (Cook, 
Inc, Bloomington, Indiana) with dilator or a 6.5-F 100-cm Eaucath sheathless guide with 
dilator (Asahi Intecc, Aichi, Japan) was exchanged using a Glidewire Advantage (Terumo 
Corp, Tokyo, Japan). Access to the mesenteric vessel was acquired with a 125 cm 4-F 
angiographic catheter. Rapid-exchange delivery systems were at 4-F or 5-F for balloons 
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and bare metal stents and 6-F for covered stent. After the procedure the radial puncture 
site was compressed with a compression device (Air-Band; Merit Medical Systems, Inc).
TBA procedure was performed as follows: the brachial artery was punctured with a 7 
cm 18 G needle and a 11 cm vascular sheath of 6-F (Brite Tip, Cardinal Health, Dublin, 
Ireland) was inserted. A 90-cm 6-F multipurpose guiding catheter (Cardinal Health) 
loaded with a 125 cm 4-F angiographic catheter was advanced to the mesenteric vessel. 
For covered stent placement, the short sheath and guiding catheter were exchanged for 
a long sheath or sheathless guiding catheter. The brachial puncture site was compressed 
manually followed by compression bandage after the procedure for 6 hours.
TFA procedure was performed as follows: the common femoral artery was punctured 
with a 7 cm 18 G needle and a 11 cm vascular sheath of 6-F (Brite Tip, Cardinal Health, 
Dublin, Ireland) was inserted. A 55-cm 6-F renal double curve guiding (RDC-guiding, 
Cardinal Health) loaded with an 80 cm 4-F angiographic catheter was advanced to the 
mesenteric vessel. For covered stenting, the short sheath and guiding were exchanged 
for a 55-cm 6-F sheath (Flexor, Cook Medical). The femoral puncture site was closed 
with a closure device (Angio-Seal; Terumo Corp).
Type of balloons used were rapid exchange systems 20 mm balloon of 4 to 7 mm 
diameter (Submarine Rapido, Invatec, Roncadelle Italy). Type of stents used were bare-
metal balloon-expandable stents (Palmaz-Blue, Cardinal Health) and covered stents 
(Advanta V12; Atrium Medical Corp, Hudson, New Hampshire).
After the mesenteric endovascular procedure was completed, patients were transferred 
to a clinical ward for observation. During follow-up, routinely ultrasound investigation 
of the access site was not performed, only on indication (e.g. symptoms of occlusion). 
Magnetic resonance imaging of the brain was not routinely performed after TBA or 
TRA, only on indication (e.g. symptoms of cerebral stroke).
Life-long acetylsalicylic acid and clopidogrel for 12 months were prescribed after stent-
placement. If only PTA was performed acetylsalicylic acid life-long was prescribed if 
atherosclerosis was present.
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Variables
Patient and procedure characteristics included age, gender, use of anti-coagulation, 
type of endovascular intervention, specific mesenteric artery (CA, SMA and/or IMA), 
sheath size, puncture side, anti-coagulation during the procedure, platelet count and 
international normalized ratio (INR) before procedure, and the hemostasis method used.
Characteristics of the mesenteric arterial endovascular procedures are shown in Table 2. 
The majority of procedures was performed in female patients (TBA 64%, TFA 51%, TRA 
67%). TFA patients were younger than TRA patients (59.9±18.1 years versus 66.6±9.2 
years, p=0.037). The majority of procedures were primary procedures (TBA 73%, TFA 
59% and TRA 72%). Used sheath sizes varied from 4-F to 7-F. A sheath size of 6-F was 
more used in TRA and TBA than in TFA procedures (TBA 86%, TFA 49%, TRA 77%, 
TRA-TFA p=0.005, TBA-TFA p<0.001), whereas a sheath size of 7-F was more used in 
TFA procedures than in TBA and TRA procedures (TBA 4%, TFA 34%, TRA 6%, TRA-
TFA p<0.001, TBA-TFA p<0.001). A puncture side on the left side of the patient was 
preferably used for TBA and TRA, but the right side was more used for TFA (left side 
TBA 83%, TFA 21%, TRA 69%, TRA-TFA p<0.001, TBA-TFA p<0.001). In the majority 
of procedures stent placement was performed, however less stent placements were 
performed in TFA procedures compared to TBA and TRA procedures (TBA 88%, TFA 
64%, TRA 84%, TRA-TFA p=0.023 and TRA-TFA p=0.005). Diagnostic angiography was 
less frequently performed in TBA procedures than in TFA procedures (TBA 2%, TFA 
20%, TBA-TFA p=0.003). The INR was lower in TRA procedure than in TBA and TFA 
procedures (TBA 1.2±0.3, TFA 1.2±0.2, TRA 1.1±0.14, TBA-TRA p=0.002 and TFA-TRA 
p=0.003), whereas platelet count was not different between the three approaches. In 
38% of all 133 interventional procedures the vessel of intervention was the SMA, in 
38% the CA, in 1% the IMA and in 23% both CA as SMA. Hemostasis was achieved with 
manual compression and pressure bandage in 92% of all TBA procedures, with Angioseal 
(Terumo Medical Corporation, Tokyo, Japan) in 89% of all TFA procedures and with an 
Airband (Merit Medical Sytems Inc., South Jordan, UT, USA) in all TRA procedures. Table 
3 shows the use of anti-coagulation at baseline and the continuation of anti-coagulation 
during the procedure. At baseline, only 16% of all patients (TBA 17%, TFA 15%, TRA 16%) 
were not on anti-coagulation therapy. In 30% of all 148 procedures (TBA 38%, TFA 26%, 
TRA 25%) no anti-coagulation was used during the procedure besides heparin.
10.1
228
Chapter 10.1
Ta
bl
e 
2.
 C
ha
ra
ct
er
is
ti
cs
 o
f t
he
 m
es
en
te
ri
c 
ar
te
ri
al
 p
ro
ce
du
re
s.
TB
A
(n
=5
2)
TF
A
(n
=3
9)
TR
A
(n
=5
7)
p
-v
al
ue
 T
R
A
-T
B
A
p
-v
al
ue
 T
R
A
-T
FA
p
-v
al
ue
 T
B
A
-T
FA
Fe
m
al
e
33
 (6
4%
)
20
 (5
1%
)
38
 (6
7%
)
0.
72
6
0.
13
0
0.
24
4
A
ge
 (y
)
65
.0
±1
2.
4
59
.9
±1
8.
1
66
.6
±9
.2
0.
45
1
0.
03
7*
0.
10
9
Pr
im
ar
y 
pr
oc
ed
ur
e
38
 (7
3%
)
23
 (5
9%
)
41
 (7
2%
)
0.
89
3
0.
18
6
0.
15
7
V
es
se
l o
f i
nt
er
ve
nti
on
 (P
TA
/s
te
nti
ng
/t
hr
om
bo
ly
si
s)
CA
19
 (3
7%
)
12
 (3
1%
)
19
 (3
3%
)
0.
72
6
0.
79
2
0.
56
6
SM
A
16
 (3
1%
)
13
 (3
3%
)
21
 (3
7%
)
0.
50
4
0.
72
4
0.
79
5
IM
A
2 
(4
%
)
0 
(0
%
)
0 
(0
%
)
0.
13
5
NA
0.
21
6
C
A
+S
M
A
14
 (2
7%
)
6 
(1
5%
)
11
 (1
9%
)
0.
34
4
0.
62
2
0.
18
8
D
ia
gn
os
ti
c 
pr
oc
ed
ur
e
1 
(2
%
)
8 
(2
1%
)
6 
(1
1%
)
0.
06
7
0.
17
3
0.
00
3*
Ty
pe
 o
f p
ro
ce
du
re
St
en
t 
pl
ac
em
en
t
46
 (8
8%
)
25
 (6
4%
)
48
 (8
4%
)
0.
52
0
0.
02
3*
0.
00
5*
PT
A
5 
(1
0%
)
5 
(1
3%
)
3 
(5
%
)
0.
38
4
0.
18
8
0.
62
9
Th
ro
m
bo
ly
si
s
0 
(0
%
)
1 
(3
%
)
0 
(0
%
)
NA
0.
22
4
0.
24
6
D
ia
gn
os
ti
c 
pr
oc
ed
ur
e
1 
(2
%
)
8 
(2
0%
)
6 
(1
1%
)
0.
06
7
0.
17
3
0.
00
3*
Sh
ea
th
 si
ze
4-
F
1 
(2
%
)
1 
(3
%
)
2 
(4
%
)
0.
61
7
0.
81
7
0.
82
0
5-
F
4 
(8
%
)
5 
(1
4%
)
7 
(1
3%
)
0.
43
2
0.
88
5
0.
38
9
6-
F
41
 (8
6%
)
17
 (4
9%
)
41
 (7
7%
)
0.
30
1
0.
00
5*
<0
.0
01
*
7-
F
2 
(4
%
)
12
 (3
4%
)
3 
(6
%
)
0.
73
0
<0
.0
01
*
<0
.0
01
*
Pu
nc
tu
re
 s
id
e 
= 
le
ft
43
 (8
3%
)
8 
(2
1%
)
37
 (6
9%
)
0.
06
6
<0
.0
01
*
<0
.0
01
*
229
Trans-radial access for mesenteric arterial procedures
Ta
bl
e 
2.
 C
on
ti
nu
ed
TB
A
(n
=5
2)
TF
A
(n
=3
9)
TR
A
(n
=5
7)
p
-v
al
ue
 T
R
A
-T
B
A
p
-v
al
ue
 T
R
A
-T
FA
p
-v
al
ue
 T
B
A
-T
FA
La
bo
ra
to
ry
 v
al
ue
s
Pl
at
el
et
s 
(1
0^
9/
L)
27
4±
10
7
28
7±
12
5
29
6±
10
2
0.
34
3
0.
73
7
0.
13
0
IN
R
1.
2±
0.
3
1.
2±
0.
2
1.
1±
0.
14
0.
00
2*
0.
00
3*
0.
71
2
He
m
os
ta
sis
A
ir
ba
nd
0 
(0
%
)
0 
(0
%
)
57
 (1
00
%
)
<0
.0
01
*
<0
.0
01
*
NA
M
an
u
al
 
co
m
p
re
ss
io
n
 
an
d 
pr
es
su
re
 b
an
da
ge
48
 (9
2%
)
4 
(1
1%
)
0 
(0
%
)
<0
.0
01
*
0.
01
1*
<0
.0
01
*
A
ng
io
se
al
3 
(6
%
)
33
 (8
9%
)
0 
(0
%
)
0.
06
6
<0
.0
01
*
<0
.0
01
*
Su
rg
ic
al
1 
(2
%
)
0 
(0
%
)
0 
(0
%
)
0.
29
3
NA
0.
39
6
D
at
a 
ar
e 
pr
es
en
te
d 
as
 N
 (p
er
ce
nt
ag
es
) o
r 
as
 m
ea
n 
± 
SD
.
* 
p
-v
al
ue
 <
0.
05
 t
es
te
d 
w
it
h 
χ2
-t
es
t 
or
 s
tu
de
nt
’s
 T
-t
es
t.
IN
R 
= 
in
te
rn
ati
on
al
 n
or
m
al
iz
ed
 r
ati
o;
 P
TA
 =
 p
er
cu
ta
ne
ou
s 
an
gi
op
la
st
y;
 T
B
A
 =
 t
ra
ns
-b
ra
ch
ia
l a
cc
es
s;
 T
FA
 =
 t
ra
ns
-f
em
or
al
 a
cc
es
s;
 T
R
A
 =
 t
ra
ns
-r
ad
ia
l a
cc
es
s.
10.1
230
Chapter 10.1
Table 3. Anti-coagulation at baseline and during the mesenteric arterial procedures.
TBA
(n=52)
TFA
(n=39)
TRA
(n=57)
Anti-coagulation at baseline
Aspirin 17 (33%) 7 (18%) 21 (37%)
Aspirin + clopidogrel 9 (17%) 9 (23%) 12 (21%)
Clopidogrel 2 (4%) 6 (15%) 5 (9%)
Aspirin + heparin 4 (8%) 2 (5%) 3 (5%)
Vit K antagonist 5 (9%) 1 (3%) 2 (3%)
Aspirin + dipyradimole 3 (6%) 1 (3%) 0 (0%)
Vit K antagonist + aspirin 1 (2%) 3 (8%) 0 (0%)
Vit K antagonist + clopidogrel 0 (0%) 3 (8%) 1 (2%)
Aspirin + ticagrelor 0 (0%) 1 (3%) 1 (2%)
Heparin 0 (0%) 0 (0%) 2 (3%)
DOAC 1 (2%) 0 (0%) 1 (2%)
Dipyradimole 1 (2%) 0 (0%) 0 (0%)
None 9 (17%) 6 (15%) 9 (16%)
Anti-coagulation continuation during procedure
Aspirin 25 (48%) 19 (49%) 28 (49%)
Aspirin + clopidogrel 2 (4%) 2 (5%) 6 (10%)
Clopidogrel 2 (4%) 3 (8%) 6 (10%)
Vit K antagonist 2 (4%) 0 (0%) 0 (0%)
Aspirin + dipyradimole 1 (2%) 1 (2%) 0 (0%)
Vit K antagonist + aspirin 0 (0%) 1 (2%) 0 (0%)
Aspirin + ticagrelor 0 (0%) 0 (0%) 1 (2%)
Heparin 0 (0%) 2 (5%) 2 (4%)
Heparin + clopidogrel 0 (0%) 1 (3%) 0 (0%)
None 20 (38%) 10 (26%) 14 (25%)
DOAC = direct oral antiocoagulants; TBA = trans-brachial access; TFA = trans-femoral access; TRA = trans-
radial access.
The primary outcomes were technical success rate vascular access specified (technical 
success related to the vascular access) and access site complication rates. Secondary 
outcomes were overall technical success rates, non-access site complication rates, 
conversion rate and mortality. Technical success is defined as achievement of the aimed 
goal of the procedure. Technical success of mesenteric revascularization was specified 
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according the Quality Improvement Guidelines for Mesenteric Angioplasty and Stent 
Placement for the Treatment of CMI(1). The complication rates were specified according 
the SIR Quality Improvement Guidelines for Diagnostic Arteriography (11).
Statistical methods
Baseline procedure characteristics were described either as numbers and percentages 
for dichotomous variables, or as means and standard deviations or medians and 
interquartile ranges (IQR) for continuous variables. Differences in baseline procedure 
characteristics, technical success rates and complication rates between the different 
approaches were determined by the χ2-test or student’s T-test. Assumption of normality 
was based on the sample size (>30)(12, 13). Univariable logistic regression analysis was 
performed to assess predictors for access site complications. Statistical significance 
was defined as p <0.05. Since the inclusion period of the TRA procedures in this study 
started simultaneously with the moment of introduction of TRA in the study center, 
a comparison of the success rate and complication rate of the first 25% of the TRA 
procedures versus the latter 75% of the TRA procedures was performed.
RESULTS
Feasibility
Table 4 shows the technical success and conversion rates specified per approach. The 
technical success rate specified for the vascular access technique differed not between 
the three access techniques (TBA 96%, TFA 87%, TRA 91%, TRA-TBA p=0.295, TBA-
TFA p=0.112, TRA-TFA p=0.524). The overall procedural technical success rate differed 
also not between the three access methods (TBA 75%, TFA 80%, TRA 83%, TRA-TBA 
p=0.341, TBA-TFA p=0.615, TRA-TFA p=0.714). Both the technical success rate vascular 
access specified (93% for the first 25% of TRA procedures versus 90% of following 
75% of TRA procedures, p=0.737) and the complication rate (27% for the first 25% of 
TRA procedures versus 43% of following 75% of TRA procedures, p=0.269) were not 
different. The conversion rate differed also not between the access methods (TBA 2%, 
TFA 8%, TRA 4%, TRA-TBA p=0.613, TBA-TFA p=0.184, TRA-TFA p=0.365). One TBA 
procedure was converted to TFA, however both approaches did not result in successful 
catheterization of the CA. In total 3 TFA procedures were converted: 1 procedure to TBA, 
which resulted in a successful procedure. Two TFA procedures were converted to the 
contralateral common femoral artery, which was unsuccessful in both cases, however 
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the procedure per TBA the following day was successful for both. Two TRA procedures 
were converted to TBA successfully, one patient suffered from radial spasm and in a 
second patient, puncture of the radial artery failed despite sufficient radial diameter. Of 
the 52 TRA procedures, 8 patients underwent a second TRA procedure with ipsilateral 
radial puncture (mean interval time between radial ipsilateral punctures: 12.0±9.0 
months). Of the 52 TBA procedures, 5 patients underwent a second TBA procedure 
with ipsilateral puncture and 1 patient underwent three procedures with ipsilateral 
brachial puncture (mean interval time between brachial ipsilateral punctures: 14.7±22.5 
months). Of the 39 TFA procedures, 3 patients underwent a second TFA procedure with 
ipsilateral puncture and 1 patient underwent 4 procedures with ipsilateral femoral 
puncture (mean interval time between femoral ipsilateral punctures: 11.9±3.9 months).
Complications
Table 5 shows the complication rates specified per approach. The overall access site 
complication rate was not different between the three approaches (TBA 42%, TFA 23%, 
TRA 35%, TRA-TBA p=0.439, TBA-TFA p=0.055, TRA-TFA p=0.208), however more major 
access site complications were reported for TBA than for TRA or TFA (TBA 17%, TFA 3%, 
TRA 2%, TRA-TBA p=0.005, TBA-TFA p=0.026, TRA-TFA p=0.785). The minor access site 
complications were not different between the three approaches (TBA 25%, TFA 20%, 
TRA 33%, TRA-TBA p=0.351, TBA-TFA p=0.615, TRA-TFA p=0.170). The non-access site 
complication rate for TFA was higher than for TRA (TBA 8%, TFA 15%, TRA 4%, TRA-TBA 
p=0.339 TBA-TFA p=0.246, TRA-TFA p=0.039). Neurological complications did not occur 
in the three groups, despite right sided performance of 31% of all TRA procedures and 
17% of all TBA procedures. Predictors for access site complications were assessed with 
univariable logistic regression analysis. Baseline characteristics significantly different 
between the three approaches were assessed (age, INR, type of procedure, sheath 
size, puncture side) combined with age, platelets and use of anticoagulation during the 
procedure. None of the assessed characteristics was a significant predictor for access 
site complications (Table 6).
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Table 6. Univariable logistic regression analysis for access site complications.
Characteristics OR (95% CI) p-value
Female 0.624 (0.305-1.277) 0.197
Age 0.979 (0.952-1.007) 0.148
Platelets 0.999 (0.995-1.002) 0.435
INR 0.981 (0.204-4.711) 0.981
Sheath size 1.054 (0.585-1.899) 0.861
Type of procedure 0.922 (0.725-1.714) 0.922
Anticoagulation during procedure 1.018 (0.908-1.142) 0.758
Puncture side = left 1.893 (0.916-3.914) 0.085
CI = confidence interval; INR = international normalized ratio; OR = odds ratio.
Follow-up and survival
During follow up (mean follow-up time of all 148 procedures: 23.0±18.0 months), 17 
of all 103 patients (17%) died. Causes of death were mesenteric ischemia (n=6), cancer 
(n=4), sepsis (n=3), unknown (n=2), ruptured aortic aneurysm (n=1) and death related to 
surgical aortic repair (n=1). None of these deaths were directly related to the procedure. 
Four patients died within 1 month after the procedure (TBA n=3, TFA n=1, all 4 stenting 
procedures), all of them because of mesenteric ischemia. Three out of four patients 
who died of mesenteric ischemia underwent a technically successful stent procedure 
as confirmed by angiography at the end of the interventional procedure. However the 
mesenteric ischemia was too extensive to prevent death after revascularization. The 
SMA of the fourth patient was successfully treated, but a synchronous total occlusion 
of the CA could not be crossed and this patient died from ongoing mesenteric ischemia. 
Two other patients died of mesenteric ischemia 2 months and 5 months after the 
procedure. The first patient underwent bypass surgery of the SMA, complicated by 
cardiac arrest and ongoing mesenteric ischemia. The second patient had end-stage 
kidney disease requiring dialysis resulting in a low-flow blood state causing ongoing 
mesenteric ischemia.
237
Trans-radial access for mesenteric arterial procedures
DISCUSSION
This study presents single-center data of 148 mesenteric arterial procedures performed 
by either a TBA, TFA or TRA approach. The data shows that TRA is a feasible approach 
for mesenteric arterial procedures with a technical success rate of 91%, not significantly 
different from the vascular access specified technical success rates of TFA and TBA. In 
addition, this study shows that TRA is safe for mesenteric arterial procedures as shown 
by a minor access site complication rate similar to TFA and TBA and a major access site 
complication rate of TRA similar to TFA but significantly lower than TBA.
This study consists of a unique series of mesenteric arterial endovascular procedures 
comparing TFA, TBA and TRA. Reported technical success rates of non-coronary artery 
procedures per TRA in literature vary from 91-99%(7, 8, 14-17). This study aimed at 
mesenteric arterial procedures shows a technical success rate of 91% for TRA, the lower 
limit of the reported technical success rates for non-coronary procedures. Posham 
et al. reported a significant higher crossover risk for renal/visceral interventions (OR 
4.91 (2.07-11.7), p=0.0003) compared to oncologic liver interventions(7). A tentative 
explanation for this higher crossover rate could be due to the complexity of renal/
visceral interventions, which include mesenteric arterial procedures. Furthermore, this 
study is performed in a tertiary referral center which possibly leads to selection of 
procedures with even higher difficulty which is substantiated by the similar technical 
success rates of TFA and TBA (technical success rate TBA 96% and TFA 87%).
The TRA procedures described in this study were included directly at the start of 
implementation of the TRA approach in this center. The described data indicates no 
learning curve for the TRA approach in the hands of experienced interventionalists, 
since the complication rate and technical success rate were not significantly different 
for the first 25% of the TRA procedures versus the latter 75% of TRA procedures.
The complication rates for non-coronary procedures per TRA reported vary from 
1.8%-8.0% (7, 14-17). These rates are difficult to compare since the reporting standards 
differ between studies and data specified for mesenteric arterial procedures are 
lacking. Madden et al. reported an overall access site complication rate of TBA for 
non-coronary procedures of 11%(18). Complication rates specifically reported for 
mesenteric arterial procedures are scarce. Oderich et al report a complication rate 
for mesenteric procedures per TBA of 32% and per TFA of 28% (19). Rajaratnam et 
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al. reports a complication rate of 20% for mesenteric procedures in a combined TBA 
and TFA cohort(20). These numbers suggest a lower complication rate for mesenteric 
procedures per TRA compared to TBA and TFA, as previously proven for major access 
site complications for coronary procedures(2).
A potential limitation of this study is that it is an analysis based on a retrospective 
cohort, which could have led to reporting bias. The chosen vascular approach was not 
randomized but based on the angle between the mesenteric vessel and the aorta at the 
discretion of the performing interventionalist before November 2014 and if TRA was not 
possible from November 2014 onwards, potentially leading to selection bias and time-
period bias. However, this study is a first step to assess the feasibility and safety of TRA 
for mesenteric arterial procedures. Ideally, a randomized controlled trial has to confirm 
the results of this study, such as conducted by Kiemeneij et al. published for coronary 
artery interventions(2). Procedure time, radiation exposure and the amount of contrast 
administered were not documented for the included patients. These characteristics 
could be interesting when comparing the different approaches in future studies. Finally, 
standard procedures did not include post procedural ultrasound of the access artery to 
assess occlusion or other access site complications after the procedure. Post procedural 
ultrasound was only performed if clinically indicated.
In conclusion, TRA is a safe and feasible technique for mesenteric arterial procedures 
and is comparable with TFA. TBA should be considered with caution, because of its 
significantly higher major complications rate. Prospective studies need to confirm the 
results of this study.
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Since November 2014, in our hospital, all non-coronary endovascular interventions 
initially selected for trans-brachial access with normal modified Allen test or Barbeau 
test result and sufficient radial artery (RA) diameter are performed per radial approach. 
We describe one rare but severe complication that occurred in 150 trans-radial 
procedures. Institutional review board approval was not required to publish this letter. 
Written informed consent was obtained from the patient.
A 36-year-old woman with a 1-year history of transient vertigo, bilateral blurred 
vision and nausea was evaluated for potential vertebrobasilar transient ischemic 
attacks. She also reported pain in the left arm. Her medical history was extensive 
with antiphospholipid syndrome, Budd-Chiari syndrome with hepatosplenomegaly, 
portal hypertension, esophageal varices, and right hemiparesis after stroke. Computed 
tomography angiography (CTA) showed a high-grade stenosis of >90% at the origin of 
the left subclavian artery (LSA) (Figure 1). Duplex ultrasonography showed no reversed 
blood flow in the left vertebral artery. The transient ischemic attacks were explained 
by microemboli to and/or hypoperfusion of the posterior circulation. The pain in the 
left arm was explained by hypoperfusion and endovascular revascularization of the 
LSA was planned.
Figure 1. CTA image showing a high-grade stenosis of > 90% at the origin of the LSA (arrow).
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The modified Allen test was normal. The RA diameter was 2 mm assessed by ultrasound 
and no anatomical variation of the RA was detected. After local anesthesia with 2% 
lidocaine, the left RA was punctured using ultrasound. An 11-cm 6-F dedicated RA 
sheath (Prelude; Merit Medical Systems, Inc, South Jordan, Utah, USA) was introduced. 
A solution containing 200 μg nitroglycerin, 2.5 mg verapamil and 5,000IE heparin 
was slowly injected intra-arterially. An 110-cm length 6-F Flexor sheath (Cook, Inc, 
Bloomington, Indiana, USA) with dilator was exchanged without resistance using a 
0.035-inch Glidewire Advantage (Terumo Corp, Tokyo, Japan). The LSA stenosis was 
passed easily, and a 6 x 16 mm covered stent (Advanta V12; Atrium Medical Corp, 
Hudson, New Hampshire, USA) compatible with a 6-F sheath was placed. Additional 
inflation using a 7-mm balloon was attempted which resulted in stent dislocation 
towards the descending aorta. A 7-F sheath was placed in the left common femoral 
artery. The covered stent was parked into the external iliac artery and dilated to 8 
mm. An 8 x 29 mm balloon expandable stent (Isthmus, CID SpA, Saluggia, Italy) was 
placed in the LSA via a femoral approach. Angiography images showed good position 
and stent patency. The femoral puncture side was closed with a closure device (Angio-
Seal; Terumo Corp).
At the end of the procedure, the trans-radial Flexor sheath resisted removal. 
Manipulation was very painful for the patient. The patient was sedated with propofol 
to relax the RA and the sheath could slowly be retracted without resistance. Small 
injury of the RA with extravasation of contrast agent was visible (Figure 2, 3), but the 
RA was shown to be patent angiographically. After complete removal of the sheath, a 
pressure bandage was placed around the forearm, and the puncture side was closed 
with a compression device (Air-Band; Merit Medical Systems, Inc). The circulation of 
the hand was assessed frequently. The patient’s left fingers were pale with normal 
sensibility and mobility. The same night, the fingertips of the left hand discolored 
blue and became painful. Surgical exploration of the left forearm was performed 
demonstrating a total rupture of the RA. A venous brachial artery–RA jump graft was 
made to restore vascularization. Fasciotomy was performed to release compartments 
of the left forearm.
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Figure 2. The sheath was removed under propofol sedation. While the sheath was halfway out, 
injection of contrast agent demonstrated partial rupture of the RA and contrast extravasation 
(arrow) in the soft tissue surrounding the rupture.
Figure 3. Minimum intensity reconstruction of CTA performed after the procedure demonstrates 
absence of contrast in the RA because of total occlusion and contrast in the soft tissue around 
the RA (arrow). Contrast in the soft tissues resulted from the invasive procedure and was not 
considered active contrast extravasation during CTA acquisition.
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The following days, the fingers remained painful, discolored, and cold and morphine 
was started. The patient was discharged 2 weeks after the procedure. She had monthly 
follow-up at the outpatient clinic. During follow-up, dry gangrene developed on the 
thumb, index finger and middle finger (Figure 4). After 1 year, the fingertips of the index 
and middle finger were lost; the thumb was still intact with dry gangrene. The patient 
was free of pain and stopped all pain medication.
Figure 4. The patient’s left hand 6 weeks after the procedure. Dry gangrene developed on the 
fingertips of the thumb, index finger and middle finger.
A severe complication of the radial access technique is described here. A relatively 
large sheath diameter(1) likely caused the severe vasospasm resisting removal of 
the RA sheath in combination with the prolonged procedure duration of 1 hour. The 
distal 25 cm of the Flexor sheath is hydrophilic coated. The remaining 85 cm of the 
sheath is not hydrophilic coated which may have contributed to this complication. 
Moreover, vasospasms may have been augmented owing to patient stress stimulating 
the adrenergic system. Because the modified Allen test indicated a sufficient palmar 
arch, insufficient radial blood flow owing to occlusion at the puncture side could not 
explain the ischemic sequelae. Small injury of the RA with extravasation of contrast 
agent was present at the end of the procedure. The RA itself was patent. Therefore, it 
is more likely that embolization of the thrombus near the target site dislodged distally 
after the procedure.
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In a case in which RA sheaths resists removal, vasodilatation should be sought by: (1) 
intra-arterial injection of vasodilatators, (2) local infiltration of the tissue around the 
RA (eg, 1 mg nitroglycerin diluted in 10 ml saline), or (3) some form of sedation. Cases 
of RA injury treated with covered stent placement have been described in literature(2). 
However, follow-up in these cases was short and long-term stent patency rates are 
unknown. Another report described treatment with long-term sheath insertion to 
cover the rupture(3). This was not considered in our case, as the sheath itself caused 
the RA injury. The clarification of distal embolization of target site thrombi was not 
considered initially but might have changed the treatment strategy. Possibly, in 
retrospect, complete RA occlusion (eg, by using coils) might have been a better option 
than external compression.
This complication should be evaluated extensively. RA diameter assessment using 
ultrasound before trans-radial procedures is now always performed in our hospital. 
Minimum outer sheath diameter equals the RA diameter plus an additional 0.2 mm 
owing to vasodilation(4): RA diameter > 2.0 mm for 4-F sheath, > 2.2 mm for 5-F sheath, 
and > 2.4 mm for 6-F sheath.
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ABSTRACT
Purpose
To assess the ability of pressure measurements to discriminate clinically significant 
celiac artery (CA) or superior mesenteric artery (SMA) stenosis in patients suspected 
chronic mesenteric ischemia (CMI).
Material and Methods
Single-center, retrospective cohort study of 41 intra-arterial pressure measurements 
during mesenteric angiography with intended revascularization, performed in 37 
patients (mean age 67.7±10.8 years, 62% female) between April 2015 and May 2017. 
Simultaneous pre-stenotic and post-stenotic pressure measurements had been obtained 
before and after intra-arterial administration of nitroglycerin. Revascularization was 
performed in 38 out of 41 procedures. Definitive diagnosis of CMI was defined as 
patient-reported symptom relief or improvement after successful revascularization.
Results
Pressure gradients obtained after vasodilator administration were significantly higher 
in CAs and SMAs with ≥50% stenosis. Pressure ratios (Pd (pressure distal)/Pa (pressure 
aorta)) obtained after vasodilator administration were significantly higher in CA’s with 
≥50% stenosis. Subgroup analysis of 22 patients with a ≥50% stenosis of either CA or 
SMA showed significantly higher pressure gradients and Pd/Pa ratios after vasodilator 
administration in CMI patients (median pressure gradient: CMI (IQR) 36 (21-40) mmHg 
versus no-CMI 20 (9-21) mmHg, p=0.041; Pd/Pa: CMI 0.703 (0.598-0.769) versus no-CMI 
0.827 (0.818-0.906), p=0.009)). A ≤0.8 Pd/Pa cut-off value after administration of a 
vasodilator best identified a clinically relevant stenosis, with 86% sensitivity and 83% 
specificity. Complications related to the pressure measurements were not observed.
Conclusion
Intra-arterial pressure measurements are feasible and safe. Low Pd/Pa ratios were 
associated with clinically relevant CA or SMA stenosis.
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INTRODUCTION
Determination of the clinical significance of a mesenteric arterial stenosis is challenging, 
since an asymptomatic mesenteric arterial stenosis is found in 11-29% of the general 
population(1). The abundant mesenteric collateral network prevents development of 
symptoms in these individuals. However, when this collateral network is insufficient and/
or the mesenteric arterial stenosis is too extensive, symptoms of chronic mesenteric 
ischemia (CMI), such as postprandial abdominal pain, food fear, and weight loss, may 
develop. Revascularization may then be beneficial. Patients with significant multi-vessel 
mesenteric arterial stenosis and corresponding symptoms are likely to have CMI and 
revascularization is therefore recommended(2). Establishing a diagnosis of CMI is 
more complex in patients with stenosis of a single mesenteric artery, in which case a 
diagnostic test assessing functional severity of the stenosis is indispensable.
Intra-arterial pressure measurements performed during angiography enable direct 
measurement of blood pressure proximal and distal to a stenosis. The myocardial 
fractional flow reserve (FFR) is a validated method to assess the hemodynamic 
significance of a coronary artery stenosis during coronary angiography(3, 4). A FFR <0.8 
implicates that a coronary artery lesion is hemodynamically significant and should be 
treated(4). Guidelines on peripheral arterial disease issued by the European Society of 
Cardiology (ESC) and European Society of Vascular Surgery (ESVS) define a significant 
renal artery stenosis as a >20 mmHg translesional systolic pressure gradient or a <0.90 
resting pressure ratio (5).
Validated cut-off values defining a significant mesenteric arterial stenosis are 
lacking. Guidelines for mesenteric endovascular interventions issued by the Society 
of Interventional Radiology (SIR) define a significant stenosis as narrowing of the 
mesenteric arterial lumen by ≥70% or >20 mmHg systolic pressure gradient across 
the lesion(6). This definition has been derived from an article by AbuRahma et al.(7). 
The ESVS guidelines on arterial and venous mesenteric diseases define a severe SMA 
stenosis as a ≥10 mmHg mean arterial pressure gradient across the lesion, referring to 
two studies which each used completely different cut-off values (>10% peak systolic 
blood pressure gradient; ≥20 mmHg mean pressure gradient)(2, 8, 9).
In conclusion, consensus on the value of pressure measurements during mesenteric 
procedures is currently lacking; cut-off values applicable to the mesenteric arteries have 
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not been defined. The aim of this study is to define a clinically significant CA or SMA 
stenosis by correlating mesenteric pressure measurements with a definitive diagnosis 
of CMI.
MATERIAL AND METHODS
Study design
All patients undergoing a digital subtraction angiography (DSA) of the mesenteric 
arteries with intended revascularization and intra-arterial pressure measurements in a 
specialized center between April 2015 and May 2017 were included in this retrospective 
cohort study. A total of 73 mesenteric angiograms with intended revascularization 
had been performed during the study period. Pressure measurements had been 
obtained during 41 procedures in 37 patients, these procedures were included in the 
study. Revascularization had been performed in 38 of the 41 procedures and these 38 
procedures were included for the clinical success analysis. Revascularization had not 
been performed in three cases because the stenoses were judged to be not significant. 
The local medical research ethics committee concluded that the Medical Research 
Involving Human Subjects Act does not apply to this study. The investigators complied 
with the Helsinki declaration on research ethics. The STROBE checklist for cohort studies 
was used to write this manuscript(10).
Standard diagnostic work-up
Patients suspected of CMI referred to the specialized center underwent a standardized 
diagnostic work-up consisting of assessment of symptoms, imaging of the mesenteric 
arteries (computed tomography angiography (CTA)) and visible light spectroscopy. 
The latter is a functional test assessing mucosal ischemia during upper gastro-
intestinal endoscopy(11). Results of the diagnostic work-up were discussed in a 
multidisciplinary meeting attended by interventional radiologists, vascular surgeons, 
and gastroenterologists, all specialized in CMI. When CMI was judged to be a likely 
explanation for the presenting symptoms and alternative diagnoses were adequately 
excluded, a presumptive diagnosis of CMI was established. Patients with a presumptive 
diagnosis of CMI based on vascular disease were scheduled for DSA with intended 
mesenteric revascularization. Patients suspected of median arcuate ligament syndrome 
(MALS) were not scheduled for DSA since treatment for MALS consists of surgical 
release. The ultimate decision to perform revascularization was made if during the 
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DSA procedure a significant stenosis was found, defined as ≥50% luminal reduction. If 
the interventional radiologist had doubts about the significance of the stenosis, a mean 
pressure gradient of >10 mmHg was an indication for revascularization. A definitive 
diagnosis of CMI was established when a patient reported relief or improvement of 
presenting symptoms after a technically successful revascularization procedure.
Data sources
Baseline and follow-up data was retrieved from the hospital records. A standardized 
follow-up protocol had been used throughout the study period, consisting of history 
and physical examination 24 hours after the procedure and at 1, 3, 6, 12, and 24 months. 
Most of the follow-up had been obtained in outpatient clinic visits or by phone.
For the purpose of this study the DSA derived during the procedure was re-examined 
by two interventional radiologists with 8 and 5 years of experience. Time between 
DSA and re-examination ranged from 12 to 36 months. The interventional radiologists 
were blinded to symptom improvement after treatment and independently graded the 
severity of CA and SMA stenoses on a scale from 0 (no stenosis) to 100 (occlusion). The 
grading was based on the luminal diameter of the stenosis and adherent normal vessel 
in two directions. In case of a ≥10% difference in severity of the stenosis established by 
the two radiologists, the DSA images were reassessed and discussed until consensus 
was reached. Information on the presence of an IMA stenosis was obtained from the 
multidisciplinary meeting reports.
Procedure and pressure measurements
Pressures were measured using a 4-F catheter — positioned just distal to the stenosis 
— and a 5-F or 6-F sheath — with the tip positioned in the aorta just proximal to the 
stenosis. Both catheter and sheath were externally connected to pressure measurement 
devices (Meritrans DTXPlus, Merit Medical, South Jordan, USA) connected to a 
monitoring system (Infinity C500, Dräger, Lübeck, Germany). In some cases, both a 
catheter and a 0.014” pressure wire (Aeris Agile, St Jude Medical, Minnesota, USA) were 
used. The catheter was pulled into the sheath before pressure wire measurements were 
obtained. Pressure measurements obtained with the pressure wire were compared 
with measurements obtained with the pressure catheter, since the diameter of the 
pressure catheter (1.33mm) is larger than the diameter of the pressure wire (0.36mm). 
Positioning a catheter through a severe stenosis reduces the luminal diameter even 
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further, thereby obstructing blood flow, possibly resulting in lower pressures distal to 
the stenosis, with subsequent larger pressure gradients.
The pressure devices were calibrated against atmospheric pressure at the level of the left 
atrium. Translesional pressure measurements were performed simultaneously, before 
and after intra-arterial injection of nitroglycerine 300 microgram(12). This vasodilator 
was injected distal to the stenosis, through the 4-F catheter, and measurements were 
obtained within seconds thereafter. These measurements were performed before and 
after endovascular intervention of the CA and/or SMA.
At the discretion of the interventionalist, the access approach was trans-radial, trans-
brachial or trans-femoral. Patients undergoing mesenteric artery stenting were treated 
with life-long acetylsalicylic acid and clopidogrel for a duration of 12 months. When 
revascularization was performed by percutaneous transluminal angioplasty (PTA) 
alone, life-long acetylsalicylic acid was prescribed. In patients undergoing DSA without 
revascularization, anticoagulation was not indicated.
Variables
Table 1 shows the patient characteristics, the presenting symptoms, and the CTA results. 
Mean age of the 37 patients was 67.7±10.8 years and most were female (62.2%). A 
definitive diagnosis of CMI had been made in 28 out of 37 patients (75.7%). Current 
smoking or a history of smoking was significantly more frequent in patients with a 
definitive diagnosis of CMI (CMI patients 96.3% versus no-CMI patients 66.7%; p=0.014). 
All patients without a definitive diagnosis of CMI presented with nausea, versus 57.9% 
of CMI patients p=0.039). Pre-procedural CTA imaging showed ≥1 mesenteric artery 
stenosis in all patients and procedures.
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Table 1. Baseline characteristics in presence or absence of a definitive diagnosis of CMI.
All patients
(n=37)
CMI patients
(n=28)
No-CMI patients
(n=9)
P-value
Patient characteristics
Age (y) 67.7 ± 10.8 68.5 ± 10.7 65.0 ± 11.1 0.37
Female 62.2% (23) 60.7% (17) 66.7% (6) 0.75
Caucasian 100.0% (37) 100.0% (28) 100.0% (9) 1.00
Weight at angiography (kg) 65.4 ± 19.8 66.0 ± 19.9 63.6 ± 20.5 0.85
BMI at angiography (kg/m2) 23.4 ± 5.6 23.3 ± 5.3 23.9 ± 6.8 0.88
Current/former smoker 88.9% (32) 96.3% (26) 66.7% (6) 0.01*
Hypertension^ 52.8% (19) 55.6% (15) 44.4% (4) 0.56
Dyslipidemia@ 47.2% (17) 51.9% (14) 33.3% (3) 0.34
Diabetes# 13.9% (5) 18.5% (5) 0.0% (0) 0.16
History of CVD 70.3% (26) 71.4% (20) 66.7% (6) 0.79
Presenting symptoms
Abdominal pain 94.6% (35) 92.9% (26) 100.0% (9) 0.41
Postprandial abdominal pain 73.0% (27) 67.9% (19) 88.9% (8) 0.22
Exercise related abdominal pain 30.0% (9) 25.0% (6) 50.0% (3) 0.23
Nausea 69.2% (18) 57.9% (11) 100.0% (7) 0.04*
Diarrhea 44.4% (16) 44.4% (12) 44.4% (4) 1.00
Obstipation 30.6% (11) 33.3% (9) 22.2%(2) 0.53
Weight loss 63.9% (23) 59.3% (16) 77.8% (7) 0.32
Abdominal bruit 32.1% (9) 33.3% (7) 28.6% (2) 0.82
Classic triad of CMI 21.1% (7) 20.0% (5) 25.0% (2) 0.76
Gastric and/or duodenal ulcer 6.1% (2) 8.3% (2) 0.0% (0) 0.37
Duration of symptoms (months) 12.5 ± 11.1 11.3 ± 8.3 16.2 ± 17.5 1.00
Stenotic mesenteric arteries on CTA per procedure
CA 9.8% (4) 14.3% (4) 0% (0) 0.56
SMA 14.6% (6) 10.6% (3) 23.0% (3) 0.29
IMA 2.4% (1) 0% (0) 7.8% (1) 0.55
CA+IMA 17.1% (7) 14.3% (4) 23.0% (3) 1.00
SMA+IMA 17.1% (7) 17.9% (5) 15.4% (2) 0.84
CA+SMA 17.1% (7) 14.3% (4) 23.0% (3) 1.00
CA+SMA+IMA 21.9% (9) 28.6% (8) 7.8% (1) 0.54
Data are presented as percentages (numbers) or as mean ± SD.
^ blood pressure ≥140/90 mmHg or use of antihypertensive medication
@ LDL-C >4.2 mmol/L or HDL-C <0.9 mmol/L or use of lipid lowering medication
#all Diabetes type II
* p<0.05
BMI = body mass index; CA = celiac artery; CMI = chronic mesenteric ischemia; CVD = cardiovascular 
disease; IMA = inferior mesenteric artery; PTA = percutaneous transluminal angioplasty; SMA = superior 
mesenteric artery.
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Table 2 contains the procedural characteristics. In most of the procedures (28/41; 
68.3%) a transradial approach was used. DSA showed an atherosclerotic stenosis in 
40 procedures (97.5%); one procedure concerned revascularization of a stenosis in a 
patient with known vasculitis (Takayasu arteritis) (2.5%). A combination of a significant 
atherosclerotic stenosis of the SMA and a non-significant CA stenosis due to external 
compression was observed in one procedure. None of the patients was diagnosed with 
MALS. Mesenteric artery stenting was the most frequent intervention (28 primary 
stent placements (68.3%) and 7 stent-in-stent placements (18.4%)). Technical success 
of revascularization was defined as a <30% residual stenosis after stenting or PTA. 
Procedural reports did not specify the precise severity of the residual stenosis. Technical 
success was achieved in 89.5% of 38 revascularizations. Stent specifications could not 
be assessed, since 19 of the 38 (50.%) revascularization procedures were included in 
an ongoing double blinded randomized controlled trial, comparing the patency of bare 
metal stents (Palmaz blue, Cordis, Baar, Switzerland) with the patency of covered stents 
(V12, Atrium Medical Corporation, Merrimack, United States of America)(13).
Table 2. Procedure characteristics.
All procedures
n=41
Cause stenosis atherosclerosis 97.5% (40)
Cause stenosis vasculitis 2.5% (1)
Radial access 68.3% (28)
Brachial access 17.1% (7)
Femoral access 14.6% (6)
Sheath size 4-F 2.6% (1)
Sheath size 5-F 13.1% (5)
Sheath size 6-F 71.1% (27)
Sheath size 7-F 10.6% (4)
Sheath size 8-F 2.6% (1)
Diagnostic angiography 7.3% (3)
Technical success rate revascularizations 89.5% (34)
Clinical success rate revascularizations 73.7% (28)
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Table 2. Continued
All procedures
n=41
Primary interventions (N=29)
Stent placement CA 23.7% (9)
Stent placement SMA 29.0% (11)
Stent placement CA + SMA 21.1% (8)
PTA CA 2.6% (1)
Re-interventions (N=9)
Stent-in-stent placement CA 7.9% (3)
Stent-in-stent placement SMA 10.5% (4)
In-stent PTA CA 2.6% (1)
In-stent PTA CA + SMA 2.6% (1)
Data are presented as percentages (number).
CA = celiac artery; PTA = percutaneous transluminal angioplasty; SMA = superior mesenteric artery.
Pressure gradients across the lesion (= pressure distal to the stenosis (Pd)–pressure aorta 
(Pa)) and Pd/Pa ratios were calculated to assess the primary outcome and the secondary 
outcomes. The primary outcome was the ability of pressure measurements to define a 
clinically significant stenosis by discriminating patients with a definitive diagnosis of CMI 
— patient-reported relief or improvement of presenting symptoms after a technically 
successful revascularization procedure — from patients without a definitive diagnosis 
of CMI. Secondary outcomes were the ability of pressure measurements to discriminate 
a <50% stenosis from a ≥50% stenosis; differences between BMI at baseline and at 12 
months after the intervention; differences in pressure readings obtained with wire and 
obtained with catheter; complication rate; and mortality rate. The complication rates 
were specified according to the SIR Quality Improvement Guidelines for Diagnostic 
Arteriography(14).
Statistical methods
Patient characteristics are described as either number and percentage for dichotomous 
variables, or as mean and standard deviation or median and interquartile range (IQR) 
for continuous variables. Differences in patient characteristics between CMI patients 
and no-CMI patients were determined by the χ2 test, independent T-test or Mann-
Whitney U test. Pressure measurement values are presented as median with IQR, since 
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the data was not normally distributed. Pressure measurements (stenosis versus no 
stenosis and patients with and without a definitive diagnosis of CMI) were compared 
with the Mann Whitney-U test. The Wilcoxon Signed Rank test served to compare BMI 
before and 12 months after intervention and to compare measurements obtained by 
catheter with measurements obtained by pressure wire. Statistical significance was 
defined as p<0.05. Receiver-operating characteristics (ROC) curves were computed to 
define pressure cut-off values for clinically significant stenosis. The area under the curve 
(AUC) or C-statistic defined the discriminative ability of the pressure measurements for 
clinical success. A C-statistic of 0.5 suggests no discrimination; C-statistic of 0.7-0.8 is 
considered acceptable discrimination, C-statistic of 0.8-0.9 as excellent discrimination; 
and a C-statistic ≥0.9 as outstanding discrimination(15). AUCs were compared with the 
DeLong test.
RESULTS
Severity of stenosis and intra-arterial pressure measurements
Re-examination of DSA images obtained before revascularization, showed a significant 
stenosis of 24 out of 41 (58.5%) imaged SMAs and 23 out of 32 (71.9%) imaged CAs 
(Table 3). Grading of stenosis severity differed ≥10% in 8 out of 75 graded stenoses (6 
CA and 2 SMA), consensus on the grading had been reached after reassessment by both 
interventional radiologists.
Table 3. Grading of severity of stenosis of CA and SMA based on DSA.
Vessel Severity stenosis All patients CMI patients No-CMI patients
CA <50% 28.1% (9) 20.8% (5) 50.0% (4)
≥50% - <70% 37.5% (12) 45.8% (11) 12.5% (1)
≥70% - <100% 25.0% (8) 25.0% (6) 25.0% (2)
100% (Occlusion) 9.4% (3) 8.4% (2) 12.5% (1)
SMA <50% 36.8% (14) 39.3% (11) 37.5% (3)
≥50% - <70% 44.8% (17) 39.3% (11) 75.0% (6)
≥70% - <100% 10.5% (4) 10.7% (3) 12.5% (1)
100% (Occlusion) 7.9% (3) 10.7% (3) 0.0% (0)
Data are presented as percentages (number).
CA = celiac artery; CMI = chronic mesenteric ischemia; DSA = digital subtraction angiography; 
SMA = superior mesenteric artery.
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Table 4 shows the results of the mean pressure gradients and Pd/Pa ratios in arteries 
with and without a significant stenosis, as classified by re-examination of the DSA 
images. Pressure gradients obtained after administration of a vasodilator were 
significantly higher in vessels with a significant stenosis (pressure gradient after 
vasodilator injection CA median (IQR): stenosis 38.5 (17.0-50.0) versus no stenosis 
12.5 (8.5-19.0), p=0.035 and SMA: stenosis 36.5 (21.0-56.0) versus no stenosis 17.0 
(13.0-31.5), p=0.047). Calculated Pd/Pa ratios obtained after injection of a vasodilator 
in the CA were significantly lower when a significant stenosis was present (Pd/Pa after 
vasodilator injection in the CA median (IQR): stenosis 0.63 (0.47-0.85) versus no stenosis 
0.86 (0.83-0.91), p=0.042).
Table 4. Pressure measurements before intervention in mmHg for the CA and SMA.
Stenosis No stenosis N p-value
CA
Pressure gradient without vasodilator 23.0 (14.5-43.0) 7.5 (3.0-13.5) 28 0.016*
Pressure gradient after vasodilator 38.5 (17.0-50.0) 12.5 (8.5-19.0) 23 0.035*
Pd/Pa without vasodilator 0.74 (0.55-0.87) 0.93 (0.89-0.97) 28 0.013*
Pd/Pa after vasodilator 0.63 (0.47-0.85) 0.86 (0.83-0.91) 23 0.042*
SMA
Pressure gradient without vasodilator 17.0 (7.5-41.5) 8.0 (5.0-13.0) 29 0.056
Pressure gradient after vasodilator 36.5 (21.0-56.0) 17.0 (13.0-31.5) 26 0.047*
Pd/Pa without vasodilator 0.84 (0.53-0.93) 0.92 (0.88-0.95) 29 0.085
Pd/Pa after vasodilator 0.68 (0.35-0.77) 0.78 (0.66-0.85) 26 0.080
Data are presented as median (IQR).
* p<0.05
CA = celiac artery; Pa = pressure aorta; Pd = pressure distal; SMA = superior mesenteric artery.
Pressure measurements had been obtained with both a catheter and a pressure wire in 
8 vessels (4 CA and 4 SMA). Measurements obtained with a catheter were significantly 
lower than measurements obtained with a pressure wire (mean pressure measurements 
by a catheter, median (IQR) 83.0 (68.0-95.0) versus pressure wire 85.0 (76.0-105.5), 
p=0.03). When comparing measurements, the catheter-derived measurements obtained 
distal to the stenosis were significantly lower (mean pressure measurements by a 
catheter, median (IQR) 75.5 (56.5-83.0) versus pressure wire 79.0 (74.3-105.5), p=0.006). 
Measured aortal pressures did not differ significantly (Table 5).
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Table 5. Mean pressures derived by catheter versus pressure wire in 4 CAs and 4 SMAs in mmHg 
before intervention.
Catheter derived Pressure wire
N Pressure N Pressure P-value
Pressure aorta 15 88.0 (82.0-116.0) 9 100.0 (82.5-130.0) 0.811
Pressure distal to stenosis 16 75.5 (56.5-83.0) 16 79.0 (74.3-89.8) 0.006*
All measurements 31 83.0 (68.0-95.0) 25 85.0 (76.0-105.5) 0.029*
Data are presented as median (IQR).
* p<0.05
CA = celiac artery; SMA = superior mesenteric artery.
Clinical outcomes and complications
Clinical success — resulting in a definitive diagnosis of CMI — was achieved in 28 out 
of 38 (73.7%) revascularizations, with a median follow-up of 17 months (range 2-37 
months, mean follow-up 17±10 months). Clinical success was achieved in all 4 (100%) 
patients with a stenosis of the CA; in 3 out of 4 (75.0%) patients with a stenosis of the 
SMA; in 4 out of 7 (57.1%) patients with a stenosis of CA and IMA; in 5 out of 7 (71.4%) 
with a stenosis of SMA and IMA; in 4 out of 7 (57.1%) with a stenosis of CA and SMA; 
and in 8 out of 9 (88.9%) with a stenosis of all three mesenteric arteries. Symptoms 
had recurred in 2 patients with a definitive diagnosis of CMI (1 in-stent stenosis, 1 stent 
fracture). A re-intervention had improved symptoms in both patients. At 12 months after 
revascularization, BMI had increased significantly in patients with a definitive diagnosis 
of CMI (BMI at revascularization 23.3±5.3 versus BMI 12 months after revascularization 
23.9±5.6, p=0.024). BMI showed a decreasing trend after revascularization in patients 
without a definitive diagnosis (BMI at revascularization 23.5±5.6 versus BMI 12 months 
after revascularization 19.9±4.3, p=0.171).
Major complications requiring intervention and/or extension of hospital admission 
had occurred in 3 of the 41 procedures (7.3%) and minor complications in 8 procedures 
(19.5%). Major complications consisted of a hematoma, a pseudoaneurysm of the 
brachial artery and a gastro-intestinal bleeding four days after the procedure. Minor 
complications were 5 hematomas, a CA dissection during recanalization of an occluded 
CA performed after successful pressure measurements in the SMA, a swollen arm 
after radial approach and a painful leg after femoral approach. Complications were 
not related to the pressure measurements. Three out of 37 patients (8.1%) died during 
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the study period. Causes of death were liver failure, urosepsis and cardiac arrest; none 
were related to the procedure.
Pressure measurements in stenosis of either CA or SMA
Subgroup analysis was performed to compare pre-interventional pressure 
measurements in patients with a significant stenosis of either CA or SMA on the re-
examined DSA images and a technically successful revascularization. Pressure gradients 
obtained after administration of a vasodilator were significantly higher in patients 
with a definitive diagnosis of CMI (pressure gradient after injection of vasodilator in 16 
CMI patients 36.0 (21.0-40.0) versus 6 patients without CMI 20.0 (9.0-21.0), p=0.041) 
(Table 6). Calculated Pd/Pa ratios obtained after administration of a vasodilator were 
significantly lower in patients with CMI compared to patients without CMI (Pd/Pa after 
injection of vasodilator in 16 CMI patients 0.70 (0.60-0.77) versus 6 patients without 
CMI 0.83 (0.82-0.91), p=0.009) (Table 6). Figure 1 shows ROC curves reflecting the 
discriminative ability of pressure measurements in the described subgroup. A ≤0.8 Pd/
Pa ratio obtained after administration of a vasodilator provided the optimal sensitivity 
(86%) and specificity (83%); the C-statistic was 0.869 (confidence interval (CI) 0.71-1.00), 
indicating excellent discrimination. The C-statistic representing the discriminative ability 
of severity of stenosis measured on DSA was lower, though not significantly lower (AUC 
0.772, CI 0.55-0.99, p=0.17).
Table 6. Pressure measurements in mmHg before intervention in patients with single-vessel 
disease or stenosis of the IMA and stenosis of either SMA or CA for patients with and without 
a definitive diagnosis of CMI.
CMI patients No-CMI patients N p-value
Pressure gradient without vasodilator 17.5 (11.0-29.0) 8.00 (4.0-15.0) 24 0.047*
Pressure gradient after vasodilator 36.0 (21.0-40.0) 20.00 (9.0-21.0) 22 0.041*
Pd/Pa without vasodilator 0.86 (0.74-0.90) 0.92 (0.90-0.96) 24 0.040*
Pd/Pa after vasodilator 0.70 (0.60-0.77) 0.83 (0.82-0.91) 22 0.009*
Data are presented as median (IQR).
* p<0.05
CA = celiac artery; CMI = chronic mesenteric ischemia; IMA = inferior mesenteric artery; Pa = pressure 
aorta; Pd = pressure distal; SMA = superior mesenteric artery.
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Figure 1. ROC curves of the ability to identify clinically relevant mesenteric artery stenosis by 
pressure measurements in a subgroup of patients with single-vessel disease or stenosis of the 
IMA and either CA or SMA.
AUC = area under the curve.
DISCUSSION
The results of this study suggest that pressure measurements of the mesenteric 
arteries, in particular after injection of a vasodilator, guide the decision to perform 
revascularization of CA or SMA stenosis in patients with presumptive CMI. Pressure 
measurements may be valuable in patients with a single-vessel stenosis, since the 
clinical significance of a single-vessel stenosis is often disputed. Furthermore, this study 
showed that pressure measurements were feasible and safe.
CMI is a challenging diagnosis because the symptoms are non-specific, mimicking 
symptoms of more prevalent diagnoses, and mesenteric artery stenoses are common 
though often not hemodynamically significant. Development of a validated test 
quantifying the hemodynamic significance of stenoses is complicated by two factors. 
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The first factor is the extensive collateral circulation, often compensating for the 
reduced post-stenotic blood flow. Van Petersen et al. showed that an extensive 
collateral circulation in MALS patients was associated with a lower clinical success 
rate after CA release(16). Translesional pressure gradients are measured only when the 
collateral circulation is unable to compensate for the reduced blood flow caused by the 
stenosis. The second factor is the dynamic process of ischemia, since ischemia is often 
temporary and elicited only after a meal(1, 2). Pre-prandial measurements could be false 
negative, since the pre-prandial blood flow is not maximal. Pressure measurements after 
administration of a vasodilator simulates the postprandial physiology of the mesenteric 
vasculature and challenges both factors needed to cause CMI, i.e. an insufficient 
collateral circulation and a stenosis severe enough to limit maximal blood flow. This 
study supports the hypothesis that ischemia in CMI is a dynamic process, since clinically 
significant stenoses were best identified after the injection of a vasodilating agent, as 
is illustrated by the ROC curves in Figure 1.
Consensus on the use of pressure measurements for mesenteric procedures is currently 
not established and validated cut-off values are lacking. This study suggests that a 
clinically relevant CA or SMA stenosis — caused by vascular disease — is identified 
by a ≤0.8 Pd/Pa ratio obtained after administering a vasodilator. This ratio is in line 
with ratios established in other vascular beds(4, 5). The increase in BMI of patients 
with clinical success and the decrease in BMI of patients without CMI is the most 
objective outcome supporting that patient-reported relief of presenting symptoms 
after a technically successful intervention indicates a definitive diagnosis of CMI and 
underlines the potential clinical value of pressure measurements.
Pressure had been measured with both a catheter and a pressure wire in 8 vessels. Mean 
pressures distal to the stenosis were slightly but significantly lower when measured 
with a catheter. Imbesi and colleagues reported similar findings when comparing 
translesional pressure measurements in an atherosclerotic human carotid bulb replica 
using catheters of different diameters(17). Pressures were lower when a larger diameter 
catheter was used. Similar differences have been reported in a clinical study by Garcia 
et al.(18), comparing both pressure wire and catheter derived measurements. The 
results of the present study suggest that cut-off values established with catheters differ 
from cut-off values established with pressure wires, which should be considered when 
designing a future study to determine cut-off values in mesenteric arteries.
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Several limitations of the study need to be addressed. First, the limitations inherent 
to the retrospective design of the study. For example, not obtaining pressure 
measurements in 32 of 73 procedures, which could potentially introduce selection 
bias, though clear selection criteria for the performance of pressure measurements 
could not be identified. Second, the large heterogeneity in number and type of affected 
mesenteric arteries. Third, clinical success had been defined as patient-reported 
symptom relief after revascularization, since a standardized or validated assessment 
is absent. Fourth, patients without significant stenosis during DSA did not undergo 
revascularization, clinical success could therefore not be assessed. Fifth, the limited 
number of patients made it impossible to suggest cut-off values per vessel, while one 
could argue that the clinical relevance and the cut-offs of CA and SMA stenoses may 
differ. Sixth, patients undergoing mesenteric artery revascularization were carefully 
selected; results of this study may therefore not be applicable to populations with a 
less thorough diagnostic work-up.
Despite these limitations, the results of this study provide a valuable first step in the 
assessment of the clinical applicability of treatment guidance by mesenteric pressure 
measurements. Larger prospective studies are needed to verify these findings and 
validate the suggested cut-off, a ≤0.8 PdP/a ratio obtained after administering a 
vasodilator. Furthermore, application of pressure measurements for the detection of 
MALS and assessment of technical success of stenting could be investigated.
In conclusion, the intra-arterial pressure measurements in the studied population 
are proven feasible and safe and may discriminate between clinically relevant CA 
or SMA stenosis and adequately compensated CA or SMA stenosis in patients with 
a presumptive diagnosis of CMI. When confirmed and validated the use of intra-
arterial pressure measurements could improve clinical success after mesenteric artery 
revascularization and prevent over-treatment with its associated risks and costs.
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Chapter 12.1
This thesis aims to provide insights in different aspects of the diagnosis and therapy of 
chronic mesenteric ischemia (CMI) to optimize the diagnostic work-up and therapy for 
this specific patient group. The disease CMI is introduced in Part I with an overview of 
the definition, epidemiology, etiology, clinical presentation, diagnostic work-up, therapy 
and clinical outcome of CMI and the anatomy of the mesenteric vasculature in Chapter 
1.1 followed by the aims and outline of the thesis in Chapter 1.2.
DIAGNOSIS
Part II discusses different aspects of the current diagnostic work-up for CMI and 
strategies and insights to optimize the diagnostic work-up. An overview of the current 
imaging modalities for the mesenteric vasculature such as duplex ultrasound (DUS), 
computed tomography angiography (CTA), magnetic resonance angiography (MRA) 
and digital subtraction angiography (DSA) is given in Chapter 2. Chapter 3 describes the 
external validation of a prediction model, previously published by our study group, to 
predict the risk of CMI based on 5 simple predictors (female gender, presence of weight 
loss, presence of cardiovascular disease (CVD), degree of celiac artery (CA) stenosis, 
and degree of superior mesenteric artery (SMA) stenosis). The performance of the 
prediction model in the new multicenter cohort was good. However, experts in the 
field discussed the absence of the etiology of the CA stenosis (median arcuate ligament 
syndrome (MALS), atherosclerosis) as a predictor in the prediction model. Therefore, we 
updated the model based on the performance of the model in the combined original and 
validation cohort, in a total of 666 patients suspected of CMI, with inclusion of the cause 
of CA stenosis. This updated model includes the predictors: presence of weight loss, 
presence of CVD, degree of CA stenosis combined with the cause of CA stenosis, and 
degree of SMA stenosis. The updated score chart shows excellent discriminative ability 
with an absolute low-risk of CMI of 19%, an intermediate risk of 45% and a high risk of 
CMI of 92%. The updated score chart is a useful tool to guide clinical decision making 
for the diagnostic work-up. We suggest a wait-and-see policy for patients stratified as 
low-risk of CMI, additional functional testing for patients stratified as intermediate risk 
of CMI and immediate vascular intervention for patients stratified as high risk of CMI. 
This strategy should lead to a more efficient diagnostic approach, reducing diagnostic 
delays due to superfluous diagnostic procedures, thereby resulting in a decrease in 
patient-burden and reduced health costs.
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Visible light spectroscopy (VLS) performed during upper endoscopy is used in 
clinical practice as a component of the diagnostic work-up of CMI. Interobserver 
and intraobserver validation of endoscopic VLS is not described in literature; 
therefore we performed an observer reliability study. We show in Chapter 4 that the 
observer reliability of VLS is fair to good with intraobserver reliability being better 
than interobserver reliability. VLS measurements during upper gastro-intestinal (GI) 
endoscopy are reproducible and our findings support the use of VLS in the diagnostic 
work-up of CMI.
In Chapter 5 we determined whether postprandial VLS measurements increase the 
discriminative ability of VLS measurements, since CMI patients are often symptomatic 
after a meal due to increased oxygen demand. Our prospective cohort study shows 
that postprandial VLS measurements have no added benefit for the diagnosis of CMI.
Chapter 6 describes the validation of the VLS technique in a porcine model based on 
3 experiments. First, we compared VLS values and calibrated microvascular oxygen 
tension (μPO
2
) measurement values at different levels of FiO
2
. We show that the VLS 
values decrease with increasing FiO
2
 in contrast to the μPO
2 
values that increase with 
increasing FiO
2
. VLS levels show a large spread at all FiO
2
 levels resulting in a poor 
linear correlation. Second, we assessed the effect of the presence of bile on the VLS 
values. We show a significant influence of bile on the measured VLS values. Finally, we 
compared VLS measurements and μPO
2
 measurements during asystole. We show that 
the VLS values, in contrast to the μPO
2 
values, did not decrease towards a value of 0 in 
the first 25 minutes of asystole. Our findings support the idea that VLS measures the 
mixed venous hemoglobin oxygen saturation and not the mucosal capillary hemoglobin 
oxygen saturation. Given the effect of bile on the measured VLS values, we advise 
to remove any fluid on the measuring area of the GI mucosa before performing VLS 
measurements.
In Chapter 7 we performed a feasibility study of a novel promising technique to 
measure mitochondrial oxygen levels during upper GI endoscopy: delayed fluorescence 
measurements of 5-aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX). This 
study in healthy volunteers shows that measurement of oxygen-dependent delayed 
fluorescence during upper GI endoscopy is feasible and we detected an oxygen-
dependent signal. We determined a dose of 5mg/kg ALA as optimal and the duodenal 
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bulb and descending duodenum as suitable measurement locations. Administration of 
butylscopolamine during the procedure did not influence the measured values.
THERAPY
Part III discusses various therapeutic elements of CMI with focus on endovascular 
revascularization. Chapter 8 describes a study protocol for a multicenter randomized 
controlled trial on covered stents versus bare-metal stents for CMI to prospectively 
confirm the superior patency of covered stents over bare-metals stents for 
atherosclerotic CMI, as suggested by a retrospective cohort study.
In Chapter 9 we evaluated the long-term clinical success rates of revascularization of 
single vessel disease based on vascular disease of the CA or SMA in a retrospective 
cohort analysis. We show persistent symptom relief in 73% of patients diagnosed with 
CMI based on single vessel disease with GI symptoms and VLS or tonometry confirmed 
mucosal ischemia.
Non-coronary endovascular interventions are performed with trans-brachial access 
(TBA) or trans-femoral access (TFA). However, coronary literature shows lower major 
access-site complication rates for trans-radial access (TRA) than for TBA and for TFA with 
similar procedural and clinical outcomes. In Chapter 10.1 we assessed the feasibility and 
safety of TRA compared to TFA and TBA for mesenteric arterial procedures. We show 
that TRA is a safe and feasible approach for mesenteric arterial procedures comparable 
to TFA, whereas TBA shows a significantly higher major complication rate. In Chapter 
10.2. however, we describe a severe complication of a TRA procedure. Brachiocephalic 
stent placement was performed in a young female patient per TRA complicated by total 
rupture of the radial artery.
Intra-arterial pressure measurements during coronary artery procedures are performed 
to define the clinical significance of a coronary artery stenosis. We performed in Chapter 
11 a cohort study to assess the feasibility of intra-arterial pressure measurements 
for definition of a clinical significant mesenteric arterial stenosis. We show that 
clinical significance of a mesenteric arterial stenosis can be predicted using pressure 
measurements.
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In Part IV we summarize the main findings of this thesis in Chapter 12.1 and provide 
an overall discussion in Chapter 12.2. Furthermore, directions for future research are 
provided in Chapter 12.3 and the last part of the thesis ends with the overall conclusion 
(Chapter 12.4).
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This thesis aims to provide insights in different aspects of the diagnosis and therapy of 
CMI to optimize the diagnostic work-up and therapy for this specific patient group. A 
general limitation of this thesis is that the studies are single-center and performed in a 
CMI specialized center, which could potentially limit the generalizability of the results. 
One study (Chapter 3) is a multicenter study performed in collaboration with another 
Dutch CMI specialized center, Medical Spectrum Twente.
DIAGNOSIS OF CMI
Symptoms and characteristics of CMI patients
The typical characteristics of CMI patients as described in current literature are 
female preponderance with a high prevalence of atherosclerotic risk factors as 
hypercholesterolemia, smoking history and CVD history(1, 2). Table 1 shows the 
characteristics of the CMI patients included in this thesis (Chapter 3, Chapter 5, Chapter 
9 and Chapter 11) which confirm current literature data. In Chapter 3 we show that 
independent characteristics predictive of CMI are the presence of weight loss, presence 
of CVD, degree of CA stenosis and degree of SMA stenosis. In this series female gender 
was not an independent predictor of CMI.
Symptoms such as postprandial abdominal pain or exercise induced abdominal pain 
are also not independent predictors in a population of patients suspected of having 
CMI, since the prevalence of postprandial abdominal pain is also high in patients 
without CMI. The only symptom with discriminative ability for the diagnosis of CMI 
is the presence of weight loss. This finding confirms the European Society of Vascular 
Surgery (ESVS) guideline, in which is stated that if substantial weight loss is absent in 
a patient suspected of CMI, further investigations for an alternative diagnosis should 
be performed(3).
Literature shows that patients with atherosclerotic CMI most likely have atherosclerosis 
on other sites as well, e.g. coronary artery disease, peripheral artery disease(2, 4). The 
prevalence of CVD in patients with CMI in our clinical studies was high varying from 
49% - 73% (Table 1) and the presence of CVD was a predictor for the score chart of CMI 
as described in Chapter 3.
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Table 1. Characteristics of CMI patients described in this thesis.
CMI patients
Cohort 
Chapter 3
n=93
CMI patients
Cohort 
Chapter 5
n=23
CMI patients
Cohort 
Chapter 9
n=37
CMI patients
Cohort 
Chapter 11
n=28
Patient characteristics
Age (y) 65.8±14.4 60.7±15.6 65.3±10.9 68.5±10.7
Female 62.4% 47.8% 54.1% 60.7%
Hypertension* 66.7% 65.2% 29.7% 55.6%
Ever smoked 85.9% 78.3% 63.9% 96.3%
Dyslipidemia# 67.4% 59.1% 27.8% 51.9%
Diabetes 26.9% 26.1% 8.1% 18.5%
BMI at presentation (kg/m2) 23.5±5.1 24.0±4.6 20.7±5.0 23.3±5.3
History of CVD 73.1% 60.9% 48.6% 71.4%
Presenting symptoms
Symptom duration (months) 18.0±31.4 21.3±36.8 35.3±67.8 11.3±8.3
Abdominal pain 94.6% 91.3% 94.6% 92.9%
Postprandial pain 70.7% 91.3% 70.3% 67.9%
Exercise related pain 28.7% 36.4% 48.6% 25.0%
Nausea 60.0% 39.1% 45.9% 57.9%
Diarrhea 36.8% 17.4% 18.9% 44.4%
Weight loss 81.7% 56.5% 73.0% 59.3%
Data are presented as N (percentages) or as mean ± SD. *Hypertension was defined as a blood pressure 
of ≥140/90 mmHg or use of antihypertensive medication. #Dyslipidemia was defined as LDL-C >4.2 
mmol/L or HDL-C <0.9 mmol/L or use of lipid lowering medication.
CMI = chronic mesenteric ischemia; BMI = body mass index; CVD = cardiovascular disease.
VLS
In 2004 Benaron et al. published the first study on endoscopic VLS measurements in 10 
patients undergoing upper GI endoscopy(5). They demonstrated the feasibility of VLS 
measurements to measure oxygen saturation during endoscopy and they demonstrated 
that VLS was a sensitive technique to show hypoxia(5). In 2007 Friedland et al. published 
a preliminary study on the use of VLS to detect GI ischemia(6). They performed VLS 
measurements in 30 healthy volunteers and 3 patients with CMI. The reported normal 
oxygen saturation in the duodenum and jejunum was 60-73% and the saturation of 
ischemic areas was 16-30% increasing to 51-60% after revascularization. In 2011 van 
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Noord et al. published a prospective cohort study of 121 patients suspected of CMI and 
determined the diagnostic accuracy of VLS during upper GI endoscopy for the detection 
of GI ischemia(7). Cut-off values for GI ischemia were determined: antrum of the 
stomach <63%, duodenal bulb <62% and descending duodenum <58%. The sensitivity 
of these cut-off values for CMI is 90% and the specificity is 60%. Since the publication 
of van Noord et al., VLS is used in clinical practice for the diagnostic work-up of CMI.
The study by Friedland et al. demonstrated that the VLS-measurements are easy to 
perform without a steep learning curve and with a good interobserver reliability with 
an average absolute difference of 2% between an experienced VLS endoscopist (>200 
cases) versus a limited experienced VLS endoscopist (<10 cases)(6). However, both 
interobserver and intraobserver reliability had not been determined at that time. We 
show in Chapter 4 a fair to good observer reliability of VLS during upper GI endoscopy 
with, as expected, a better intraobserver reliability than interobserver reliability.
Further validation of endoscopic VLS measurements was performed in Chapter 6 
in a porcine model study. We compared VLS measurements with calibrated μPO
2 
measurements and show an inverse relationship of the mucosal oxygen saturation 
measurements by VLS with FiO
2
. Furthermore, we show that VLS still measured a 
reasonable oxygen saturation 25 minutes after asystole. These findings confirm the 
idea that VLS measures mixed venous oxygen saturation instead of the mucosal capillary 
hemoglobin oxygen saturation. It is not known whether the mixed venous oxygen 
saturation is reliable to assess ischemia of the GI tract.
Spectros, the manufacturer of the T-Stat 303 Microvascular Oximeter, states that the 
measurement surface must be cleaned of any bile remnants since these will influence 
the measured VLS values. The exact influence of bile on the VLS values was not 
investigated yet. We show in Chapter 6 a significant influence of different bile mixtures 
on the measured VLS values. The exact influence, an increase of the measured VLS 
values or a decrease of the measured VLS values, was dependent of the sort of bile 
mixture present (porcine bile mixture from the stomach or from the small bowel). Our 
results assume that the exact content of the bile and also the amount of bile present and 
the thickness of the bile layer influence the light absorption by the bile and subsequently 
effect the measured VLS value. Our results confirm the advice to remove any fluid on 
the measurement surface before performing the VLS measurements.
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In Chapter 5 we assessed the hypothesis that VLS measurements after a meal would 
have a higher discriminative ability for the diagnosis of CMI than VLS measurements in 
fasting state, since CMI patients are usually symptomatic after a meal due to increased 
oxygen demand. Surprisingly, we found that postprandial VLS measurement do not 
provide additional discriminative ability for the diagnosis of CMI. Possibly, this result 
is also an effect of the finding in Chapter 6 that VLS measures mixed venous oxygen 
saturation instead of the mucosal capillary hemoglobin oxygen saturation. Most 
likely, postprandial hyperemia has less influence on the oxygen level of the venous 
compartment than on the oxygen level of the microvascular arterial compartment.
Table 2 shows an overview of the reported normal values of VLS measurements in the 
literature and Table 3 shows the reported VLS values in patients with CMI in literature. 
The two studies of van Dijk et al. are part of this thesis (Chapter 4 and Chapter 5). 
The overall trend shown in Table 2 and Table 3 is that VLS values are lower in the 
distal part of the upper GI tract. However, the normal values provided in the early 
publications of Benaron et al.(5) and Friendland et al.(6) are higher than those found 
by our group(8, 9) (Table 2). A hypothesis could be that normal values for GI mucosal 
saturation are age related and possibly comorbidity related. In Chapter 5 we performed 
VLS measurements in healthy controls (mean age 35.2 ± 8.1 years, smoking 43.8%, 
dyslipidemia 0.0%, diabetes 0.0%, no presenting symptoms, hypertension 6.3% and 
0.0% history of CVD) and no-CMI patients (mean age 59.1±13.2 years, smoking 81.1%, 
dyslipidemia 40.5%, diabetes 13.5%, presenting symptoms as abdominal pain 86.5% 
and weight loss 64.9%, hypertension 43.2% and 35.1% history of CVD). The preprandial 
mucosal oxygen saturation levels between the healthy controls and no-CMI patients 
were not significantly different in any of the three measurements locations, which did 
not confirm the hypothesis that normal values for GI mucosal saturation are age related 
and possibly comorbidity related.
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Table 2. Overview of described normal values of endoscopic VLS in literature.
Antrum Duodenal bulb Descending 
duodenum
Benaron et al. 2004(5)
Control patients
70 (4)
n=5
- 71 (3)
n=10
Friedland et al. 2007(6)
Healthy controls and no-CMI patients
72 (4)
n=30
- 66 (5)
n=25
Van Noord et al. 2011(7)
No-CMI patients
66 (4)
n=30
62 (5)
n=29
59 (5)
n=31
Van Dijk et al. 2018(8)
Control patients
61 (4)
n=24
56 (4)
n=24
53 (4)
n=24
Van Dijk et al. 2019(9)
Healthy controls
62 (60-65)
n=16
58 (54-63)
n=16
54 (49-56)
n=16
Van Dijk et al. 2019(9)
no-CMI patients
61 (60-63)
n=37
58 (55-60)
n=37
55 (51-57)
n=37
VLS measurements in percentages described as mean (SD) or median (interquartile range).
Table 3. Overview of described ischemic values of endoscopic VLS in literature.
Antrum Duodenal bulb Descending 
duodenum
Van Noord et al. 2011(7) 63.4 (4.8)
n=85
59.3 (4.9)
n=80
53.9 (6.2)
n=89
Van Dijk et al. 2019(9) 59 (55-62)
n=23
54 (51-58)
n=23
51 (48-53)
n=23
VLS measurements in percentages described as mean (SD) or median (interquartile range)
In conclusion, we determined several limitations of endoscopic VLS measurements 
for the diagnosis of CMI: 1. VLS seems to measure the mixed venous oxygen 
saturation rather than the mucosal capillary hemoglobin oxygen saturation, 2. the 
measurement location for VLS should be free of any bile fluids since bile influences the 
measurement values, 3. peristaltic movements influence the VLS measurements and 
4. the discriminatory value of VLS is not improved in a postprandial state. Given these 
limitations and a sensitivity of 90% and a specificity of 60% for CMI, there is a need for 
a new easy-to-use and reliable functional test to detect GI ischemia.
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Functional test to assess GI ischemia: what’s on the horizon?
In Chapter 7 we show that measurements of oxygen-dependent delayed fluorescence 
of ALA-induced PpIX during upper GI endoscopy are feasible and safe. We demonstrated 
measurements of an oxygen dependent signal during upper GI endoscopy in healthy 
volunteers. The next step would be to perform these endoscopic measurements in 
patients suspected of CMI to assess the discriminative ability of oxygen-dependent 
delayed fluorescence of ALA-induced PpIX measurements for the diagnosis of CMI. 
Furthermore, measurements during enteroscopy could be performed to assess mucosal 
ischemia of the small bowel vascularized by the SMA. Since upper GI endoscopy is 
usually performed in the diagnostic work-up for CMI to exclude other diagnosis as peptic 
ulcer, a functional test performed during upper endoscopy is not invasive for the patient. 
In contrast, pressure measurements performed during DSA as described in Chapter 11 
are not eligible to include in the standard diagnostic work-up for patients suspected 
of CMI, since DSA is an invasive investigation, currently reserved for the patients with 
a consensus diagnosis of CMI. Pressure measurements may have additional value to 
guide clinical decision-making during a DSA procedure, especially in case of single vessel 
disease or a mesenteric stenosis of 50-70%.
If endoscopic oxygen-dependent delayed fluorescence of ALA-induced PpIX 
measurements have shown to be discriminative for the diagnosis of CMI, the technique 
can be further refined. Endoscopic oxygen-dependent delayed fluorescence of ALA-
induced PpIX measurements have the potential to become the new functional test for 
detection of mucosal ischemia.
THERAPY FOR CMI
Covered stents versus bare-metal stents
In Chapter 8 we present a study protocol for a multicenter randomized controlled trial in 
patients with atherosclerotic CMI to compare covered stents versus standard care bare-
metal stents. Oderich et al.(10) show better patency rates for covered stents than bare-
metal stents in their retrospective cohort study. However, prospective confirmation is 
needed to issue any recommendations for the use of covered stents as standard care 
in atherosclerotic CMI patients. For long mesenteric arterial stenosis the covered stent 
is not applicable since the covered stent will obstruct blood flow when mesenteric 
side-branches are over-stented. However, mesenteric arterial stenoses are often ostial 
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stenoses(11, 12). Furthermore, this trial will generate data on the quality of life of CMI 
patients at baseline and after revascularization. Quality of life studies are currently 
lacking in literature for patients with CMI.
Single vessel
Revascularization in mesenteric multi-vessel disease is generally accepted, however 
controversy exists on single vessel disease. The presence of a large mesenteric collateral 
network should prevent symptomatic disease from single vessel stenosis. However, we 
show in Chapter 9 that symptomatic single vessel disease does exist. The challenge is to 
select those patients with single vessel disease who will benefit from revascularization. 
We show that 73% of revascularized patients with single vessel atherosclerotic disease 
of the CA or SMA with GI symptoms and confirmed mucosal ischemia experienced long-
term symptom relief. Given the increase in abdominal imaging and as a consequence 
an increase in incidentally discovered single vessel mesenteric disease this is a relevant 
finding for clinical practice. When a single vessel mesenteric arterial stenosis based 
on atherosclerosis is incidentally discovered and a patient reports GI symptoms, 
mucosal ischemia has to be confirmed before revascularization. This should lead to 
less overtreatment in this patient group.
Approach of endovascular mesenteric intervention
Current guidelines state that TBA and TFA are the approaches for mesenteric arterial 
interventions. Given the positive experience of TRA in coronary artery interventions we 
described in Chapter 10.1 a retrospective cohort study comparing TRA with TBA and TFA 
for mesenteric arterial interventions. We show that TRA is a feasible and safe approach, 
comparable with TFA. TBA shows significantly more major complications. Given the 
retrospective design of the study, prospective confirmation is needed, preferably 
through a randomized controlled trial. Posham et al.(13) published in 2016 a large 
retrospective cohort study of 1,512 non-coronary endovascular procedures per TRA, 
including mesenteric arterial procedures. Their study shows that TRA is safe and well-
tolerated for non-coronary interventions, however they did not specify their results 
for mesenteric arterial interventions. They performed TRA according the description 
of Fischman et al.(14). The occurrence of a severe complication during a TRA procedure 
as described in Chapter 10.2 resulted in the fact that now in every patient planned for 
TRA a radial artery (RA) diameter assessment using ultrasound is performed. Since 
diameter assessment of the RA using ultrasound was not described in the publication 
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of Fischman et al.(14), it should be added to the standard procedure to prevent severe 
complications such as a total rupture of the RA.
Pressure measurements
Intra-arterial pressure measurements are used during coronary artery interventions 
to define the clinical significance of a coronary artery stenosis. In Chapter 11 we 
assessed the feasibility of intra-arterial pressure measurements to define a clinical 
significant mesenteric arterial stenosis. We show that mesenteric intra-arterial pressure 
measurements are able to predict the clinical significance of a stenosis. Since consensus 
on the use of pressure measurements for mesenteric stenosis is lacking, this study is the 
first step in defining cut-off values of pressure measure measurements to guide clinical 
decision making. We propose a cut-off value based on our cohort analysis, however this 
needs to be confirmed prospectively.
As mentioned before, pressure measurements will not be added to the standard 
diagnostic work-up of CMI suspected patients, given the invasive character of the 
measurements. Pressure measurements are reserved for those patients with a 
consensus diagnosis of CMI who are planned for angiography to guide the decision of 
performing revascularization of a mesenteric vessel or not.
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The level of evidence for recommendations on the clinical management of CMI is 
low, since literature specific on CMI is scarce and prospective cohort studies and 
randomized controlled trials with sufficient patient numbers are lacking. Recently, three 
guidelines for CMI management have been published: a clinical practice guideline of 
the ESVS(3), criteria on radiological management by the American College of Radiology 
(ACR)(15) and quality improvement guidelines for endovascular revascularization by 
the Society of Interventional Radiology (SIR)(16). Multidisciplinary guidelines on CMI 
are awaited in 2020 from United European Gastroenterology (UEG), in collaboration 
with European Association for Gastroenterology, Endoscopy and Nutrition (EAGEN), 
European Society of Gastrointestinal and Abdominal Radiology (ESGAR), Cardiovascular 
and Interventional Radiological Society of Europe (CIRSE), Netherlands Association of 
Hepatogastroenterologists (NVMDL), Hellenic Society of Gastroenterology (HSG) and 
Dutch Mesenteric Ischemia Study group (DMIS). Specific topics for future research on 
CMI are summarized in this chapter.
DIAGNOSIS
The most important limitation of clinical studies on CMI is the absence of a gold 
standard test to diagnose CMI. A definitive diagnosis of CMI is currently established 
when symptom relief is reported after technically successful therapy for CMI. However, 
symptom relief is a subjective outcome and only patients with a consensus diagnosis of 
CMI are eligible for therapy. Furthermore, the current diagnostic work-up is cumbersome 
and time-consuming. Several diagnostic investigations have to be performed for every 
patient suspected of CMI. Therefore, the quest for a gold standard test to diagnose CMI 
is the most important topic for research on CMI. When a potential functional test has 
been discovered, the discriminative ability of this potential test has to be validated in 
patients suspected of CMI. Also the test must be performed before and after successful 
therapy to demonstrate the ability of the test to detect improvement after therapy.
In Chapter 4, Chapter 5 and Chapter 6 we validated the currently used functional test 
VLS. We concluded that VLS measures the mixed venous compartments and further 
research is needed to establish whether GI ischemia is optimally assessed by mucosal 
hemoglobin saturation of the mixed venous compartment.
In Chapter 7 we performed a pilot study of a novel promising technique to measure 
oxygen levels in the cells of the GI tract during upper GI endoscopy. We show that 
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the ALA-induced PpIX measurements performed during upper endoscopy are feasible, 
oxygen dependent and safe. Further research needs to be conducted to assess if 
the ALA-induced PpIX measurements have discriminative ability for CMI patients 
and to define site specified cut-off values for GI mucosal ischemia. Furthermore, 
calibrations constants in the human GI tract are unknown and therefore we presented 
our measurements as reciprocal lifetimes 1/τ (μs-1). The assessment of calibrations 
constants for the human gastro-duodenal tract will result in presentation of the 
measurements in a more general and better comparable and understandable unit as 
mmHg. Our pilot-study shows very short delayed fluorescent lifetimes in the gastric 
antrum, possibly due to the histological composition and function of the gastric antrum 
mucosa which interferes with the excitation light of the delayed fluorescent signal. The 
ability of these cells to accumulate PpIX might be lower due to a relatively slow cellular 
turnover compared to the duodenal mucosal cells which results in unreliable short 
lifetimes. This hypothesis should be studied in the future. Furthermore, the design of 
the endoscopic probe could be improved by developing a pressure sensor on the probe 
tip, to avoid unintended application of pressure on the GI mucosa while measuring. 
Finally, the optimal excitation wavelength for measurements in the GI tract could be 
determined. We used 515 nm wavelength since this wavelength is used by the COMET 
device.
Mesenteric blood flow measurements performed by magnetic resonance (MR) imaging 
could be a useful functional test for CMI. Several studies performed mesenteric blood 
flow measurements with MRI both in fasting state and post-prandial state in healthy 
volunteers and CMI patients(17-21). Physiologically, the flow in the mesenteric vessels 
increases after a meal referred to as hyperemia. However, this increase in post-prandial 
flow compared to pre-prandial appears to be less pronounced in CMI patients compared 
to the healthy volunteers. In some CMI patients, even a decrease of the post-prandial 
blood flow compared to the pre-prandial blood flow was observed. MR blood flow 
measurements after food stimulation might be able to distinguish patients with CMI 
from patients without CMI. A clinical study, including patients suspected of CMI, is 
currently performed by our group using this MR blood flow measurement technique 
in fasting state and after the intake of nutritional drink.
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A simple blood test to determine a CMI specific biomarker would be the ultimate goal 
for the diagnosis of CMI. A sensitive and specific biomarker in blood however is currently 
not yet identified.
Currently, validated questionnaires specific for CMI do not exist. Future research on 
CMI would also be more accurate and reliable if CMI reporting standards would be 
developed and validated, along with specific CMI patient reported outcome measures 
(PROMs). 
In Chapter 3 an updated version of the prediction model for CMI is presented. Further 
research on this topic would consists of prospective validation of this updated version 
of the prediction model in a new multicenter cohort and assessment of the cost-
effectiveness of the model used with the proposed risk stratified strategy.
Finally, literature on chronic NOMI is scarce. Studies in these patients are needed to 
better understand this entity and to improve diagnostic and therapeutic strategies.
THERAPY
The protocol for a multi-center randomized controlled trial of covered versus bare-
metal stents is described in Chapter 8. The CoBaGI trial is performed by our group 
and inclusion has currently been completed. The two-years follow-up period after 
stent-placement has to be awaited before the final results can be published. We 
hypothesized that covered stents will have better patency rates than bare metal stents. 
If our hypothesis is confirmed, covered stents will become standard of care in the 
future. The CoBaGI trial will also provide data on the quality of life of CMI patients and 
cost-effectiveness. Further research topics on endovascular therapy of CMI will be the 
assessment of the best strategy for in-stent stenosis: covered stent placement or PTA 
alone, follow-up strategy after revascularization to detect in-stent stenosis (routine 
radiologic assessment or symptom driven radiologic assessment) and assessment of 
anti-platelet strategy for mesenteric interventions, since consensus on anti-platelet 
strategy is lacking for this specific patient group.
We show in Chapter 10 that radial approach of mesenteric endovascular interventions 
is feasible and safe. Since we performed a retrospective cohort study, prospective 
confirmation of our results is needed. A randomized controlled trial comparing brachial, 
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femoral and radial approach would be the most ideal design. Besides technical success 
rate and complication rate, other outcome measures to include in such a study are 
procedure time, radiation exposure and the amount of contrast agents used.
Interventional cardiologists use intravascular pressure measurements to guide 
treatment decisions. We show in Chapter 11 that pressure measurements during 
mesenteric endovascular interventions are feasible to perform and predictive of clinical 
response. We suggest cut-off values but these need to be validated.
In Chapter 9 we show that a single vessel mesenteric stenosis may cause symptomatic 
disease and that if the patients are selected carefully, 73% of the treated patients 
will experience symptom relief after successful revascularization. Since this was a 
retrospective cohort study, prospective confirmation, preferably by others, is needed. 
Furthermore, our cohort study consisted of patients with single vessel stenosis based 
on atherosclerosis. Future studies with inclusion of patients with single vessel disease 
based on MALS would of interest, since the existence of MALS is a debate in literature.
DUTCH MESENTERIC ISCHEMIA STUDY GROUP (DMIS)
Multicenter, multidisciplinary 
collaboration is needed to 
perform high quality studies 
on CMI. The Dutch Mesenteric 
Ischemia Study group (DMIS) 
is a Dutch multicenter and 
multidisciplinary study group with focus on mesenteric ischemia. The DMIS is founded 
in 2015. The aim of the DMIS is to improve diagnostics, therapy and medical care 
for patients with acute and chronic mesenteric ischemia through scientific research, 
consultation and centralization. The most important features of the DMIS are: 
multidisciplinary collaboration, multicenter studies, joint discussion about study 
protocols and joint publication with inclusion of all participating hospitals. Twice a year, 
a study group meeting is organized in Utrecht. On the map (Figure 1) the centers on the 
DMIS mailing list are shown and the centers with a red bullet are actively participating 
in a clinical trial at the moment. Publications described in this thesis on behalf of the 
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DMIS are the validation of the score chart to predict the risk of CMI (Chapter 3), the 
review on the clinical management of CMI (Chapter 1.1 is based on this publication) 
and the protocol for the multicenter randomized controlled trial of covered versus 
bare-metals stents (Chapter 8).
Figure 1. Map of the Netherlands showing all centers on the DMIS mailing list. The centers with 
a red bullet are actively participating in a clinical trial at the moment.
Several clinical studies and projects are currently pursued by the DMIS. First, a 
randomized controlled trial on celiac artery release versus sham procedure for patients 
with MALS (CARoSO) is under construction, to finally end the debate on the existence 
of MALS. Second, a single-center study on pre-prandial and postprandial MR blood 
flow measurements for the diagnosis of CMI is currently performed by our center, 
however multicenter implementation by the DMIS would accelerate the inclusion 
and increase the generalizability of the results. Thereby, endoscopic ALA-induced 
PpIX measurements in patients suspected of CMI will be added to the study protocol 
to assess the discriminative ability of these measurements for the diagnosis of CMI. 
Furthermore, the DMIS is implementing a patient registry and biobank initiative for 
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mesenteric ischemia patients. Finally, the DMIS was one of the initiators of the up-
coming CMI guidelines of the UEG.
Conclusion future perspectives
The perfect future for research on CMI would be a time in which well-designed, high 
quality, clinical studies are conducted, prospective and if applicable in a randomized 
controlled setting, under the auspician of a multicenter, multidisciplinary (international) 
study group. Such studies should aim to find and validate a new functional test eligible 
as gold standard test for diagnosis of CMI and to determine the best therapeutic 
strategy for CMI patients in an evolving field of therapeutic innovative developments. 
The DMIS was established with exactly those goals in mind.
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CONCLUSION
The incidence of CMI is increasing and is expected to increase even further the 
upcoming years due to the aging population. The current diagnostic work-up of CMI 
is cumbersome and time-consuming, due to the absence of a specific test. Literature 
on different aspects of therapy specific for CMI is scarce. This thesis aims to provide 
insights in different aspects of the diagnosis and therapy of CMI to optimize the 
diagnostic work-up and therapy for this specific patient group. We validated a score 
chart to predict the risk of CMI and developed an update of the prediction model with 
inclusion of the cause of CA stenosis to stratify patients suspected of CMI in a low-
risk, intermediate-risk and high-risk group to guide clinical decision making. We show 
that VLS measurements during upper GI endoscopy are reproducible with a fair to 
good observer reliability with intraobserver reliability being better than interobserver 
reliability. Since VLS measurements are performed in fasting state and CMI patients 
are mostly symptomatic after a meal due to increased oxygen demand, we performed 
VLS measurements after luminal feeding to determine the discriminative ability of 
postprandial VLS measurements. We show that postprandial VLS measurements have 
no added benefit for the diagnosis of CMI. Furthermore, we show that VLS measures the 
mixed venous hemoglobin oxygen saturation and not the mucosal capillary hemoglobin 
oxygen saturation and that the presence of bile significantly influenced the measured 
VLS values. Given the limitations of VLS for the diagnosis of CMI, we performed a 
feasibility study of a novel promising technique to measure mitochondrial oxygen levels: 
delayed fluorescence measurements of ALA-induced PpIX. We demonstrate that this 
technique is feasible and safe to perform during upper GI endoscopy and we detected 
an oxygen-dependent signal with this technique. In the part of the thesis on therapy 
for CMI we presented a study protocol for a multicenter randomized controlled trial on 
covered stents versus bare-metal stents for atherosclerotic CMI. Furthermore, we show 
in a retrospective cohort analysis that revascularization of single vessel disease of the CA 
or SMA in patients with GI symptoms and confirmed mucosal ischemia resulted in long-
term symptom relief in 73% of patients. We assessed the feasibility and safety of TRA 
for mesenteric arterial endovascular procedures compared to TFA and TBA and show 
that TRA is a feasible and safe approach comparable to TFA. TBA was associated with a 
significantly higher major complication rate. We described one severe complication of 
a TRA procedure complicated by a total rupture of the RA. Finally, we show that intra-
arterial pressure measurements performed during angiography are able to predict 
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the clinical significance of a mesenteric arterial stenosis. In conclusion, research on 
diagnosis and treatment for CMI is evolving. However collaboration in multicenter 
and multidisciplinary study groups is needed to conduct high-quality research with 
prospective inclusion of sufficient patient numbers.
12.4
300
Chapter 12.4
REFERENCES
1. Mensink PB, Moons LM, Kuipers EJ. Chronic gastrointestinal ischaemia: shifting paradigms. 
Gut. 2011;60(5):722-37.
2. Sana A, van Noord D, Mensink PB, Kooij S, van Dijk K, Bravenboer B, et al. Patients with 
chronic gastrointestinal ischemia have a higher cardiovascular disease risk and mortality. 
Atherosclerosis. 2012;224(1):235-41.
3. Bjorck M, Koelemay M, Acosta S, Bastos Goncalves F, Kolbel T, Kolkman JJ, et al. Editor’s 
Choice - Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice 
Guidelines of the European Society of Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 
2017;53(4):460-510.
4. Veenstra RP, ter Steege RW, Geelkerken RH, Huisman AB, Kolkman JJ. The cardiovascular 
risk profile of atherosclerotic gastrointestinal ischemia is different from other vascular 
beds. Am J Med. 2012;125(4):394-8.
5. Benaron DA, Parachikov IH, Friedland S, Soetikno R, Brock-Utne J, van der Starre PJ, et al. 
Continuous, noninvasive, and localized microvascular tissue oximetry using visible light 
spectroscopy. Anesthesiology. 2004;100(6):1469-75.
6. Friedland S, Benaron D, Coogan S, Sze DY, Soetikno R. Diagnosis of chronic mesenteric 
ischemia by visible light spectroscopy during endoscopy. Gastrointestinal endoscopy. 
2007;65(2):294-300.
7. Van Noord D, Sana A, Benaron DA, Pattynama PM, Verhagen HJ, Hansen BE, et al. 
Endoscopic visible light spectroscopy: a new, minimally invasive technique to diagnose 
chronic GI ischemia. Gastrointestinal endoscopy. 2011;73(2):291-8.
8. van Dijk LJD, van der Wel T, van Noord D, Moelker A, Verhagen HJM, Nieboer D, et al. 
Intraobserver and interobserver reliability of visible light spectroscopy during upper 
gastrointestinal endoscopy. Expert Rev Med Devices. 2018;15(8):605-10.
9. van Dijk LJD, Harki J, van Noord D, de Vries AC, Moelker A, Verhagen HJM, et al. Detection 
of mesenteric ischemia by means of endoscopic visible light spectroscopy after luminal 
feeding. Gastrointestinal endoscopy. 2019;89(1):94-102.
10. Oderich GS, Erdoes LS, Lesar C, Mendes BC, Gloviczki P, Cha S, et al. Comparison of covered 
stents versus bare metal stents for treatment of chronic atherosclerotic mesenteric arterial 
disease. Journal of vascular surgery. 2013;58(5):1316-23.
11. Landis MS, Rajan DK, Simons ME, Hayeems EB, Kachura JR, Sniderman KW. Percutaneous 
management of chronic mesenteric ischemia: outcomes after intervention. J Vasc Interv 
Radiol. 2005;16(10):1319-25.
12. Sheeran SR, Murphy TP, Khwaja A, Sussman SK, Hallisey MJ. Stent placement for treatment 
of mesenteric artery stenoses or occlusions. J Vasc Interv Radiol. 1999;10(7):861-7.
301
Conclusion
13. Posham R, Biederman DM, Patel RS, Kim E, Tabori NE, Nowakowski FS, et al. Transradial 
Approach for Noncoronary Interventions: A Single-Center Review of Safety and Feasibility 
in the First 1,500 Cases. J Vasc Interv Radiol. 2016;27(2):159-66.
14. Fischman AM, Swinburne NC, Patel RS. A Technical Guide Describing the Use of Transradial 
Access Technique for Endovascular Interventions. Tech Vasc Interv Radiol. 2015;18(2):58-65.
15. Fidelman N, AbuRahma AF, Cash BD, Kapoor BS, Knuttinen MG, Minocha J, et al. ACR 
Appropriateness Criteria((R)) Radiologic Management of Mesenteric Ischemia. Journal of 
the American College of Radiology : JACR. 2017;14(5s):S266-S71.
16. Pillai AK, Kalva SP, Hsu SL, Walker TG, Silberzweig JE, Annamalai G, et al. Quality Improvement 
Guidelines for Mesenteric Angioplasty and Stent Placement for the Treatment of Chronic 
Mesenteric Ischemia. J Vasc Interv Radiol. 2018;29(5):642-7.
17. Burkart DJ, Johnson CD, Ehman RL. Correlation of arterial and venous blood flow in the 
mesenteric system based on MR findings. 1993 ARRS Executive Council Award. AJR Am J 
Roentgenol. 1993;161(6):1279-82.
18. Naganawa S, Cooper TG, Jenner G, Potchen EJ, Ishigaki T. Flow velocity and volume 
measurement of superior and inferior mesenteric artery with cine phase contrast magnetic 
resonance imaging. Radiat Med. 1994;12(5):213-20.
19. Li KC, Whitney WS, McDonnell CH, Fredrickson JO, Pelc NJ, Dalman RL, et al. Chronic 
mesenteric ischemia: evaluation with phase-contrast cine MR imaging. Radiology. 
1994;190(1):175-9.
20. Li KC, Hopkins KL, Dalman RL, Song CK. Simultaneous measurement of flow in the superior 
mesenteric vein and artery with cine phase-contrast MR imaging: value in diagnosis of 
chronic mesenteric ischemia. Work in progress. Radiology. 1995;194(2):327-30.
21. Dalman RL, Li KC, Moon WK, Chen I, Zarins CK. Diminished postprandial hyperemia in 
patients with aortic and mesenteric arterial occlusive disease. Quantification by magnetic 
resonance flow imaging. Circulation. 1996;94(9 Suppl):II206-10.
12.4
CHAPTER
A
Appendices
304
Nederlandse  samenvatting
NEDERLANDSE SAMENVATTING
Dit proefschrift heeft tot doel inzicht te verschaffen in de verschillende aspecten van 
de diagnose en de behandeling van chronische mesenteriaal ischemie (CMI) om zo 
de diagnose en de behandeling voor deze patiëntengroep te optimaliseren. De ziekte 
CMI wordt geïntroduceerd in Deel I met een overzicht van de definitie, epidemiologie, 
etiologie, klinische presentatie, diagnostiek, therapie en klinische uitkomst van CMI en 
de anatomie van de mesenteriale vasculatuur in Hoofdstuk 1.1, gevolgd door de doelen 
en de opzet van de thesis in Hoofdstuk 1.2.
Diagnose
In Deel II worden de verschillende aspecten van de huidige diagnostische work-up 
voor CMI en strategieën en inzichten om de diagnostiek te optimaliseren besproken. 
In Hoofdstuk 2 wordt een overzicht van de huidige beeldvormende modaliteiten voor 
de mesenteriale vasculatuur zoals duplex echografie, computer tomografie angiografie, 
magnetische resonantie angiografie en digitale substractie angiografie gegeven. 
Hoofdstuk 3 beschrijft de externe validatie van een predictiemodel, reeds gepubliceerd 
door onze studiegroep, om het risico op CMI in te schatten op basis van 5 eenvoudige 
voorspellers (vrouwelijk geslacht, aanwezigheid van gewichtsverlies, aanwezigheid van 
hart- en vaatziekten (HVZ), mate van stenose van de arteria coeliacus (AC); en mate 
van stenose van de arteria mesenterica superior (AMS). Het huidige predictiemodel 
presteerde goed in het nieuwe validatie cohort. Deskundigen op het gebied van CMI 
betwistten echter de afwezigheid van de etiologie van de AC-stenose (median arcuate 
ligament syndrome, atherosclerose) als voorspeller in het gepubliceerde predictiemodel. 
Daarom hebben we het model aangepast op basis van de prestatie van het model in het 
gecombineerde originele en validatiecohort (totaal 666 patiënten verdacht van CMI), 
waarbij we nu wel de oorzaak van AC-stenose hebben meegenomen. Dit ge-update 
model bestaat uit de voorspellers: aanwezigheid van gewichtsverlies, aanwezigheid 
van HVZ, mate van AC-stenose gecombineerd met de oorzaak van AC-stenose en mate 
van AMS-stenose. Dit ge-update predictiemodel toont een uitstekend onderscheidend 
vermogen met een absoluut laag risico op CMI van 19%, een gemiddeld risico van 45% 
en een hoog risico op CMI van 92%. Het ge-update voorspellingsmodel is een handig 
hulpmiddel wat gebruikt kan worden bij de klinische besluitvorming ten aanzien van 
de diagnostiek. We stellen een afwachtend beleid voor bij de patiënten gestratificeerd 
als laag risico op CMI, bij de patiënten met een gemiddeld risico op CMI stellen we een 
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aanvullende functionele test voor en we stellen onmiddellijke vasculaire interventie 
voor bij de patiënten gestratificeerd als hoog risico op CMI. Deze strategie zou moeten 
leiden tot minder onnodige diagnostische procedures voor patiënten zonder CMI en een 
betere identificatie van patiënten met CMI met snellere behandeling, wat uiteindelijk 
zou moeten leiden tot minder belasting van de patiënt en lagere gezondheidskosten.
Visible light spectroscopy (VLS) uitgevoerd tijdens gastroduodenoscopie wordt in 
de klinische praktijk gebruikt in de diagnostische work-up van CMI. Interobserver en 
intraobserver validatie van endoscopische VLS wordt niet beschreven in de literatuur; 
daarom hebben we een observer validatie onderzoek voor VLS metingen uitgevoerd. We 
tonen in Hoofdstuk 4 aan dat de observer validiteit van VLS redelijk tot goed is, waarbij 
de intraobserver betrouwbaarheid beter is dan de interobserver betrouwbaarheid. 
VLS-metingen tijdens gastroduodenoscopie zijn reproduceerbaar en onze bevindingen 
ondersteunen het gebruik van VLS als onderdeel van de diagnostiek naar CMI.
In Hoofdstuk 5 hebben we gekeken of postprandiale VLS-metingen het onderscheidend 
vermogen van VLS-metingen verhogen omdat CMI-patiënten na een maaltijd meestal 
klachten ervaren door postprandiale hyperemie. Met een prospectieve cohortstudie 
tonen we aan dat postprandiale VLS-metingen het onderscheidend vermogen voor de 
diagnose van CMI niet verhogen ten opzichte van de nuchtere metingen.
Hoofdstuk 6 beschrijft de validatie van de VLS-techniek op basis van 3 experimenten 
in een big studie. Eerst hebben we de VLS-waarden vergeleken met gekalibreerde 
microvasculaire zuurstofspanning (μPO
2
) meetwaarden op verschillende FiO
2
-niveaus. 
We hebben aangetoond dat de VLS-waarden afnemen als de FiO
2
 toeneemt in 
tegenstelling tot de μPO2-waarden die juist toenemen als de FiO
2 
toeneemt waarbij een 
grote spreiding te zien is van de gemeten VLS-waarden en FiO
2
-niveaus met een slechte 
lineaire correlatie. Als tweede hebben we het effect van de aanwezigheid van gal op de 
gemeten VLS-waarden bekeken. We hebben hierbij aangetoond dat de aanwezigheid 
van gal een significante invloed heeft op de gemeten VLS-waarden. Ten slotte hebben 
we de VLS-waarden en μPO
2
-waarden vergeleken tijdens asystolie. We tonen aan dat 
de VLS-waarden, in tegenstelling tot de μPO
2
-waarden, in de eerste 25 minuten na 
asystolie niet dalen naar een waarde van 0. Onze bevindingen ondersteunen het idee 
dat VLS de zuurstofsaturatie van het gemengd veneuze compartiment meet en niet de 
zuurstofsaturatie van het mucosale capillaire compartiment. Gezien het significante 
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effect van de aanwezigheid van gal op de gemeten VLS-waarden, adviseren wij om, 
voordat VLS-metingen worden uitgevoerd, vloeistof op de gastro-intestinale mucosa 
te verwijderen.
In Hoofdstuk 7 hebben we een pilot-studie uitgevoerd van een nieuwe veelbelovende 
techniek om zuurstof te meten op mitochondriaal niveau tijdens gastroduodenoscopie: 
vertraagde fluorescentiemetingen van 5-aminolevulinezuur (ALA) geïnduceerd 
protoporfyrine IX. We tonen met deze studie in gezonde vrijwilligers aan dat 
zuurstofafhankelijke vertraagde fluorescentie metingen uitvoerbaar zijn tijdens 
gastroduodenoscopie en we detecteren met deze techniek een zuurstofafhankelijk 
signaal. We hebben bepaald dat de optimale orale dosis van ALA 5 mg/kg is en dat de 
bulbus en het duodenum descendens geschikt zijn als meetlocaties. Toediening van 
butylscopolamine tijdens de procedure had geen invloed op de gemeten waarden.
Behandeling
Deel III omvat verschillende therapeutische elementen van CMI met de focus op 
endovasculaire revascularisatie. Een retrospectieve cohortstudie heeft aangetoond 
dat de doorgankelijkheid van covered stents beter is dan de doorgankelijkheid van 
bare-metal stents in patiënten met atherosclerotisch CMI. Hoofdstuk 8 beschrijft 
een studieprotocol voor een multicenter gerandomiseerde studie waarin covered 
stents worden vergeleken met bare-metal stents in patiënten met CMI op basis van 
atherosclerose om dit gevonden resultaat prospectief te bevestigen.
In Hoofdstuk 9 hebben we middels een retrospectieve cohortanalyse de lange termijn 
klinische succespercentages vergeleken van revascularisatie bij eenvatslijden van de 
AC of AMS. We tonen met deze studie aan dat 73% van de patiënten met CMI op basis 
van eenvatslijden met gastro-intestinale symptomen en bewezen mucosale ischemie 
blijvend verbetering van symptomen heeft na revascularisatie.
Niet-coronaire endovasculaire interventies worden uitgevoerd via de arteria brachialis 
of arteria femoralis. Literatuur op het gebied van coronaire interventies toont echter 
lagere complicatie percentages voor procedures via de arteria radialis dan voor 
procedures via de arteria brachialis of arteria femoralis met vergelijkbare procedurele 
en klinische uitkomsten. We hebben in Hoofdstuk 10.1 de haalbaarheid en veiligheid 
van radialis toegang voor endovasculaire mesenteriaal procedures vergeleken met 
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femoralis en brachialis toegang voor deze specifieke procedures. We tonen aan dat 
radialis toegang een veilige en haalbare benadering is voor mesenteriale procedures 
vergelijkbaar met femoralis toegang, terwijl brachialis toegang een significant hoger 
complicatiepercentage laat zien. In Hoofdstuk 10.2 beschrijven we een ernstige 
complicatie van een endovasculaire procedure via de arteria radialis. Bij een jonge 
patiënte ontstond een ruptuur van de arteria radialis na een stentplaatsing van de 
arteria brachiocephalica via radialis toegang.
Intra-arteriële drukmetingen worden uitgevoerd tijdens procedures van de 
kranslagaders om de klinische betekenis van een stenose van de kransslagader te 
bepalen. In Hoofdstuk 11 hebben we een cohortstudie uitgevoerd om de haalbaarheid 
te bepalen van intra-arteriële drukmetingen om een klinisch significante mesenteriaal 
stenose te voorspellen. We tonen aan dat we de klinische significantie van een 
mesenteriaal stenose kunnen voorspellen met behulp van deze drukmetingen.
In Deel IV vatten we de belangrijkste bevindingen van dit proefschrift samen gevolgd 
door de algemene discussie van dit proefschrift. Hierna wordt er richting gegeven voor 
toekomstig onderzoek op het gebied van CMI en het laatste deel van het proefschrift 
eindigt met de algemene conclusie.
A
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ABBREVIATIONS
ACNES  Anterior Cutaneous Nerve Entrapment Syndrome
ACR  American College of Radiology
ALA  5-aminolevulinic acid
AMI  acute mesenteric ischemia
AUC  area under the curve
BMI  body mass index
BMS  bare-metal stents
CA  celiac artery
CI  confidence interval
CIRSE  Cardiovascular and Interventional Radiological Society of Europe
CMI  chronic mesenteric ischemia
CS  covered stents
CT  computed tomography
CTA  computed tomography angiography
CVD  cardiovascular disease
DMC  data monitoring committee
DMIS  Dutch Mesenteric Ischemia Study group
DSA  digital subtraction angiography
DUS  duplex ultrasound
EAGEN  European Association for Gastroenterology, Endoscopy and Nutrition
EDV  end diastolic velocity
eGFR  estimated glomerular filtration rate
ESC  European Society of Cardiology
ESGAR  European Society of Gastrointestinal and Abdominal Radiology
ESVS  European Society of Vascular Surgery
FFR  fractional flow reserve
FMD  fibromuscular dysplasia
GFR  glomerular filtration rate
GI  gastro-intestinal
HSG  Hellenic Society of Gastroenterology
IBS  irritable bowel syndrome
I-FAPB  intestinal fatty-acid binding protein
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IMA  inferior mesenteric artery
IMV  inferior mesenteric vein
INR  international normalized ratio
ICC  intraclass correlation coefficient
IQR  interquartile range
LSA  left subclavian artery
MAL  median arcuate ligament
MALS  median arcuate ligament syndrome
mitoPO
2  
mitochondrial oxygen tension
μPO
2  
microvascular oxygen tension
MR  magnetic resonance
MRA  magnetic resonance angiography
MDCT  multi-detector computed tomography
NA  numerical aperture
NIS  National (Nationwide) Inpatient Sample
NOMI  non-occlusive mesenteric ischemia
NVGE  Nederlandse Vereniging voor Gastro-enterologie
NVMDL  Netherlands Association of Hepatogastroenterologists
OR  odds ratio
OSMAR  open surgical mesenteric artery repair
Pa  pressure aorta
PCO
2
  pressure of carbon dioxide
Pd  palladium
Pd  pressure distal
PMAS  percutaneous mesenteric artery stenting
PO
2  
oxygen tension
PpIX  protoporphyrin IX
PpIX-TSLT protoporphyrin IX-triplet state lifetime technique
PROMs  patient reported outcome measures
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Het boek is af en als allerlaatste schrijf ik dit laatste (en meest gelezen) hoofdstuk. 
Deze thesis vertegenwoordigt een groot deel van het werk dat ik tijdens mijn 3.5 jaar 
fulltime aanstelling als PhD kandidaat en daarna nog ruim een jaar naast mijn werk 
als arts-assistent in opleiding heb verricht. Ik zeg ‘groot deel’ want ik heb in deze tijd 
naast het werk van deze thesis ook mijn aandacht geschonken aan andere zaken zoals 
onderwijs, beursaanvragen, de ischemie poli, DMIS, begeleiding van studenten en 
congressen maar bovenal heb ik vriendschappen voor het leven gesloten. Deze thesis 
was er nooit gekomen en mijn tijd als PhD kandidaat was nooit zo mooi geweest zonder 
de betrokkenheid, ondersteuning en hulp van collega’s, vrienden en familie. Een aantal 
wil ik hierna specifiek bedanken.
Allereerst wil ik graag mijn promotor vanuit de afdeling Maag-, Darm- en Leverziekten, 
prof. dr. M.J. Bruno, bedanken. Beste Marco, zonder het vertrouwen dat jij mij gaf 
had ik dit PhD project nooit kunnen voltooien. Ik voelde mij gesteund in alle stappen 
die ik moest zetten en daarmee kon ik de vrijheid die ik kreeg voor de invulling van 
dit PhD traject aan. Ik heb heel veel geleerd van jou op wetenschappelijk vlak maar 
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dankbaar voor.
Hierna volgt mijn co-promotor van de afdeling Maag-, Darm- en Leverziekten, Dr. D. 
Leemreis-van Noord. Beste Desirée, toen ik jou had ontmoet bij mijn sollicitatie wist 
ik het meteen, met jou als co-promotor wil ik dit project aangaan. Ik kon met jou 
fijn sparren over de invulling van projecten en studies, ik kon bij jou mijn ei kwijt als 
het even wat minder ging maar ook klopte ik bij jou als eerste aan om te jubelen 
over de successen. Dat ik vorig jaar ook nog eens bij jou in de kliniek startte met de 
vooropleiding maakte dat ik je nu ook midden in de nacht wakker bel om een patiënt 
te overleggen. Ik bewonder hoe jij je leven organiseert met je werk als specialist, co-
promotor van inmiddels meerdere promovendi en een gezinsleven.
A
324
Dankwoord
Vervolgens wil ik graag mijn begeleiding vanuit de afdeling Radiologie bedanken. 
Allereerst mijn tweede promotor, Prof. dr. G.P. Krestin. Wij hebben elkaar gedurende 
mijn PhD traject een aantal maal gesproken tijdens de voortgangsbesprekingen. U 
overzag dan alle projecten snel en stelde kritisch vragen. Dank voor uw ondersteuning.
Verder mijn tweede co-promotor Dr. A. Moelker. Beste Adriaan, dank voor jouw 
begeleiding aan mij als niet-radiologische promovendus. Je hebt me nog wel eens 
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jouw interventie kunsten zeer, voor jou is niets klinisch onmogelijk en dat je van jouw 
vak houdt is duidelijk te zien. Op research gebied kunnen wij goed discussiëren en is 
jouw (radiologische) kijk verfrissend. Multidisciplinair onderzoek doen heb ik op deze 
manier echt als een verrijking ervaren.
Geachte leden van de leescommissie: Prof. dr. H.J.M. Verhagen, Prof. dr. J.J. Kolkman 
en Dr. E.G. Mik: dank voor de interesse in en beoordeling van dit proefschrift. Beste 
Hence, speciaal dank voor jouw betrokkenheid en inzet bij dit proefschrift maar 
ook bij de kliniek en research omtrent maagdarm ischemie zodat deze aandoening 
multidisciplinair kan worden behandeld en onderzocht. Beste Jeroen, dank voor de 
prettige samenwerking en jouw ongelimiteerde energie als het over maagdarm ischemie 
gaat. Beste Bert, wij kwamen elkaar vrij toevallig tegen in het Erasmus MC en daaruit 
is een mooie samenwerking gekomen. Ik ben dan ook verheugd en dankbaar dat jij in 
de leescommissie zitting wilde nemen.
Geachte overige leden van de commissie, Prof. dr. R.H. Geelkerken en Prof. dr. 
J.A. Reekers, dank voor uw bereidheid om als opponent deel te nemen in de grote 
commissie. Ik kijk er naar uit om van gedachten met u te wisselen. Beste Bob, ik heb met 
veel plezier met jou samengewerkt en jouw enthousiasme ten aanzien van maagdarm 
ischemie is zeer aanstekelijk. Ik hoop dat de Caroso studie spoedig van start gaat en 
we eindelijk het antwoord zullen krijgen op die ene belangrijke vraag.
Hierna wil ik alle co-auteurs bedanken voor de prettige samenwerking wat tot vele 
mooie artikelen heeft geleid.
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Het stokje binnen de maagdarm ischemie onderzoekslijn mocht ik overnemen van 
Jihan waarbij het fijn was dat er al een paar mooie projecten liepen waarmee ik verder 
mocht werken, waarvoor dank! Ik heb het stokje weer doorgegeven aan Luke. Luke, 
wij verschillen enorm qua karakter maar de liefde voor maagdarm ischemie hebben we 
gemeen. Leuk dat de laatste publicatie voor mijn thesis de eerste publicatie voor jouw 
thesis is. Het was heel fijn om met je samen te werken.
Lieve Carla, als jij iets regelt weet je zeker dat het goed komt. Dank voor alle hulp tijdens 
mijn PhD traject, geen afspraak was voor jou te moeilijk om te plannen.
Supervisoren van de ischemiepoli, Dr. J.W. Poley en Dr. A.C. de Vries, beste JW 
en Annemarie, dank voor alle supervisie momenten. De kliniek was een welkome 
afwisseling naast de wetenschap. Ook veel dank aan de poli-dames en -man en in 
het bijzonder Minou voor alle ondersteuning van de ischemiepoli. Ook de endoscopie 
verpleegkundigen wil ik graag bedanken, en in het bijzonder de dames die veel op het 
VLS programma hebben gestaan en tevens de ischemie assistenten voor hun hulp en 
geduld bij alle studiepatiënten. En natuurlijk alle studiepatiënten zelf, zonder inclusies 
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Mijn PhD tijd was nooit zo leuk geweest zonder alle fijne collega’s op het Dak en later 
Na-6. Lief en leed is daar gedeeld met als hoogtepunten de congressen, skitrips en 
vrijmibo’s. Lieve duifjes, Eline, Els, Esmee, Floor, Shannon, Sil en de Achterhoede: 
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alle drie dezelfde specialist, wel lijken we hetzelfde pad te volgen. Ik koester onze 
vriendschap.
Prof. dr. C.J. van der Woude, beste Janneke, veel dank voor het in mij gestelde 
vertrouwen door mij op te leiden tot Maag-, Darm- en Leverarts. Dr. Y.C. Schrama, beste 
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Gasthuis & Vlietland, dank voor de fijne werksfeer en het prettige opleidingsklimaat.
Dank aan alle lieve vrienden -de Beestenboel clan, clubgenootjes, 95 ladies, Vughtse 
kleutervriendinnen, mijn dierbaarste penvriendin, mocktail -maar bijna weer cocktail- 
babes, kroketlunchvriendin en eenieder die zich niet onder een naam laat scharen- voor 
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alle steun en betrokkenheid de afgelopen jaren, voor de afleiding en de vele bijzondere 
momenten samen.
Lieve paranimfen, dank dat jullie op deze bijzondere dag achter mij willen staan zoals 
jullie beiden al tijdens deze gehele PhD periode hebben gedaan. Lieve Joany, op dezelfde 
dag begonnen wij als PhD kandidaten en hebben wij al die jaren op het Dak naast elkaar 
gezeten. Jij wist al dat ik er aan kwam ’s ochtends als je mijn voetstappen op de gang 
hoorde en zonder te spreken (al deden we dat zelden niet) wisten we al hoe het met 
de ander ging. De MDL opleiding volg jij nu in Amsterdam wat maakt dat wij elkaar nu 
minder zien, maar gelukkig blijven we ons leven lang collega’s en gaat kwaliteit boven 
kwantiteit. Lieve Ef, na jaren met jou te hebben gewoond in het allermooiste huis gingen 
wij in dezelfde tijd een PhD doen in het Erasmus MC. Zo konden we wekelijks lunchen en 
was het reuze fijn om bij iemand van een andere afdeling ons hart te kunnen luchten. 
Ik heb heel veel bewondering voor jouw doorzettingsvermogen van de afgelopen jaren 
en vind het heel fijn om te zien dat alles nu zo voorspoedig gaat. Zullen we na mijn 
promotie de wekelijkse lunches oppakken maar dan als borrel in het café op de hoek?
Lieve (schoon)familie, ik dank jullie voor alle ondersteuning, interesse en betrokkenheid 
bij mijn promotie de afgelopen jaren. Lieve papa en mama, dank voor alles wat jullie 
mij in dit leven hebben meegegeven, dat heeft mij gemaakt tot wie ik nu ben. Lieve Vic, 
mijn grote broer, bij jou blijf ik me toch altijd het kleine zusje voelen. Het was bijzonder 
dat ik voor de PhD onderdelen die ik uitvoerde in Enschede bij jou mocht logeren en zo 
mee mocht draaien in het leven van Lars en jou. Dat maakte die werkbezoeken tot een 
feest. Lieve Died, kleine die niet zo klein meer is. Ik heb jouw wiskundebrein nog eens 
mogen gebruiken voor een sample size. Ik vind het leuk te zien hoe jouw leven zich nu 
ontwikkeld en vind het stiekem heel fijn dat jij niet zo ver bij me vandaan woont. Kom 
je snel weer eens eten?
De laatste woorden zijn voor jou, Bernt, het is cliché maar volledig waar: zonder jou 
was dit boek er niet geweest. Jij geeft mij ruimte waar ik die nodig heb, ondersteunt me 
als ik daar behoefte aan heb en zorgt voor afleiding en ontspanning als jij vindt dat dat 
nodig is. Jouw grenzeloze vertrouwen geeft mij vleugels: met jou kan ik de hele wereld 
aan. En sinds deze zomer doen we dat niet meer met zijn tweeën maar stappen wij 
door deze wereld samen met onze allerliefste dochter Livia op de arm. Ik kijk uit naar 
het verdere leven samen met jullie!
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